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Chapter 1  
General introduction 
 
 
 
 
 
 
 
 
 
 
Part of this chapter will be published in Advanced Food Toxicology (de Jonge et al., 
2009). 
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Preface 
The studies described in this thesis have been performed to gain more insight in the 
factors and mechanisms that determine the outcome of immune responses to orally 
administered food allergens. 
 
More specifically, the aims of this thesis are: 
Development of an oral sensitization model in the rat to investigate immune re-
sponses to the food allergen peanut as a model compound. 
Comparing the effect of different routes of exposure to peanut on peanut specific-
allergen recognition patterns. 
Investigating the influence of the probiotic Lactobacillus casei Shirota (LcS) in the rat 
peanut allergy model and comparing it’s effect with the effects of immunotoxic 
(bis(tributyltin)oxide (TBTO)) and immunostimulating (cholera toxin (CT)) com-
pounds. 
Elucidation of changes at the gene expression level in the rat peanut allergy model 
1. Food allergy 
1.1 Definitions 
Adverse reactions to food can either be of toxic or non-toxic nature (reviewed by 
Sampson (Sampson, 2003)). Toxic reactions are due to factors inherent to a food 
and will thus occur in any exposed individual given an appropriate dose. Non-toxic 
food reactions affect only those individuals that are susceptible and can be divided 
in non-immune-mediated (food intolerance) or immune-mediated (food allergy). 
Food intolerances are adverse physiologic responses caused by unique characteris-
tics of the host, such as a direct pharmacologic effect of a chemical present in food 
(e.g. tyramine induced nausea, emesis, headache) or metabolic disorders (e.g. lac-
tase or disaccharidase deficiency). Food allergy can be further classified into immu-
noglobulin E (IgE)-mediated and non-IgE-mediated reactions. Non-IgE-mediated 
reactions to food are caused by aberrant immune reactions to proteins in food 
without inducing IgE, e.g. celiac disease induced by gluten. IgE-mediated food al-
lergy accounts for the majority of food allergic reactions and is characterized by the 
presence of antigen (Ag)-specific serum IgE antibodies. This chapter will only focus 
on IgE-mediated food allergy. 
IgE-mediated food allergy is an adverse reaction to an otherwise harmless food or 
food component that involves an abnormal response of the immune system to spe-
cific protein(s) in foods. Food allergy can be caused by foods that are ingested; this 
is called class 1 food allergy. In addition, allergic responses to food can occur in 
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individuals that are sensitized by allergens to which they are exposed via the respi-
ratory tract, this is called class 2 food allergy. For example, in birch-pollen sensitized 
individuals allergic reactions can occur after ingestion of apple, pear, cherries and 
hazelnuts. Certain epitopes in these foods are structurally related to epitopes in 
birch-pollen. 
1.2 Clinical manifestations and diagnosis 
The clinical manifestations of food allergy can vary from mild to fatal anaphylactic 
reactions. Symptoms can manifest themselves in the oropharyngeal region (mouth 
itching, lip swelling), the gastrointestinal tract (nausea, vomiting, abdominal pain, 
diarrhea), skin (atopic dermatitis, urticaria, angioedema, contact dermatitis), the 
respiratory apparatus (wheeze, cough, asthma, stridor, rhinoconjunctivitis) and 
cardiovascular system (anaphylaxis caused by collapse due to hypotension). 
One of the first steps in the diagnosis of food allergy is a medical history in order to 
find out if the complaints are associated with a certain food. It is not always possible 
to identify the implicated food. Sensitization to food allergens can be measured 
with a skin prick test or by measuring specific IgE in serum. Although those assays 
can confirm sensitization, they do not always predict clinical reactivity. Only ap-
proximately 50% of the sensitized individuals react with clinical symptoms. The 
double-blind, placebo-controlled food challenge (DBPCFC) remains the golden stan-
dard to confirm symptomatic food allergy (Sampson, 1999b). At present there is no 
therapy to treat food allergy and patients can only prevent allergic reactions by 
avoiding the consumption of the food responsible for the allergy. 
1.3 Prevalence of food allergy 
The prevalence of food allergy, in the Western world, is estimated to be 2-6% in 
infants, and 1-2% in adults as demonstrated by DBPCFC (Sampson, 2005). Approxi-
mately 80% of early childhood allergies to milk, egg, soy, and wheat usually resolve 
by school age (Wood, 2003). Although peanut, tree nut, and seafood allergies are 
generally considered permanent, 20% of young children with peanut allergy experi-
ence resolution by the age of 5 years (recurrence is also possible) (Fleischer et al., 
2003). 
In the Netherlands, anaphylactic reactions due to food are thought to be responsi-
ble for approximately 100-200 hospital admissions every year. Approximately one to 
at the most a few fatalities occur annually in the Netherlands 
(Health_Council_of_the_Netherlands, 2007). 
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1.4 Food allergens 
In infants, the most important allergens are milk, egg, peanut, soy and wheat. These 
allergens account for 90% of food allergic reactions in children, whereas peanut, 
tree nuts, fish and shellfish account for 85% of reactions in adults and adolescents 
(Sampson, 1992). Considering the wide variety of foods consumed in the average 
diet, it is remarkable that allergic responses occur to so few foods. 
The major food allergens are glycoproteins, 10-70 kd in size, that are abundantly 
present in the allergic food. Furthermore, food allergens are generally water-soluble 
and fairly stable to heat, acid, and proteases (Sampson, 1999a). In addition, some 
physiochemical properties shared by many food allergens such as binding various 
types of ligands, glycolisation, interaction with lipid structures, and aggregation may 
additionally enhance stability and promote allergenicity (Breiteneder and Mills, 
2005). Importantly, thermal processing as well as other processing events can alter 
the structure and characteristics of food proteins, causing either an increase or 
decrease in allergenicity (Maleki, 2004); peanut for example can loose allergenicity 
by cooking, while roasting can increase it’s allergenicity. 
Furthermore, the food matrix itself may play a role in the allergenicity of the food 
allergen. The presence of interactions between different compounds (proteins, 
lipids, carbohydrates and non-nutrients) may either affect the gut immune response 
or the digestion process. In general, allergenic foods contain high protein, high lipid, 
and low carbohydrate concentrations. The high protein content enhances the likeli-
hood to be exposed to substantial amounts of allergenic protein. High levels of fat 
may be involved in protecting allergenic molecules during the digestive process and 
may act as immunostimulating agents (oil emulsions and other lipid structures are 
widely used as adjuvants). Furthermore, colocalized proteins such as certain phyto-
chemicals or lectins, have been shown to act as immunostimulatory and Th2-
skewing proteins, respectively (Lehrer et al., 2002). 
1.5 Immunological mechanisms 
1.5.1 Mucosal immune system 
The human gastrointestinal tract comprises of an enormous mucosal surface area 
(200-400 m2), which is exposed daily to vast amounts of food antigens, commensal 
bacteria and pathogens. The immune system of the intestine is constantly trying to 
avoid potentially harmful adverse responses to innocent food proteins and com-
mensal flora, while effectively responding to microbes. In order to prevent infection 
by pathogens, the gut has several lines of defense. The first is called immune exclu-
sion, which attempts to prevent passage of antigens. The mucosal barrier, formed 
by a single layer of gut epithelium, joined by tight junctions and covered by a mucus 
layer, is involved in this immune exclusion. Several factors help to strengthen the 
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barrier, e.g. enzymes, bile salts and extremes of pH. In addition, antibody-secreting 
B-cells play a key role in maintaining immunological silence. The most prominent 
antibody present at mucosal surfaces is IgA; this secretory IgA serves as a first line of 
defense by inhibiting adhesion of microorganisms and by preventing absorption of 
intact proteins. Binding of serum IgA to antigens does not trigger inflammatory 
responses, thereby preventing the development of chronic intestinal inflammation 
(MacDonald, 2003). 
The gut microflora also plays an important role in the prevention against pathogenic 
microbes. The numerous commensal bacteria protect the host against colonization 
of ingested bacteria by a phenomenon called colonization resistance. Several 
mechanisms are involved, including competition for substrates and adhesion sites 
(Vollaard and Clasener, 1994). 
Despite the mucosal barrier, some proteins of either innocent or pathogenic origin 
can pass the epithelium and enter the body. These antigens are presented to the 
mucosal immune system: the gut associated lymphoid tissue (GALT). The GALT con-
sists of immune structures that are involved in the induction of immune responses, 
the Peyer’s Patches (PPs), the mesenteric lymph nodes (MLNs) and isolated immune 
cells (predominantly lymphocytes) scattered throughout the epithelium (intraepi-
thelial lymphocytes) and lamina propria (LP) (Fig. 1). PPs are raised areas in the 
intestinal submucosa and consist of groups of large B-cell follicles and intervening T-
cell areas. A single layer of columnar epithelial cells separates the lymphoid areas 
from the gut lumen. In this epithelial layer, microfold cells (M cells) are present, 
which are specialized enterocytes that are involved in the uptake of antigens. The 
MLNs are the largest lymph nodes in the body and drain the intestines. Within a few 
hours after feeding a protein, antigen recognition takes place in the MLNs and acti-
vation and division of active T-cells occurs predominantly in the MLN. Both the PPs 
and the MLN are involved in the induction phase of intestinal immune responses 
and are important sites for the priming of lymphocytes by antigen.  
Besides PPs and MLNs the GALT consists of IgA-secreting plasma cells and CD4+ and 
CD8+ effector T-cells that are scattered through the lamina propria. Although het-
erogenous with regard to their phenotype and function, almost all T-cell popula-
tions in the lamina propria and overlying epithelium display characteristics of an 
effector/memory type. Together, these effector cells are the first line of defense 
cells to encounter invading pathogens. Furthermore, the GALT plays an important 
role in maintaining immunological tolerance against dietary proteins (MacDonald, 
2003). Tolerance is a selective rather than an absolute phenomenon, therefore a 
more accurate description is immunological hypo-responsiveness. 
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Figure 1. Mucosal immune system of the gut. 
The epithelium overlying organized gut-associated lymphoid tissue (GALT) contains specialized microfold 
cells (M cells) that constantly transport gut bacteria and antigens from the gut lumen into the lymphoid 
tissue. Dendritic cells (DC) in the lamina propria (LP) reach through epithelial cells and also sample gut 
bacteria. The epithelium is filled with CD8+ T cells, and the LP contains many CD4 T cells, macrophages, 
and IgA antibody–producing plasma cells. Potentially tissue-damaging T cell responses may be inhibited 
by immunosuppressive cytokines and regulatory T cells. From: (MacDonald and Monteleone, 2005). 
Reprint with permission of AAS. 
1.5.2 Sensitization and effector phase 
The normal response of the GALT to soluble dietary proteins is the induction of 
systemic hyporesponsiveness, also known as oral tolerance (Weiner, 2000). Oral 
tolerance is a state of active inhibition of immune responses to an ingested antigen. 
Similar suppressive responses are induced towards antigens from the commensal 
microbial flora. Several mechanisms by which oral tolerance may be mediated have 
been described, including T-cell deletion and T-cell anergy (a state of non-
responsiveness), and active suppression by regulatory T cells (Tregs) (Chehade and 
Mayer, 2005). There is convincing evidence that a high dose of antigen induces 
clonal deletion and anergy, whereas multiple low-dose feeds are more likely to 
induce active suppression by Tregs (Friedman and Weiner, 1994). Three different 
subgroups of Tregs are described: Th3 cells, Tr1 cells and CD4+CD25+Foxp3+ T cells 
(Chehade and Mayer, 2005). Th3 and Tr1 cells regulate suppression mainly via pro-
duction of the immunosuppressive cytokines, transforming growth factor-β (TGF- β) 
and IL-10, respectively. CD4+CD25+ T Foxp3+ cells are naturally occurring Tregs 
which mediate suppression via cell surface bound TGF-β. Failure to induce oral tol-
erance or abrogation of oral tolerance may result in the development of food al-
lergy. 
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The IgE-dependent food allergic reaction is composed of two phases (Fig. 2); (I) 
sensitization, e.g. the initiation phase in which specific IgE anti-allergen antibodies 
are produced which are then fixed on mast cells in target organs; and (II) elicitation, 
e.g. the effector phase, in which the clinical symptoms develop after a second en-
counter with the allergen (Figure 2). 
 
 
Figure 2. Schematical overview of cellular mechanisms of food allergic responses.  
Food proteins are taken up via M-cells of the Peyer’s Patches. After recognition and ingestion by DCs the 
protein is digested and presented to naïve T cells in the mesenteric lymph nodes. Antigen-specific Th2 
cells are generated and Th2-derived cytokines, such as IL-4 and IL-13 promote IgE production by B cells. 
Mast cells bind circulating IgE. Upon subsequent ingestion, antigenic fragments may interact directly with 
receptor-bound IgE on mast cells and cross-linking of receptors triggers the release of the preformed and 
newly formed inflammatory mediators responsible for clinical symptoms. Antigen-presentation may also 
lead to a rapid T-cell activation and the secretion of Th2 cytokines, triggering mediator release by baso-
philic and eosinophilic granulocytes. 
 
In the sensitization phase, proteins are taken up via M cells of the PP. After inges-
tion, APCs process and digest the proteins and migrate to the MLNs, where they 
present parts of the protein (epitopes) on their major histocompatability complex 
class II (MHCII) molecules to resting immature T cells. This results in proliferation 
and activation of T cells into mature effector and memory T cells. T cells can differ-
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entiate into type 1 (e.g. T helper (Th)1) or type 2 (Th2), dependent on the cytokine 
profile that is induced: interleukin (IL)-4 drives the maturation towards the Th2 
direction, whereas interferon-γ (IFN-γ) drives the maturation towards the Th1 direc-
tion. Typically, Th1 cells are involved in cellular immunity to fight viruses and other 
intracellular pathogens, eliminate cancerous cells, and stimulate delayed-type hy-
persensitivity skin reactions whereas Th2 initiate humoral immunity and up-regulate 
antibody production directed against extracellular organisms. Th2 cells are involved 
in the development of IgE producing B-cells. Release of cytokines including IL-4, IL-5, 
IL-10 and IL-13 induces an isotype switch in B cells to become IgE synthesizing 
plasma cells. In most persons the immunologic response to foreign proteins in food 
is that of the induction of oral tolerance. However, some proteins are able to breach 
the state known as oral tolerance, such proteins are allergens and can induce food 
allergic reactions in persons that are susceptible to such allergens. One of the al-
terations in the case of food allergy is that of reciprocal T(h)1-T(h)2 control of DCs’ 
function within the inductive site of the gut immune system (Temblay et al., 2007), 
which results in altered antigen presentation in combination with Th2-prone immu-
nological reactivity that will ultimately lead to the clinical symptoms as seen with 
food allergy. 
In the sensitization phase, antigen-specific IgE binds to IgE receptors (Fc receptors) 
on the cell surface of the mast cells. Mast cells play a key role in the development of 
clinical symptoms that are elicited during renewed exposure to the food. In this 
elicitation phase, allergen-specific IgE becomes cross-linked on the surface of the 
mast cell, and this initiates intracellular signaling events that activate the cell. When 
activated, a mast cell rapidly releases its granules with preformed mediators such as 
histamine and various other mediators are synthesized and secreted (such as 
chemokines, cytokines, prostaglandins and leukotrienes) into the immediate ex-
tracellular environment. These mediators attract circulating basophils, eosinophils, 
neutrophils and Th2 lymphocytes to the site of mast cell activation, where they 
amplify the immune reaction and mediate the symptoms of food allergy. 
2. Risk assessment in food allergy 
In toxicology risk assessment is used to estimate the risk of adverse health effects 
from exposure of a population to a certain substance. In food allergy, this approach 
can be used to assess the risk from food allergens to allergic individuals (Crevel et 
al., 2007). For proper risk assessment, data on the amount of (hidden) allergens 
present in food products and the total intake of these products is necessary. How-
ever, at the moment it is unknown what kinds of foodstuffs allergic individuals con-
sume. Risk assessment in food allergy is still in its infancy. However, data that is 
needed for this approach is emerging and this will lead to more insight in the risks of 
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unintended contamination of allergens in foodstuffs. Valid information on the risks 
will lead to more awareness of the problems that food allergic individuals encounter 
and this will hopefully improve the labeling of products. In addition to the allergen, 
other factors have been shown to influence the induction of food allergy and as 
such might have an impact on risk assessment. 
3. Factors influencing food allergy 
Several factors that affect the development of IgE-mediated food allergy have been 
identified, the most important being genetic and environmental factors. 
Genetic predisposition plays an important role in the development of allergic dis-
eases. An atopic phenotype (e.g. predisposition to mount IgE responses per se) in 
one or both parents substantially increases the chances of atopy in the offspring. 
However, the majority of infants, even those genetically predisposed to atopy, are 
still spared from allergic diseases. Therefore, it is generally assumed that against a 
genetic background of increased susceptibility, environmental factors also affect the 
outcome of allergic disease. These factors include, among others, the age at which 
food antigen is introduced, formula versus breastfeeding, diet, composition of the 
gut microflora, gastrointestinal infection status and pre- and postnatal exposures 
such as smoking (Halken and Host, 2001). 
One environmental factor that is thought to play an important role in allergic, but 
also other immune mediated disorders, is the change into a more hygienic lifestyle 
that has occurred in Westernized countries during the last decades. The so-called 
‘hygiene hypothesis’ has been proposed about 19 years ago by Strachan (Strachan, 
1989) to explain the rise in allergic diseases. The hygiene hypothesis is based on 
circumstantial evidence and there is a lot of debate on the underlying mechanisms 
that can explain the effects on the immune system. At the moment three different 
hypotheses exists, which will be shortly outlined. At first, it was proposed that a 
reduction in infections in early infancy predisposes to allergic responses. The im-
mune response to microbial antigens is accompanied by preferential expression of 
Th1 cytokines that counterbalance the Th2-polarized cytokine production of neo-
nates and protect against the development of allergy, which is predominantly a Th2 
response (Shah and Walker, 2002). However, the Th1/Th2 paradigm of the original 
hygiene hypothesis cannot explain the rise in Th1-mediated diseases (e.g. multiple 
sclerosis, diabetes) in Westernized countries. The original Th1/Th2 hypothesis is 
being replaced by newer data which indicate that reduced microbial exposure, af-
fects the maturation of the immune system, thereby reducing the development of 
immunoregulatory mechanisms, for instance the functioning of Tregs, which regu-
late both Th1 and Th2 mediated immune responses. An alternative interpretation of 
the hygiene hypothesis has been postulated recently, which suggests that perturba-
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tions in gut microflora composition early in life caused by lifestyle changes result in 
disruption of mechanisms that are involved in maintaining mucosal barrier function, 
immune regulation, and the development of tolerance (Halken and Host, 2001; 
Kalliomaki et al., 2001). The status of the microflora can have a strong influence on 
the development of food allergy, as for example investigated by the group of Bjork-
sten et al. (Bjorksten et al., 1999; Bjorksten et al., 2001). At the moment there is 
however no direct scientific evidence that microbial factors influence the preva-
lence of food allergy. 
4. Immunomodulatory food components 
4.1 Immunomodulators 
The induction of food allergy is not only dependent on the allergen itself, other 
factors play a role as well (Ilback and Friman, 2007). Such factors include the food 
matrix in which the allergen is presented to the gastrointestinal immune system and 
also immunomodulatory food components. 
The presence of immunomodulatory components that are present in food as addi-
tives or contaminants might also influence the food allergic response. In which way 
these immunomodulators affect food allergy is dependent on the type of immuno-
modulation they exert, e.g. immunosuppression or immunostimulation. 
Immunosuppressants are capable of preventing or inhibiting immunological activity. 
Since the majority of immunosuppressants act non-selectively, the immune system 
loses or is hampered in its ability to successfully resist infections and spreading of 
malignant cells. Immunostimulators are capable of stimulating the immune system 
by either inducing activation or increasing activity of any of its components. There 
are two main categories of immunostimulators: (I) specific immunostimulators, 
which provide antigenic specificity in an immune response, such as vaccines or any 
antigen and (II) non-specific immunostimulators, which act irrespective of antigenic 
specifity to augment immune responses of other antigens or stimulate components 
of the immune system without antigenic specificity, such as adjuvants and non-
specific immunostimulators. 
Immunomodulating agents can be present in the environment and/or (as contami-
nants of) our food, and those immunomodulators are therefore of particular impor-
tance in the case of food allergy. Diet is one of the major exogenous factors modu-
lating individual immunocompetence (Albers et al., 2005). Examples of such immu-
nomodulating food constituents are: probiotics (see chapter 3.4), prebiotics (Moro 
et al., 2006), polyunsaturaded fatty acids (Shaikh and Edidin, 2006), vitamin D (Kal-
ueff and Tuohimaa, 2007) and CpG motifs in plant DNA (Wang et al., 2007). 
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Examples of immunomodulating food contaminants are: polychlorinated biphenyls 
(PCBs) (Mori et al., 2008; Tryphonas et al., 1991), 2,3,7,8-Tetrachlorodibenzo-p-
dioxin (TCDD, or dioxin) and dioxin-like compounds (DLCs) (Yoshizawa et al., 2007), 
TBTO (see chapter 3.33), and CT (see chapter 3.2). 
Our aim was to study effects of CT, TBTO and the probiotic strain LcS, on the food 
allergic response. These immunomodulatory compounds are chosen because they 
are all present in food as additives or contaminants and therefore of relevance for 
food allergic responses. In addition, one of the aims of this thesis is to investigate 
and position the effect of LcS on the food allergic respons and to compare this with 
two model compounds that are expected to suppress (TBTO) or stimulate (CT) food 
allergic response. 
 
 
4.2 Lactobacillus casei Shirota 
Probiotics are defined as ‘live microorganisms which when administered in ade-
quate amounts confer a health benefit on the host ‘ (FAO/WHO, 2001a, 2002; Kal-
liomaki and Isolauri, 2002; Tannock, 2004). Many of the probiotics that are currently 
used are lactobacilli or bifidobacteria, which are widely used in the production of 
fermented foods and beverages and contribute both to the sensory qualities of the 
food and to the prevention of spoilage. Moreover, they are present in large num-
bers in the normal human and animal gastrointestinal flora. In recent decades, much 
attention has been paid to the health-promoting (probiotic) properties of lactic acid 
bacteria. In order to exert health benefits, probiotic microorganisms not only should 
be capable of surviving passage through the digestive tract but also should have the 
capability to proliferate in the gut (FAO/WHO, 2001a). Another factor for proper and 
healthy functioning of the intestinal microflora is that the resulting intestinal micro-
flora after probiotic intake should be balanced (homeostasis). Several probiotics 
have been shown to survive transit through the human gastrointestinal tract and to 
maintain a balanced intestinal microflora (FAO/WHO, 2001a; Tannock, 2004). 
Lactobacillus casei strain Shirota (LcS) is contained in the commercial fermented 
milk product Yakult (Yakult Ltd., Tokyo, Japan) and is widely studied for its immune 
effects, especially in rodent models (Baken et al., 2006a; de Waard et al., 2002; de 
Waard et al., 2001; Ezendam and van Loveren, 2008; Matsuzaki and Chin, 2000; 
Matsuzaki et al., 1998; Sgouras et al., 2004; Yasui et al., 1999). One of the mecha-
nisms by which LcS can influence the immune response is by stimulating Th1 re-
sponses (Kato et al., 1999; Shida et al., 2002). This could beneficially affect allergic 
(Th2-mediated) responses. Shida et al. (Shida et al., 2002) have shown that LcS re-
duced serum ovalbumin (OVA)-specific IgE and IgG1 responses and diminished sys-
temic anaphylaxis in a mouse model for food allergy. In this model, LcS skewed the 
immune response towards Th1 immunity, thereby reducing the Th2-mediated aller-
gic responses. In another study, LcS stimulated IFN-γ production by mouse spleno-
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cytes in vivo and in vitro, possibly via macrophage-activation and IL-12 production 
and subsequent enhancement of Th1 cell functions (Kato et al., 1999). Effects of LcS 
have also been studied in a rat model for Th1-mediated autoimmunity (experimen-
tal autoimmune encephalomyelitis (EAE) and LcS aggravated clinical symptoms 
indicating that stimulation of Th1 immunity can also induce unwanted effects 
(Baken et al., 2006a; Ezendam and van Loveren, 2008). Taken together these data 
suggest that immunomodulatory effects of LcS can lead to both beneficial and ad-
verse effects. 
Besides stimulating Th1 immunity, other mechanisms are proposed to explain the 
beneficial effects of probiotics on allergic responses. These are summarized in Table 
1. The precise mechanisms by which probiotics may influence allergic responses are 
still unknown and are highly strain-dependent. Data on efficacy in human studies 
are limited. Effects of LcS have been studied in humans, but these studies focused 
predominantly on natural killer (NK) cell activity (Nagao et al., 2000; Spanhaak et al., 
1998; Takeda and Okumura, 2007). One randomized double-blind, placebo-
controlled study assessed the effect of LcS in patients with allergic rhinitis directed 
against Japanese cedar pollen and found that LcS does not prevent allergic symp-
toms in patients sensitive to Japanese cedar pollen, but might delay the occurrence 
of allergic symptoms in moderate to severe patients (Tamura et al., 2007). 
 
Table 1: Mechanisms by which probiotics could beneficially affect allergies 
Mechanism References 
Stabilizing intestinal barrier function, thereby also reducing 
antigen load in the gut 
(Bongaerts and Severijnen, 2005; 
Isolauri et al., 1993; Kalliomaki and 
Isolauri, 2002; Rosenfeldt et al., 2004) 
Stimulation of IgA response (Malin et al., 1996; Marschan et al., 
2008; Rautava et al., 2006; Viljanen et 
al., 2005) 
Activation of immunomodulatory genes via Toll-like receptors 
through two structural components of bacteria, the lipopoly-
saccharide portion of Gram-negative bacteria and specified 
CpG motif in bacterial DNA 
(Kalliomaki and Isolauri, 2002). 
Stimulation of IL-10 production  (Frossard et al., 2007) 
Effect on DC maturation and differentiation  (Christensen et al., 2002; Niers et al., 
2007) 
Th1-stimulating and Th2-inhibiting properties (Kim et al., 2008; Shida et al., 2002)  
Stimulation of regulatory T cells (Tregs), which suppress both 
Th1- and Th2-associated responses 
(Prioult et al., 2004; Rook et al., 2004) 
 
 
Effects of probiotics on allergy in humans have been studied mostly in children suf-
fering in atopic eczema. In addition, prevention of atopic diseases has been exten-
sively studied in atopic children that received probiotics in the first period of their 
lives. Recently, a meta-analysis, including twelve randomized trials, has demon-
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strated that probiotics significantly reduce infant eczema. However, when the 
analysis was restricted to studies on IgE-dependent atopic eczema the reduction in 
eczema was no longer significant. In addition, it was shown that no benefits were 
reported for any other allergic disease or (food) hypersensitivity outcome (Osborn 
and Sinn, 2007). Savilathi et al. (Savilahti et al., 2008) recently reviewed the effect of 
pre- and probiotics on food allergy and concluded that recent studies using probiot-
ics in the prevention and treatment of food allergy and other allergic diseases show 
at best a modest effect. Hence, effects of probiotics are mainly studied in infants 
with atopic eczema. To further explore the effects of probiotics on food allergic 
responses, we have studied the effects of LcS in the Brown Norway rat model for 
peanut allergy.  
 
 
4.3 Cholera toxin 
Cholera is the illness caused by eating food or drinking water that is contaminated 
with a bacterium called Vibrio Cholerae (V. Cholerae). It infects people’s intestines, 
causing diarrhea, vomiting and leg cramps. 
V. Cholerae exports its major virulence factor, the enterotoxin cholera toxin (CT), 
from its periplasm into the lumen of the gastro-intestinal tract of the host (Aben-
droth et al., 2004). Here CT intrudes the mucosal layer of the intestines, leading to 
increased mucosal wall permeability, which results in a more efficient immune re-
sponse if an allergen is applied as well (Kroghsbo et al., 2003). The result is an in-
creased allergic response with lower dosage of the allergen needed. For this reason 
CT is often used as a mucosal adjuvant (Kaper et al., 1995; Keusch et al., 1967; Lange 
et al., 1998; Sack et al., 2004; Sasmal et al., 1995; Yardley and Brown, 1973). Fur-
thermore, CT has been shown to stimulate strong responses to mucosally delivered 
antigens, by inducing an antigen-specific type 2 response (Bashir et al., 2002; Chris-
tensen et al., 2003; Helm et al., 2002; Li et al., 1999; Li et al., 2000; Li et al., 2001; 
Williams et al., 1999) or a mixed Th1 + Th2 response (Hornquist and Lycke, 1993; 
Marinaro et al., 1995), with a bias toward Th2 (Marinaro et al., 1995; Wilson et al., 
1991; Xu-Amano et al., 1993). We included CT as an immunostimulating compound 
and investigated its effect on the food allergic response in our BN rat model of food 
allergy. 
 
 
4.4 Bis(tributyltin)oxide 
Organotin contamination of harbours and marinas has been a significant environ-
mental concern, because they disrupt endocrine and reproductive functions and 
have immunotoxic properties at very low concentrations (Fent, 1996; Vos et al., 
2000). Bis(tributyltin)oxide (TBTO; C24H54OSn2) is used as a biocidal preservative for 
wood, cotton textiles, paper and paints and stains for residential homes and is also 
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added as an anti-fouling agent in numerous formulations of marine paints (WHO, 
1999). As a result of its low water solubility and liphophilic character, tributyltin 
(TBT) adsorbs readily onto particles. Its half-life in the water column ranges from a 
few days to weeks and TBT may persist in sediments for several years (WHO, 1999). 
It bioaccumulates in organisms, with the highest concentrations found in liver and 
kidney (WHO, 1999). 
TBTO is present as a contaminant in the food chain (Aluoch and Whalen, 2005; 
Ikeda et al., 2001; Sekizawa, 1998; WHO-IPCS, 1999). Uptake from food is more 
important than uptake directly from water (WHO, 1999). TBTO has been detected in 
human foods as well as in human blood (Aluoch and Whalen, 2005). Some studies 
have related human exposure to TBT to the dietary uptake of TBT in Japan (Ikeda et 
al., 2001; Sekizawa, 1998). No information is available on the toxicity of TBTO in 
humans following long-term exposure. Although some data and case reports indi-
cate that TBTO is a severe dermal and respiratory irritant in humans, these data are 
not adequate to characterize the exposure-response relationships (WHO, 1999). 
In several studies with laboratory animals, both short term and long term, it has 
been demonstrated that TBTO is an immunotoxic chemical (Aluoch and Whalen, 
2005; Ikeda et al., 2001; Sekizawa, 1998; WHO-IPCS, 1999). Immunosuppression by 
TBTO in rats is characterized by a direct action of TBTO on cortical thymocytes, re-
sulting in suppressed T-cell dependent immune responses. Vos et al. (Vos et al., 
1984; Vos et al., 1990) found TBTO to reduce OVA-induced Delayed Type Hypersen-
sitivity (DTH) reactions in rats. TBTO also decreased innate immune responses, such 
as Natural Killer (NK) cell (Aluoch and Whalen, 2005; Dudimah et al., 2006) and 
macrophage activity (Vandebriel et al., 1998; Vos et al., 1984). In host resistance 
models TBTO suppressed resistance to the infectious agents Listeria monocytogenes 
(Vos et al., 1990) and Trichinella (T.) spiralis (Vos et al., 1984). In the T. spiralis 
model TBTO suppressed serum T. Spiralis-specific IgE titres (Vos et al., 1984). 
Food allergic processes are highly T-cell dependent, and regulation of T-cell re-
sponses play an important role in IgE-synthesis, further substantiating a possible 
effect of TBTO on food allergy. From its effects on specific IgE responses to parasites 
and its effect on T-cells, one may speculate that TBTO could also influence the food 
allergic reaction to food proteins, which is largely dependent on IgE responses. For 
this reason, research of the immunosuppressive effect of TBTO in our BN rat model 
for food allergy are included in the present studies. 
 
5. Animal models for food allergy 
In food allergy research, animal models are mainly being used for elucidating 
mechanisms. In the past decade, several food allergy models in rodents have been 
developed. It has been demonstrated that rodents can be sensitized to food pro-
teins with or without the use of an adjuvant and that allergic responses upon re-
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exposure to the offending food reflected the human situation (Knippels et al., 1999; 
Li et al., 2000). 
A validated animal model for food allergy should meet several criteria (Dearman 
and Kimber, 2009; Penninks and Knippels, 2001), which include the induction of 
allergic parameters that are clinically relevant for humans and of antibody re-
sponses that are directed to similar proteins/epitopes as found in patient sera. One 
important issue in the development of a food allergy model is the route of expo-
sure. Sensitization can be induced either via intraperitoneal injection or oral expo-
sure. The latter is preferred, because it involves the normal route of exposure in 
humans and several factors, such as gastro-intestinal acid denaturation, enzymatic 
digestion and mucosal/epithelial layers might influence the allergenicity of proteins. 
In addition, several animal models use adjuvants in order to achieve sensitization. 
The use of adjuvants is controversial, because it is not clear how adjuvants affect 
the immune response in the sensitization process and therefore it is impossible to 
determine the inherent potential of a given protein to induce allergic sensitization. 
A predictive model without adjuvant is therefore desirable, because it would reduce 
the risk of false positives. 
A complete recapitulation of the human experience should not be the goal of ani-
mal model development. Rather, the objective is to provide a model that will pro-
vide useful and reliable information that when used in tandem with other relevant 
data will allow sound judgements to be made about the nature of likely hazards 
(Dearman and Kimber, 2009). For an animal model to be truly of value in this con-
text there is a need to understand performance characteristics and to 
acknowledge limitations, particularly with respect to reliability under different cir-
cumstances. 
Food allergy is a complex disease, with genetic predisposition, environmental fac-
tors and exposure conditions all contributing to inter-individual differences in sus-
ceptibility (Boulay et al., 2008; Kimber and Dearman, 2002). Another commonly 
held opinion is that the usefulness of animal models is limited due to the wide varia-
tion among different animal strains and species with respect to immune respon-
siveness to particular proteins (Goodman et al., 2005; Holt et al., 1981; McClain and 
Bannon, 2006; Spok et al., 2005; Vaz et al., 1971; Vaz et al., 1970). It is therefore 
very unlikely that a single method using experimental animals will be developed 
that is capable of predicting accurately all aspects of the likely prevalence, persis-
tence and severity of food allergy among human populations exposed to a novel 
allergen in the diet. However, the first step of any safety assessment process is to 
identify accurately intrinsic hazard, or lack of it, and it is for this purpose that cur-
rent approaches to the development of animal models of food allergy are directed 
(Dearman and Kimber, 2009). Once intrinsic hazard has been identified, the next 
steps in the risk assessment process are to determine the characteristics of that 
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hazard and to define the likely conditions and extent of exposure, and on those 
bases assess likely risks to human health. 
In conclusion, animal models for food allergy are useful to study mechanisms, but 
before these can be used as predictive models, a lot of validation studies remain to 
be done. 
 
 
6. Approaches for prediction of the allergenicity of novel foods 
Animal models can not only be used to investigate the influence of immunomodula-
tory food constituents or food contaminants on the food allergic response, they are 
also needed to solve many questions of a more mechanistic nature. Furthermore, a 
validated animal model for food allergy could be useful in the screening of novel 
foods for potential allergenicity. Novel foods are products that have never been 
used as food, and include foods that are modified by genetic manipulation. One of 
the major issues in the safety assessment of these genetically modified foods is the 
assessment of the potential allergenicity of the newly expressed proteins. 
Theoretically there are three scenarios in which a novel protein may be a risk for 
allergenicity: identity/crossreactivity with a known allergen, the potential to in-
crease the endogenous allergenicity of the target (commonly allergenic) food due to 
unintended effects on plant metabolism (that impact on the level of expression of 
endogenous allergens), or the novel protein may be a de novo allergen that has not 
previously been experienced by the 
human population (Goodman et al., 2008; Lehrer and Bannon, 2005). It has been 
suggested that the primary risk is the introduction of a known allergen, or a cross-
reactive allergen, into a food crop. One example that is relevant to recall in this 
context is the halt of the development of a transgenic (genetically modified (GM)) 
soybean, when it was discovered that the methionine-rich Brazil nut protein intro-
duced to improve the nutritional quality of the crop was an important allergen 
(Nordlee et al., 1996). In addition, animal models may also play a part in the as-
sessment of foods modified for reduction of allergenicity (del Val et al., 1999; Nig-
gemann et al., 2001) and in the characterization of the modulating effects of food 
processing and the influence of the food matrix on allergenic potential (Mills and 
Mackie, 2008; Orlandi et al., 2004; Rupa et al., 2007). 
Therefore, approaches to assess the safety of novel foods have been formulated, 
such as the decision tree of the Food and Agriculture Organization and the World 
Health Organization (FAO/WHO) (FAO/WHO, 2001b). More recently, it has been 
suggested that instead of using a step-wise decision tree approach, more factors 
should be taken into account, especially since there is neither a single factor recog-
nized as an identifier for protein allergenicity, nor a single test available to assess 
this. The weight of evidence approach, suggested by the Codex takes into account a 
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variety of factors and approaches for an overall assessment of allergenic potential 
(CAC, 2003). This weight-of-evidence approach is summarized in Table 2. 
The guidelines of the Codex will be briefly placed into context. Independent of the 
source, e.g. allergenic or non-allergenic, determination of amino acid sequence 
homology can be done by using several databases. However, it is important to real-
ize that homology of 6-8 amino acids, might lead to many false-positves because not 
all sequence homologues will be clinically relevant (Ladics, 2008). Of greater scien-
tific merit is consideration of the degree of identity over the length of the whole 
protein, with high identity matches with one or more known allergens (470%) indi-
cating a high potential for crossreactivity. Lower degrees of homology (435%) will be 
associated with a lower potential for cross-reactivity (Goodman et al., 2005; Good-
man et al., 2008). In addition, protein digestibility is used, since most food allergens 
are resistant to digestive degradation. Again, this endpoint has value in a weight of 
evidence approach but cannot be used as a standalone assay. For proteins from an 
allergenic source, assessment of binding to specific IgE present in sera from patients 
allergic to this specific protein can be used. In addition to these endpoints, Codex 
considers several other methods, including animal models, that might be useful. 
However, these approaches are only applicable when they are thoroughly evaluated 
or validated for predicting protein allergenicity (Ladics, 2008). 
 
Table 2: Codex Guidance (2003)  
Codex recommended allergy assessment 
1. If protein is introduced from a non-allergenic source 
• Assess amino acid sequence similarity to known allergens 
• Assess in vitro pepsin resistance 
2. If protein is introduced from an allergenic source 
• Assess amino acid sequence similarity to known allergens 
• Assess in vitro pepsin resistance 
• Assess specific IgE binding 
• Assess skin prick testing on appropriate individuals 
Other considerations such as scientific knowledge and technology evolve 
• Exposure level of the introduced protein 
• As science and technology evolve other methods may be considered 
o Targeted serum screens 
o Animal models 
o Examination of newly expressed proteins for T-cell epitopes and structural motifs as-
sociated with allergens  
Adapted from (Ladics, 2008). 
 
 
Despite many efforts that have been made in the last years, the only approach that 
currently can be used is a weight of evidence approach. A validated and reliable 
animal model that can predict allergenicity of novel proteins would be very useful in 
this approach. In such a model, conventional parameters, e.g. measurement of 
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allergen-specific IgE, release of mast cell mediators, cytokine respones, are normally 
used to study the food allergic response. 
Additionally, studying transcriptome profiles could also proof to be useful in this 
area. Genomics is the study of an organism’s entire genome. The publication of the 
sequence of the human genome has resulted in a dramatic increase in knowledge in 
the field of genomics (Gatzidou et al., 2007) and as a consequence, during the past 
two decades great advances have been achieved in molecular biology. One of the 
most recent techniques accountable for these advances is the microarray tech-
nique. DNA microarrays permit the quantitative measurement of the expression 
levels of thousands of individual genes in different biological samples at the same 
time. Another benefit of this technique is that it allows the investigation of early 
parameters of biological effect. Several studies have shown that it is possible to 
detect changes in the gene expression profile after exposure to immunomodulating 
agents, both in vivo (Ezendam et al., 2004) and in vitro (Schoeters et al., 2007). So 
far no studies have been performed that assessed the expression profile in food 
allergy. 
Seen in this light, genomics might have the potential to advance our knowledge of 
food allergy. Allergogenomics would herein be defined as a form of analysis by 
which the activity of a particular allergen on living tissue can be identified upon a 
profiling of its known effect on genetic material. Our study was the first published 
that described the effect of food allergic sensitization on the level of gene expres-
sion profiles. 
 
 
7. Outline of this thesis 
In order to gain more insight in both the factors and the mechanisms that deter-
mine the outcome of immune responses to orally administered food allergens the 
studies described in this thesis have been performed. 
 Chapter 2 describes a rat model of peanut hypersensitivity in which peanut-
specific responses are measured following oral exposure to the aqueous fraction of 
peanut. Data from this study compare the allergic response in an oral model for 
food allergy of animals that were bred and kept naïve for the allergen of interest 
with that of animals that were bred for multiple generations and kept naïve for the 
allergen of interest as well as cross-reactive proteins. Furthermore, in this chapter 
effects of route of exposure and the mucosal adjuvant CT on the food allergic re-
sponse are investigated. 
In Chapter 3 the effect of the immunotoxic compound TBTO on the food allergic 
process against peanut or ovalbumin is investigated. 
In the next part of the thesis the emphasis lies on the potential immunomodulating 
capacities of the probiotic LcS on the food allergic process. 
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Chapter 4 investigates whether the probiotic LcS could influence the food allergic 
response against peanut, suppression of the Th2-dependent response and thus a 
reduced allergic response was expected. 
One factor that was apparent in all the previous chapters is that in experimental 
models for food allergy parameters of multiple levels of the food allergic process 
should be investigated. One new tool that could play an important role is the micro-
array technique, which offers the possibility to look at thousands of genes similarly. 
Therefore, the emphasis of the last part of the thesis lies on food allergy on the 
gene expression level. Chapter 5 describes the effect of sensitization to the food 
allergen peanut on the level of gene expression as analyzed with the microarray 
technique. 
Finally, the results and significance of our findings are discussed in Chapter 6. 
 
 
References 
Abendroth, J., Bagdasarian, M., Sandkvist, M., Hol, W.G., 2004, The structure of the cytoplasmic domain 
of EpsL, an inner membrane component of the type II secretion system of Vibrio cholerae: an un-
usual member of the actin-like ATPase superfamily. J Mol Biol 344, 619-633. 
Albers, R., Antoine, J.M., Bourdet-Sicard, R., Calder, P.C., Gleeson, M., Lesourd, B., Samartin, S., Sander-
son, I.R., Van Loo, J., Vas Dias, F.W., Watzl, B., 2005, Markers to measure immunomodulation in hu-
man nutrition intervention studies. Br J Nutr 94, 452-481. 
Aluoch, A.O., Whalen, M.M., 2005, Effects of interleukins 2 and 12 on TBT-induced alterations of MAP 
kinases p38 and p44/42 in human natural killer cells. J Appl Toxicol. 
Baken, K.A., Ezendam, J., Gremmer, E.R., de Klerk, A., Pennings, J.L., Matthee, B., Peijnenburg, A.A., van 
Loveren, H., 2006a, Evaluation of immunomodulation by Lactobacillus casei Shirota: Immune func-
tion, autoimmunity and gene expression. Int J Food Microbiol 112, 8-18. 
Baken, K.A., van Loveren, H., Pennings, J.L.A., de Vries, A., Breit, T.M., van Steeg, H., 2006b, Gene Expres-
sion Profiling of Bis(tri-n-butyltin)oxide (TBTO)-Induced Immunotoxicity in Mice and Rats. Journal of 
Immunotoxicology 3, 227-244. 
Baken, K.A., Vandebriel, R.J., Pennings, J.L., Kleinjans, J.C., van Loveren, H., 2007, Toxicogenomics in the 
assessment of immunotoxicity. Methods 41, 132-141. 
Bashir, M.E., Andersen, P., Fuss, I.J., Shi, H.N., Nagler-Anderson, C., 2002, An enteric helminth infection 
protects against an allergic response to dietary antigen. J Immunol 169, 3284-3292. 
Bjorksten, B., Naaber, P., Sepp, E., Mikelsaar, M., 1999, The intestinal microflora in allergic Estonian and 
Swedish 2-year-old children. Clin Exp Allergy 29, 342-346. 
Bjorksten, B., Sepp, E., Julge, K., Voor, T., Mikelsaar, M., 2001, Allergy development and the intestinal 
microflora during the first year of life. J Allergy Clin Immunol 108, 516-520. 
Bongaerts, G.P., Severijnen, R.S., 2005, Preventive and curative effects of probiotics in atopic patients. 
Med Hypotheses 64, 1089-1092. 
Boulay, A., Houghton, J., Gancheva, V., Sterk, Y., Strada, A., Schlegel-Zawadzka, M., Sora, B., Sala, R., van 
Ree, R., Rowe, G., 2008, A EuroPrevall review of factors affecting incidence of peanut allergy: priori-
ties for research and policy. Allergy 63, 797-809. 
Breiteneder, H., Mills, E.N., 2005, Plant food allergens--structural and functional aspects of allergenicity. 
Biotechnol Adv 23, 395-399. 
CAC, C.A.C., 2003, Alinorm 03/34: Joint FAO/WHO Food Standard Programme, Codex Alimentarius Com-
mission, Twenty-Fifth Session, Rome, Italy, 30 June-5 July, 2003. Appendix III, Guideline for the con-
duct of food safety assessment of foods derived from recombinant-DNA plants, and Appendix IV, 
Annex on the assessment of possible allergenicity. 
Thesis De Jonge V9.pdf   25 9-10-2009   11:37:04
 26 
Chehade, M., Mayer, L., 2005, Oral tolerance and its relation to food hypersensitivities. J Allergy Clin 
Immunol 115, 3-12; quiz 13. 
Christensen, H.R., Frokiaer, H., Pestka, J.J., 2002, Lactobacilli differentially modulate expression of cyto-
kines and maturation surface markers in murine dendritic cells. J Immunol 168, 171-178. 
Christensen, H.R., Kjaer, T.M., Frokiaer, H., 2003, Low-dose oral tolerance due to antigen in the diet 
suppresses differentially the cholera toxin-adjuvantized IgE, IgA and IgG response. Int Arch Allergy 
Immunol. 132, 248-257. 
Crevel, R.W., Briggs, D., Hefle, S.L., Knulst, A.C., Taylor, S.L., 2007, Hazard characterisation in food aller-
gen risk assessment: the application of statistical approaches and the use of clinical data. Food Chem 
Toxicol 45, 691-701. 
de Jonge, J.D., Ezendam, J., Van Loveren, H., 2009, Chapter 21: Food Allergy. In: Advanced Food Toxicol-
ogy. Wageningen Academic Publishers, Wageningen, The Netherlands. 
de Waard, R., Garssen, J., Bokken, G.C., Vos, J.G., 2002, Antagonistic activity of Lactobacillus casei strain 
shirota against gastrointestinal Listeria monocytogenes infection in rats. Int.J.Food Microbiol. 73, 93-
100. 
de Waard, R., Garssen, J., Snel, J., Bokken, G.C., Sako, T., Veld, J.H., Vos, J.G., 2001, Enhanced antigen-
specific delayed-type hypersensitivity and immunoglobulin G2b responses after oral administration 
of viable Lactobacillus casei YIT9029 in Wistar and Brown Norway rats. Clin Diagn Lab Immunol 8, 
762-767. 
Dearman, R.J., Kimber, I., 2009, Animal models of protein allergenicity: potential benefits, pitfalls and 
challenges. Clin Exp Allergy 39, 458-468. 
del Val, G., Yee, B.C., Lozano, R.M., Buchanan, B.B., Ermel, R.W., Lee, Y.M., Frick, O.L., 1999, Thioredoxin 
treatment increases digestibility and lowers allergenicity of milk. J Allergy Clin Immunol 103, 690-
697. 
Dudimah, F.D., Odman-Ghazi, S.O., Hatcher, F., Whalen, M.M., 2006, Effect of tributyltin (TBT) on ATP 
levels in human natural killer (NK) cells: Relationship to TBT-induced decreases in NK function. J Appl 
Toxicol. 
Ezendam, J., Staedtler, F., Pennings, J., Vandebriel, R.J., Pieters, R., Harleman, J.H., Vos, J.G., 2004, Toxi-
cogenomics of subchronic hexachlorobenzene exposure in Brown Norway rats. Environ Health Per-
spect 112, 782-791. 
Ezendam, J., van Loveren, H., 2008, Lactobacillus casei Shirota administered during lactation increased 
the duration of autoimmunity in rats and enhanced lung inflammation in mice. BrJ Nutr 99, 83-90. 
FAO/WHO, 2001a, Health and nutritional properties of probiotics in food including powder milk with live 
lactic acid bacteria, a joint FAO/WHO expert consultation. 1 - 4 October. Cordoba, Argentina, 2001. 
website: http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf; visited 
December 2, 2004, 1-34. 
FAO/WHO, 2002, Guidelines for the Evaluation of Probiotics in Food: Joint FAO/WHO Working Group 
meeting, London Ontario, Canada, 30 April-1 May 2002. website: http://www.who.int/foodsafety/-
fs_management/en/probiotic_guidelines.pdf; visited December 2, 2004, 1-11. 
FAO/WHO, F.a.A.O.W.H.O., 2001b, FAO/WHO Expert Consultation on Foods Derived from Biotechnology. 
Evaluation of Allergenicity of Genetically Modified Foods. Rome: FAO. 
Fent, K., 1996, Ecotoxicology of organotin compounds. Crit Rev Toxicol 26, 1-117. 
Fleischer, D.M., Conover-Walker, M.K., Christie, L., Burks, A.W., Wood, R.A., 2003, The natural progres-
sion of peanut allergy: Resolution and the possibility of recurrence. J Allergy Clin Immunol 112, 183-
189. 
Friedman, A., Weiner, H.L., 1994, Induction of anergy or active suppression following oral tolerance is 
determined by antigen dosage. Proc.Natl.Acad.Sci.U.S.A 91, 6688-6692. 
Frossard, C.P., Steidler, L., Eigenmann, P.A., 2007, Oral administration of an IL-10-secreting Lactococcus 
lactis strain prevents food-induced IgE sensitization. J Allergy Clin Immunol 119, 952-959. 
Gatzidou, E.T., Zira, A.N., Theocharis, S.E., 2007, Toxicogenomics: a pivotal piece in the puzzle of toxico-
logical research. J Appl Toxicol 27, 302-309. 
Thesis De Jonge V9.pdf   26 9-10-2009   11:37:04
 27 
Goodman, R.E., Hefle, S.L., Taylor, S.L., van Ree, R., 2005, Assessing genetically modified crops to mini-
mize the risk of increased food allergy: a review. Int Arch Allergy Immunol 137, 153-166. 
Goodman, R.E., Vieths, S., Sampson, H.A., Hill, D., Ebisawa, M., Taylor, S.L., van Ree, R., 2008, Allergenic-
ity assessment of genetically modified crops--what makes sense? Nat Biotechnol 26, 73-81. 
Halken, S., Host, A., 2001, Prevention. Curr Opin Allergy Clin Immunol 1, 229-236. 
Health_Council_of_the_Netherlands, 2007, Food allergy. The Hague: Health council of the Netherlands 
publication no. 2007/07. 
Helm, R.M., Furuta, G.T., Stanley, J.S., Ye, J., Cockrell, G., Connaughton, C., Simpson, P., Bannon, G.A., 
Burks, A.W., 2002, A neonatal swine model for peanut allergy. J Allergy Clin Immunol 109, 136-142. 
Holt, P.G., Rose, A.H., Batty, J.E., Turner, K.J., 1981, Induction of adjuvant-independent IgE responses in 
inbred mice: primary, secondary, and persistent IgE responses to ovalbumin and ovomucoid. Int Arch 
Allergy Appl Immunol 65, 42-50. 
Hornquist, E., Lycke, N., 1993, Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur J 
Immunol 23, 2136-2143. 
Ikeda, M., Takatsuki, M., Yakabe, Y., Arimoto, Y., Fukuma, T., Higashikawa, K., 2001, Experiences on 
persistent organic pollutants under the Law concerning the Examination and Regulation of Manufac-
ture, etc. of Chemical Substances, Japan, with references to biodegradation and bioaccumulation. Int 
Arch Occup Environ Health 74, 295-301. 
Ilback, N.G., Friman, G., 2007, Interactions among infections, nutrients and xenobiotics. Crit Rev Food Sci 
Nutr 47, 499-519. 
Isolauri, E., Majamaa, H., Arvola, T., Rantala, I., Virtanen, E., Arvilommi, H., 1993, Lactobacillus casei strain 
GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 
105, 1643-1650. 
Kalliomaki, M., Isolauri, E., 2002, Pandemic of atopic diseases--a lack of microbial exposure in early in-
fancy? Curr Drug Targets Infect Disord 2, 193-199. 
Kalliomaki, M., Salminen, S., Arvilommi, H., Kero, P., Koskinen, P., Isolauri, E., 2001, Probiotics in primary 
prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357, 1076-1079. 
Kalueff, A.V., Tuohimaa, P., 2007, Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr 
Opin Clin Nutr Metab Care 10, 12-19. 
Kaper, J.B., Morris, J.G.J., Levine, M.M., 1995, Cholera. Clin Microbiol Rev 8, 48-86. 
Kato, I., Tanaka, K., Yokokura, T., 1999, Lactic acid bacterium potently induces the production of inter-
leukin-12 and interferon-gamma by mouse splenocytes. Int J Immunopharmacol 21, 121-131. 
Keusch, G.T., Atthasampunna, P., Finkelstein, R.A., 1967, A vascular permeability defect in experimental 
cholera. Proc Soc Exp Biol Med 124, 822-825. 
Kim, J.Y., Choi, Y.O., Ji, G.E., 2008, Effect of Oral Probiotics (Bifidobacterium lactis AD011 and Lactobacil-
lus acidophilus AD031) Administration on Ovalbumin-Induced Food Allergy Mouse Model. J Micro-
biol Biotechnol 18, 1393-1400. 
Kimber, I., Dearman, R.J., 2002, Factors affecting the development of food allergy. Proc.Nutr.Soc. 61, 435-
439. 
Knippels, L.M., Penninks, A.H., Smit, J.J., Houben, G.F., 1999, Immune-mediated effects upon oral chal-
lenge of ovalbumin-sensitized Brown Norway rats: further characterization of a rat food allergy 
model. Toxicol. Appl. Pharmacol. 156, 161-169. 
Kroghsbo, S., Christensen, H.R., Frokiaer, H., 2003, Experimental parameters differentially affect the 
humoral response of the cholera-toxin-based murine model of food allergy. Int.Arch.Allergy Immu-
nol. 131, 256-263. 
Ladics, G.S., 2008, Current codex guidelines for assessment of potential protein allergenicity. Food Chem 
Toxicol 46, S20-S23. 
Lange, S., Delbro, D.S., Jennische, E., Johansson, E., Lonnroth, I., 1998, Recombinant or plasma-derived 
antisecretory factor inhibits cholera toxin-induced increase in Evans blue permeation of rat intestinal 
capillaries. Dig Dis Sci 43, 2061-2070. 
Thesis De Jonge V9.pdf   27 9-10-2009   11:37:04
 28 
Lehrer, S.B., Ayuso, R., Reese, G., 2002, Current understanding of food allergens. Ann N Y Acad Sci 964, 
69-85. 
Lehrer, S.B., Bannon, G.A., 2005, Risks of allergic reactions to biotech proteins in foods: perception and 
reality. Allergy 60, 559-564. 
Li, X.M., Schofield, B.H., Huang, C.K., Kleiner, G.I., Sampson, H.A., 1999, A murine model of IgE-mediated 
cow’s milk hypersensitivity. J Allergy Clin Immunol 103, 206-214. 
Li, X.M., Serebrisky, D., Lee, S.Y., Huang, C.K., Bardina, L., Schofield, B.H., Stanley, J.S., Burks, A.W., Ban-
non, G.A., Sampson, H.A., 2000, A murine model of peanut anaphylaxis: T- and B-cell responses to a 
major peanut allergen mimic human responses. J Allergy Clin Immunol 106, 150-158. 
Li, X.M., Zhang, T.F., Huang, C.K., Srivastava, K., Teper, A.A., Zhang, L., Schofield, B.H., Sampson, H.A., 
2001, Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. 
J Allergy Clin Immunoll 108, 639-646. 
MacDonald, Monteleone, 2005, Fig 1. SCIENCE 307, 1920. 
MacDonald, T.T., 2003, The mucosal immune system. Parasite Immunol 25, 235-246. 
Maleki, S.J., 2004, Food processing: effects on allergenicity. Curr Opin Allergy Clin Immunol 4, 241-245. 
Malin, M., Suomalainen, H., Saxelin, M., Isolauri, E., 1996, Promotion of IgA immune response in patients 
with Crohn’s disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 40, 137-145. 
Marinaro, M., Staats, H.F., Hiroi, T., Jackson, R.J., Coste, M., Boyaka, P.N., Okahashi, N., Yamamoto, M., 
Kiyono, H., Bluethmann, H., al., e., 1995, Mucosal adjuvant effect of cholera toxin in mice results 
from induction of T helper 2 (Th2) cells and IL-4. J Immunol 155, 4621-4629. 
Marschan, E., Kuitunen, M., Kukkonen, K., Poussa, T., Sarnesto, A., Haahtela, T., Korpela, R., Savilahti, E., 
Vaarala, O., 2008, Probiotics in infancy induce protective immune profiles that are characteristic for 
chronic low-grade inflammation. Clin Exp Allergy 38, 611-618. 
Matsuzaki, T., Chin, J., 2000, Modulating immune responses with probiotic bacteria. Immunol.Cell Biol. 
78, 67-73. 
Matsuzaki, T., Yamazaki, R., Hashimoto, S., Yokokura, T., 1998, The effect of oral feeding of Lactobacillus 
casei strain Shirota on immunoglobulin E production in mice. J Dairy Sci. 81, 48-53. 
McClain, S., Bannon, G.A., 2006, Animal models of food allergy: opportunities and barriers. Curr Allergy 
Asthma Rep 6, 141-144. 
Mills, E.N., Mackie, A.R., 2008, The impact of processing on allergenicity of food. Curr Opin Allergy Clin 
Immunol 8, 249-253. 
Mori, C., Morsey, B., Levin, M., Gorton, T.S., De Guise, S., 2008, Effects of organochlorines, individually 
and in mixtures, on B-cell proliferation in marine mammals and mice. J Toxicol Environ Health A 71, 
266-275. 
Moro, G., Arslanoglu, S., Stahl, B., Jelinek, J., Wahn, U., Boehm, G., 2006, A mixture of prebiotic oligosac-
charides reduces the incidence of atopic dermatitis during the first six months of age. Arch Dis Child 
91, 814-819. 
Nagao, F., Nakayama, M., Muto, T., Okumura, K., 2000, Effects of a fermented milk drink containing 
Lactobacillus casei strain Shirota on the immune system in healthy human subjects. Biosci Biotechnol 
Biochem 64, 2706-2708. 
Niers, L.E., Hoekstra, M.O., Timmerman, H.M., van Uden, N.O., de Graaf, P.M., Smits, H.H., Kimpen, J.L., 
Rijkers, G.T., 2007, Selection of probiotic bacteria for prevention of allergic diseases: immunomodu-
lation of neonatal dendritic cells. Clin Exp Immunol 149, 344-352. 
Niggemann, B., Nies, H., Renz, H., Herz, U., Wahn, U., 2001, Sensitizing capacity and residual allergenicity 
of hydrolyzed cow’s milk formulae: results from a murine model. Int Arch Allergy Immunol 125, 316-
321. 
Nordlee, J.A., Taylor, S.L., Townsend, J.A., Thomas, L.A., Bush, R.K., 1996, Identification of a Brazil-nut 
allergen in transgenic soybeans. N Engl J Med 334, 688-692. 
Orlandi, A., Grasso, F., Corinti, S., Marinaro, M., Bonura, A., Boirivant, M., Colombo, P., Di Felice, G., 2004, 
The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evalua-
tion in a murine model of allergic sensitization. Clin Exp Allergy 34, 470-477. 
Thesis De Jonge V9.pdf   28 9-10-2009   11:37:05
 29 
Osborn, D.A., Sinn, J.K., 2007, Probiotics in infants for prevention of allergic disease and food hypersensi-
tivity. Cochrane Database Syst Rev, CD006475. 
Penninks, A.H., Knippels, L.M., 2001, Determination of protein allergenicity: studies in rats. Toxicol.Lett. 
120, 171-180. 
Prioult, G., Pecquet, S., Fliss, I., 2004, Stimulation of interleukin-10 production by acidic beta-
lactoglobulin-derived peptides hydrolyzed with Lactobacillus paracasei NCC2461 peptidases. Clin Di-
agn Lab Immunol 11, 266-271. 
Rautava, S., Arvilommi, H., Isolauri, E., 2006, Specific probiotics in enhancing maturation of IgA responses 
in formula-fed infants. Pediatr Res 60, 221-224. 
Rook, G.A., Adams, V., Hunt, J., Palmer, R., Martinelli, R., Brunet, L.R., 2004, Mycobacteria and other 
environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin 
Immunopathol 25, 237-255. 
Rosenfeldt, V., Benfeldt, E., Valerius, N.H., Paerregaard, A., Michaelsen, K.F., 2004, Effect of probiotics on 
gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pe-
diatr 145, 612-616. 
Rupa, P., Nakamura, S., Mine, Y., 2007, Genetically glycosylated ovomucoid third domain can modulate 
Immunoglobulin E antibody production and cytokine response in BALB/c mice. Clin Exp Allergy 37, 
918-928. 
Sack, D.A., Sack, R.B., Nair, G.B., Siddique, A.K., 2004, Cholera. Lancet 363, 223-233. 
Salminen, S., Isolauri, E., Salminen, E., 1996, Clinical uses of probiotics for stabilizing the gut mucosal 
barrier: successful strains and future challenges. Antonie Van Leeuwenhoek 70, 347-358. 
Sampson, H.A., 1992, The immunopathogenic role of food hypersensitivity in atopic dermatitis. Acta 
Derm Venereol Suppl (Stockh) 176, 34-37. 
Sampson, H.A., 1999a, Food allergy. Part 1: immunopathogenesis and clinical disorders. J Allergy Clin 
Immunol 103, 717-728. 
Sampson, H.A., 1999b, Food allergy. Part 2: diagnosis and management. J Allergy Clin Immunol 103, 981-
989. 
Sampson, H.A., 2003, 9. Food allergy. J.Allergy Clin.Immunol. 111, 540-547. 
Sampson, H.A., 2005, Food allergy--accurately identifying clinical reactivity. Allergy 60 Suppl 79, 19-24. 
Sasmal, D., Guhathakurta, B., Ghosh, A.N., Pal, C.R., Datta, A., 1995, Studies on adhesion, haemagglutina-
tion and other biological properties of Vibrio cholerae O139. FEMS Immunol Med Microbiol 10, 199-
205. 
Savilahti, E., Kuitunen, M., Vaarala, O., 2008, Pre and probiotics in the prevention and treatment of food 
allergy. Curr Opin Allergy Clin Immunol 8, 243-248. 
Schoeters, E., Verheyen, G.R., Nelissen, I., Van Rompay, A.R., Hooyberghs, J., Van Den Heuvel, R.L., Wit-
ters, H., Schoeters, G.E., Van Tendeloo, V.F., Berneman, Z.N., 2007, Microarray analyses in dendritic 
cells reveal potential biomarkers for chemical-induced skin sensitization. Mol Immunol. 
Sekizawa, J., 1998, [Health and environmental risk assessment of organotin pollution in Japan] [Article in 
Japanese]. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku, 126-131. 
Sgouras, D., Maragkoudakis, P., Petraki, K., Martinez-Gonzalez, B., Eriotou, E., Michopoulos, S., Kalant-
zopoulos, G., Tsakalidou, E., Mentis, A., 2004, In vitro and in vivo inhibition of Helicobacter pylori by 
Lactobacillus casei strain Shirota. Appl Environ Microbiol 70, 518-526. 
Shah, U., Walker, W.A., 2002, Pathophysiology of intestinal food allergy. Adv Pediatr 49, 299-316. 
Shaikh, S.R., Edidin, M., 2006, Polyunsaturated fatty acids, membrane organization, T cells, and antigen 
presentation. Am J Clin Nutr 84, 1277-1289. 
Shida, K., Takahashi, R., Iwadate, E., Takamizawa, K., Yasui, H., Sato, T., Habu, S., Hachimura, S., Kami-
nogawa, S., 2002, Lactobacillus casei strain Shirota suppresses serum immunoglobulin E and immu-
noglobulin G1 responses and systemic anaphylaxis in a food allergy model. Clin Exp Allergy 32, 563-
570. 
Thesis De Jonge V9.pdf   29 9-10-2009   11:37:05
 30 
Spanhaak, S., Havenaar, R., Schaafsma, G., 1998, The effect of consumption of milk fermented by Lacto-
bacillus casei strain Shirota on the intestinal microflora and immune parameters in humans. Eur J 
Clin Nutr 52, 899-907. 
Spok, A., Gaugitsch, H., Laffer, S., Pauli, G., Saito, H., Sampson, H., Sibanda, E., Thomas, W., van Hage, M., 
Valenta, R., 2005, Suggestions for the assessment of the allergenic potential of genetically modified 
organisms. Int Arch Allergy Immunol. 137, 167-180. 
Strachan, D.P., 1989, Hay fever, hygiene, and household size. BMJ 299, 1259-1260. 
Takeda, K., Okumura, K., 2007, Effects of a fermented milk drink containing Lactobacillus casei strain 
Shirota on the human NK-cell activity. J Nutr 137, 791S-793S. 
Tamura, M., Shikina, T., Morihana, T., Hayama, M., Kajimoto, O., Sakamoto, A., Kajimoto, Y., Watanabe, 
O., Nonaka, C., Shida, K., Nanno, M., 2007, Effects of probiotics on allergic rhinitis induced by Japa-
nese cedar pollen: randomized double-blind, placebo-controlled clinical trial. Int Arch Allergy Immu-
nol 143, 75-82. 
Tannock, G.W., 2004, A special fondness for lactobacilli. Appl Environ Microbiol 70, 3189-3194. 
Temblay, J.N., Bertelli, E., Arques, J.L., Regoli, M., Nicoletti, C., 2007, Production of IL-12 by Peyer patch-
dendritic cells is critical for the resistance to food allergy. J Allergy Clin Immunol 120, 659-665. 
Tryphonas, H., Luster, M.I., Schiffman, G., Dawson, L.L., Hodgen, M., Germolec, D., Hayward, S., Bryce, F., 
Loo, J.C., Mandy, F., et al., 1991, Effect of chronic exposure of PCB (Aroclor 1254) on specific and 
nonspecific immune parameters in the rhesus (Macaca mulatta) monkey. Fundam Appl Toxicol 16, 
773-786. 
Vandebriel, R.J., Meredith, C., Scott, M.P., Roholl, P.J., Van Loveren, H., 1998, Effects of in vivo exposure 
to bis(tri-n-butyltin)oxide, hexachlorobenzene, and benzo(a)pyrene on cytokine (receptor) mRNA 
levels in cultured rat splenocytes and on IL-2 receptor protein levels. Toxicol Appl Pharmacol 148, 
126-136. 
Vaz, N.M., Phillips-Quagliata, J.M., Levine, B.B., Vaz, E.M., 1971, H-2-linked genetic control of immune 
responsiveness to ovalbumin and ovomucoid. J Exp Med 134, 1335-1348. 
Vaz, N.M., Vaz, E.M., Levine, B.B., 1970, Relationship between histocompatibility (H-2) genotype and 
immune responsiveness to low doses of ovalbumin in the mouse. J Immunol 104, 1572-1574. 
Viljanen, M., Kuitunen, M., Haahtela, T., Juntunen-Backman, K., Korpela, R., Savilahti, E., 2005, Probiotic 
effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis 
syndrome infants. Pediatr Allergy Immunol 16, 65-71. 
Vollaard, E.J., Clasener, H.A., 1994, Colonization resistance. Antimicrob Agents Chemother 38, 409-414. 
Vos, J.G., de Klerk, A., Krajnc, E.I., Kruizinga, W., van Ommen, B., Rozing, J., 1984, Toxicity of bis(tri-n-
butyltin)oxide in the rat. II. Suppression of thymus-dependent immune responses and of parameters 
of nonspecific resistance after short-term exposure. Toxicol Appl Pharmacol 75, 387-408. 
Vos, J.G., De Klerk, A., Krajnc, E.I., Van Loveren, H., Rozing, J., 1990, Immunotoxicity of bis(tri-n-
butyltin)oxide in the rat: effects on thymus-dependent immunity and on nonspecific resistance fol-
lowing long-term exposure in young versus aged rats. Toxicol Appl Pharmacol 105(144-155. 
Vos, J.G., Dybing, E., Greim, H.A., Ladefoged, O., Lambre, C., Tarazona, J.V., Brandt, I., Vethaak, A.D., 
2000, Health effects of endocrine-disrupting chemicals on wildlife, with special reference to the 
European situation. Crit Rev Toxicol 30, 71-133. 
Wang, Y., Zhou, J., Liu, B., 2007, Decreased suppression of immune stimulatory CpG motifs in plant DNA. 
Immunol Lett 114, 73-80. 
Weiner, H.L., 2000, Oral tolerance, an active immunologic process mediated by multiple mechanisms. J 
Clin Invest 106, 935-937. 
WHO, 1999, Concise International Chemical Assesment Document 14: Tributyltinoxide. website: 
http://www.who.int/ipcs/publications/cicad/en/cicad14.pdf; visited at December 7, 2004 Geneva 
1999, Switzerland, 1-29. 
WHO-IPCS, 1999, Concise International Chemical Assesment Document 14: Tributyltinoxide. website: 
http://www.who.int/ipcs/publications/cicad/en/cicad14.pdf; visited at December 7, 2004 Geneva 
1999, Switzerland, 1-29. 
Thesis De Jonge V9.pdf   30 9-10-2009   11:37:05
 31 
Williams, N.A., Hirst, T.R., Nashar, T.O., 1999, Immune modulation by the cholera-like enterotoxins: from 
adjuvant to therapeutic. Immunol Today 20, 95-101. 
Wilson, A.D., Bailey, M., Williams, N.A., Stokes, C.R., 1991, The in vitro production of cytokines by muco-
sal lymphocytes immunized by oral administration of keyhole limpet hemocyanin using cholera toxin 
as an adjuvant. Eur J Immunol 21, 2333-2339. 
Wood, R.A., 2003, The natural history of food allergy. Pediatrics 111, 1631-1637. 
Xu-Amano, J., Kiyono, H., Jackson, R.J., Staats, H.F., Fujihashi, K., Burrows, P.D., Elson, C.O., Pillai, S., 
McGhee, J.R., 1993, Helper T cell subsets for immunoglobulin A responses: oral immunization with 
tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tis-
sues. J Exp Med 178, 1309-1320. 
Yardley, J.H., Brown, G.D., 1973, Horseradish peroxidase tracer studies in the intestine in experimental 
cholera. Lab Invest 28, 482-493. 
Yasui, H., Shida, K., Matsuzaki, T., Yokokura, T., 1999, Immunomodulatory function of lactic acid bacteria. 
Antonie Van Leeuwenhoek 76, 383-389. 
Yoshizawa, K., Heatherly, A., Malarkey, D.E., Walker, N.J., Nyska, A., 2007, A Critical Comparison of Mur-
ine Pathology and Epidemiological Data of TCDD, PCB126, and PeCDF. Toxicol Pathol 35, 865-879. 
 
Thesis De Jonge V9.pdf   31 9-10-2009   11:37:05
 Thesis De Jonge V9.pdf   32 9-10-2009   11:37:05
 33 
 
Chapter 2   
The importance of dietary control in the 
development of a peanut allergy model 
in Brown Norway rats 
 
 
 
 
Published in Methods 41, 99-111 (2007).
Thesis De Jonge V9.pdf   33 9-10-2009   11:37:05
 34 
ABSTRACT 
This report describes the further development of a peanut allergy model in Brown 
Norway (BN) rats and in particular the importance of allergen-free breeding of the 
laboratory animals for the allergen to be used. For this purpose BN rats were bred 
for 3 generations on soy- and peanut-free feed since it is known that the legumes 
peanut and soy are cross-reactive. In addition, the effect of cholera toxin (CT), an 
oral adjuvant often used to increase the sensitivity of food allergy models, was in-
vestigated in the BN rat model. BN rats that were bred on both soy- and peanut-free 
feed could be sensitized orally to peanut (all exposed rats developed peanut-specific 
IgE, IgG2a and IgG1) and the adjuvant CT could only enhance this sensitization to a 
limited extent. We also found different protein recognition patterns against purified 
peanut allergens (Ara h1, Ara h2 and Ara h3) between intraperitoneally (i.p.) and 
orally sensitized BN rats. Orally sensitized rats recognized all tested allergens 
whereas i.p. sensitized rats only recognized Ara h1 and Ara h2. Our conclusion is 
that a model for food allergy should preferably be (A) oral and (B) if possible with-
out the use of adjuvantia. Our model in BN rats unites these preferred characteris-
tics. In addition, we show the importance of dietary control when conducting oral 
sensitization studies. Special attention must be paid to unscheduled dietary pre-
exposure of the animals to the protein under investigation to obtain optimal oral 
sensitization. 
 
 
INTRODUCTION 
The incidence of adult food allergy is estimated at approximately 3%, but in young 
children it is thought to be as high as 6% [1]. Although food allergic children often 
outgrow their food allergy, once established in adults food allergy is rarely cured [2]. 
There are indications that the prevalence of food allergy has risen substantially over 
the past decade [1,3]. Food allergic individuals often have difficulties in determining 
which food products they can safely consume. Recently, the European Union, the 
USA, and other countries have released new regulations to ensure that major aller-
genic foods and products derived from them, or composed ingredients, are labelled 
on pre-packaged foods when present based on recipe [4]. It should be noted, how-
ever, that contamination of pre-packaged food with allergens is not covered by this 
Directive. The major allergenic foods that are concerned in the new EU directive [5] 
on labelling of foods (Directive 2003/89/EC) include peanuts, cereals containing 
gluten, crustaceans, eggs, fish, soybeans, milk, nuts, celery, mustard, and sesame 
seeds. Peanut allergy deserves special attention for several reasons. Peanut domi-
nates the list of food allergens implicated in fatal and near-fatal allergic reactions 
and as many as one third of peanut-sensitive patients have severe challenge reac-
tions [6]. Unlike most food allergies peanut allergy tends to be a lifelong problem 
for approximately 80% of the peanut allergic population [7,8]. Several peanut pro-
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teins belonging to different families of seed storage proteins have been identified 
by immunoblotting as major or minor allergens for humans and seven of them have 
been characterized and officially termed Ara h1-7 [9]. Although the allergens listed 
in the EU-Directive are responsible for the majority of allergic reactions, many other 
allergenic proteins are not covered by this labelling directive. An issue that received 
much attention during the past years is the possible introduction of new allergens 
by genetic modification of foods. Such techniques may be associated with the po-
tential risks of allergic reactions to proteins expressed by the newly introduced 
genes. The need for a widely accepted and validated animal model to test the po-
tential allergenicity and potency of (novel) proteins has therefore become an impor-
tant issue for their safety evaluation. 
Animal models have been suggested as a tool that could help to evaluate the poten-
tial allergenicity of such foods. In addition to identifying new food allergens, such 
models may also be helpful in investigating the influence of the food matrix, includ-
ing food additives and contaminants, on dose-response relationships of allergens 
and food allergic responses. This is of importance since some food constituents 
have the potential to modulate allergic responses to allergens. 
 
An oral food allergy model in the Brown Norway rat 
Food allergy is a type I (IgE-mediated) hypersensitivity reaction to an offending 
food. This IgE-dependent allergic reaction is composed of two phases; a sensitiza-
tion and a challenge phase. During the sensitization phase the immune system of 
the host is sensitized by the allergen, resulting in production of specific anti-allergen 
IgE antibodies. These antibodies are fixed by mast cells in various organs and tis-
sues. In the challenge phase, the renewed exposure to the allergen will result in 
binding of the allergens to these fixed IgE antibodies and the release of various 
mediators from these mast cells which are responsible for the subsequent clinical 
reactions. For evaluating the allergenicity of food antigens, both phases should be 
examined by appropriate tests in in vivo animal models [10]. An important aspect 
for these food allergy models is that attention must be given to the unscheduled 
dietary pre-exposure of the test animals and their parental generations to the aller-
gen under investigation as this may result in tolerance induction. In addition, sensi-
tization and challenge should preferably be orally, because natural barriers (for 
instance gastro-intestinal acid denaturation, enzymatic digestion and muco-
sal/epithelial layers) and intestinal flora might influence the allergenicity of pro-
teins. If possible, adjuvants should not be used as these may add to the complexity 
of the model. Test animals must be capable of producing significant amounts of IgE- 
and/or other Th2-specific antibody (sub)classes, and these antibody responses 
should be directed to similar proteins (and allergenic epitopes) as found in patient 
sera. Ideally, test animals should show clinical reactions with respect to organ sensi-
tivities that reflect responses seen in humans upon a challenge with the allergen. 
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Finally, the model should be relatively easy to conduct and reproducible in time and 
different laboratories [11]. Although all these criteria are difficult to attain in one 
model, an oral food allergy model developed in Brown Norway (BN) rats might pro-
vide a suitable model to study the allergenicity of food proteins in humans [12-23]. 
This high-immunoglobulin (particularly IgE) responder rat strain resembles, to a 
certain degree, atopic humans in their genetic predisposition to react with an over-
production of IgE to antigens. In addition, clinical reactions, like an increased gut 
permeability and changes in blood pressure and respiratory function, were ob-
served in BN rats after an oral challenge [23] and the profile of allergens recognized 
by the immune system of the BN rat appeared comparable with the profile of aller-
gens recognized by allergic patients [24]. An important advantage of the BN rat 
model above other animal models [25-28] is the oral application of proteins without 
the use of an adjuvant, which mimics the relevant route of exposure in humans. 
The standard protocol for sensitizing BN rats is based on the results of various stud-
ies with mainly ovalbumin (OVA) as allergen [12-15]. These studies revealed that the 
best results were obtained from daily intragastric dosing with allergen during 42 
days. The sensitizing effects of allergens were determined by measurements of 
allergen-specific IgE and IgG antibodies in sera. In rats, IgE and IgG2a are considered 
to be controlled by Th2 cytokines, whereas IgG1 is known to be controlled by Th1 
cytokines. For evaluation of the in vivo challenge reactions by an allergen, sensitized 
rats can be orally challenged with a high dose of the allergen followed by e.g. de-
termination of the level of rat mast cell protease II (RMCP-II) in the serum. This 
protease is selectively expressed by intestinal mucosal mast cells in the rat and is a 
specific marker for mast cell activation that can be measured in serum [29]. 
Soybean and peanut are members of the legume family and share several common 
antigenic fractions. Patients allergic to one of these foods have serum IgE antibodies 
that immunologically cross-react with other legumes [30,31]. Because exposure of 
the parental generation to the antigen under investigation influences the outcome 
of oral sensitization studies with the offspring, at least two generations of animals 
should be bred on a diet free of the antigen under investigation or of antigens that 
can cross-react with this antigen for animals to be immunologically naïve. Knippels 
et al. [32] described that soy-specific IgG antibodies could not be detected after two 
generations bred on soy-free diet. 
We describe herein the further development of the food allergy model in the BN rat 
as earlier presented by Knippels et al. [15], and in particular the importance of aller-
gen-free breeding of the laboratory animals used for this model [32,33], for this 
purpose we used BN rats that were bred 3 generations on soy- and peanut-free 
feed. As in our original efforts to use the BN model to study allergenicity of peanuts 
often animals did not respond, we also investigated the effect of cholera toxin (CT), 
an oral adjuvant [34-38] often used in food allergy models to increase the sensitivity 
of the model [27,39-45]. CT is a major enterotoxin produced by the bacterium Vibrio 
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Cholerae. It is known for its properties to increase gut permeability [46-51], thereby 
enhancing allergen uptake. Adjuvation with CT is often used in food allergy models 
because oral administration of Ag with CT stimulates strong responses to mucosally 
delivered antigens, by inducing an antigen-specific type 2 response [26,27,34,39-
41,52] or a mixed Th1 + Th2 response [53,54], including IgE, but with a bias toward 
Th2 [54-56]. 
The use of adjuvantia is controversial especially for the development of predictive 
animal models, because it is not clear how adjuvants affect the immune response in 
the sensitization process and therefore it is impossible to determine the inherent 
potential of a given protein to induce allergic sensitization (IgE antibody responses). 
A predictive model without adjuvant is therefore desirable, because it would reduce 
the risk of false positives. 
 
 
DESCRIPTION OF METHODS 
Animals 
Oral sensitization was studied in young Brown Norway (BN) rats. In the first study 
(experiment A) Brown Norway (BN Rij:Hsd) rats obtained from Harlan Netherlands 
B.V. (Horst, the Netherlands) were used. These rats were bred and raised on a pea-
nut and soy protein-free diet obtained from Harlan Netherlands B.V (2016S Teklad 
Global 16% Protein Rodent Diet) at our institute. In this experiment, female rats of 
the third generation (F3) and onwards were used and fed the peanut and soy pro-
tein-free diet during the experiments. At study initiation rats were 3-4 weeks old. 
In the second study (experiment B) male BN rats directly obtained from Charles 
River (Sulzfeld, Germany) were used. These rats were raised on a commercially 
available peanut- and whey-protein-free diet (LAD1, Special Diet Services, Witham, 
England). 
The rats were housed in an animal room maintained at 23 ± 30C, with a light/dark 
cycle of 14 h/10 h, and a relative humidity of 30-70% during the experiment and for 
at least 7 days prior to study initiation. The animals were housed in stainless-steel 
wire (Macrolon III) cages in groups of two (experiment A) or five (experiment B) and 
had free access to food and tap-water. Approval from the Institutional Animal Ethics 
Committee was obtained for all experimental procedures involving animals. 
 
Preparation of peanut extract 
Lightly blanched (100°C) peanuts (Arachis Hypogaea) from the USA Runner cultivar 
were kindly provided by IMKO Gelria (Doetinchem, The Netherlands) and were 
stored at 4°C until use. Peanut extract was prepared according to the method de-
scribed by Koppelman et al. [57] with some minor modifications. Peanuts were 
ground using a food mixing machine equipped with shredding knifes and stored at -
20°C. Extracts for sensitization were prepared by mixing 1 kg ground peanut with 4 
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L PBS and for the oral challenge by mixing 750 g ground peanut with 500 ml PBS at 
room temperature. After stirring the mixture overnight at 4°C, the aqueous fraction 
was collected by centrifugation for 30 minutes at 3000 G at room temperature. The 
aqueous fraction was subsequently centrifuged for 30 minutes at 8000 G at room 
temperature, to remove residual traces of fat and insoluble particles. The remaining 
aqueous fraction was homogenized and is further referred to as peanut extract (PE) 
and protein concentrations were determined using a bicinchoninic acid (BCA) pro-
tein assay obtained from Pierce (Rockford, USA) according to the manufacturer’s 
instructions. Separate portions of 1 and 10 mg/ml PE for sensitizing and 50 mg/ml 
PE for the oral challenge were stored at -20°C in aliquoted portions until use. 
 
Endotoxin content 
The endotoxin content of the PE (33.6 mg/ml in PBS) was assessed chromatographi-
cally by quantitative limulus amebocyte (LAL) assay according to the manufacturer’s 
instructions in a microtitre 96 flat-bottomed well plate format (Cambrex BioSci-
ences, Wokingham, UK). Serial dilutions of proteins were generated using en-
dotoxin-free water (Cambrex) in endotoxin free test tubes, and all solutions were 
vortexed for 1 min prior to diluting or plating. Protein solution (100 l) or endotoxin 
standard (Escherica coli 055:B5 endotoxin; range 0.005 to 50 EU/ml) was incubated 
(10 min at 37˚C in an incubating plate reader) prior to addition of the Kinetic-QCL 
reagent (a co-lyophilized mixture of lysate prepared from the circulating amoebo-
cytes of the horse shoe crab Limulus polyphemus and chromogenic substrate; 100 
µl per well (Cambrex)). Samples were monitored automatically over time in an incu-
bating plate reader for the appearance of a yellow color. The reaction time is in-
versely proportional to the amount of endotoxin present; that is, the higher the 
concentration of endotoxin, the shorter the reaction time. Samples were tested in 
quadruplicate, with two of these containing the test protein alone and two of these 
containing test protein which is spiked with 0.5 EU endotoxin, as a quality control to 
check the recovery of endotoxin by the assay. Endotoxin standards were tested in 
duplicate. PBS was used as negative control sample. All the PE samples had en-
dotoxin levels < 0.01 EU/ml and since levels of endotoxin of 100 EU/mg of protein 
appear to be without marked effect on IgE anti-protein responses, these endotoxin 
levels were considered very low. 
 
Purification of Ara h1, Ara h2 and Ara h3 
Ara h1 and Ara h2 were purified as described by de Jong et al. [58] and Ara h3 was 
purified as described by Koppelman et al. [57]. 
All steps were performed at room temperature. Lyophilized crude peanut extract 
was dissolved in 20 mM Tris-bis-propane (TBP), pH 7.2 to a final concentration of 1 
mg/ml. Undissolved particles were removed by centrifugation (15 min. at 3000 G) 
and the solution was applied on a 8 ml source Q column (1x10 cm), equilibrated 
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with TBP. After rinsing the column with 80 ml of TBP, a linear gradient of 200 ml (0-
1M NaCl in TBP) was applied to elute the bound proteins (2 ml/min.) Fractions of 4 
ml were collected and analyzed by SDS-PAGE using 8-25% gels essentially as de-
scribed under header SDS-PAGE. To remove traces of peanut lectin from Ara h2 (less 
than 1%), Ara h2 was dialyzed against 50 mM NaAc, pH 5.0 and loaded on a 1 ml 
Source S column (0.5x5 cm) equilibarated with 50 mM NaAc, pH 5.0. After washing 
with 10 ml of 50 mM NaAc, pH 5.0, the column was eluted using a 25 ml linear gra-
dient (0-500 mM NaCl in 50 mM NaAc, pH 5.0) with a flow velocity of 0.25 ml/min. 
Fractions of 0.5 ml were collected and analyzed by SDS-PAGE. Peanut allergens were 
stored at -30°C until use. Purified Ara h1 and Ara h2 blotted on PVDF membranes 
and blot fragments were N-terminal sequenced using a gas-phase sequenator (per-
formed at SECU, Utrecht, the Netherlands). Ara h3 was purified essentially in the 
same way. 
 
SDS-PAGE 
To verify whether the peanut extract contained the major allergens (Ara h1, Ara h2 
and Ara h3) SDS-PAGE was performed essentially according to Laemlli [59] using a 
BioRad Mini Protean II system (BioRad, Hercules, CA) with 15% acrylamide gels 
(15 cm × 10 cm). Pre-stained molecular weight markers (BioRad) with molecular 
weights of 6.4, 21.3, 29.2, 35.8, 49.8, 93, 115 and 198 kDa were used as reference. 
Undiluted sample, 2x diluted sample and 10x diluted sample were mixed in a 1 : 1 
ratio with 2x concentrated SDS-PAGE extraction buffer (130 mM Tris with 4.6% 
(w/v) SDS, 20% (v/v) glycerol and 0.02% bromophenol blue, pH 8.0) containing 0.5% 
dithiotreitol (DDT) and were subsequently boiled for 5 min. The electrophoresis was 
performed in electrophoresis buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) at 80 V 
for approximately 20 min. and hereafter at 200 V until the samples were reaching 
the end of the gel. The stacking gel part was cut-off after which the staining steps 
were started. Gels were stained with Coomassie Brilliant Blue R-250 solution (0.25% 
(w/v) Coomassie Brilliant Blue R-250 in methanol-water-glacial acetic acid (5-5-1)) 
overnight. The gels were destained with decoloration fluid (volume ratios of acetic 
acid:ethanol:distilled water as follows: 1:3:6). After destaining, gels were scanned 
with a Hewlett-Packard ScanJet IIC/ADF obtained from Hewlett-Packard France 
(Paris, France). 
The protein composition profile of peanut extract as used for experiment A can be 
found in Figure 1 and was comparable to that described by de Jong et al. [58]. In 
addition, the protein composition for experiment B as prepared by TNO Quality of 
Life (Zeist, The Netherlands) was also similar to the composition as used for experi-
ment A. Furthermore, the protein composition profiles displayed the Ara h1, Ara h2 
and Ara h3 bands as described by Koppelman et al. [57]. 
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FIGURE 1. Peanut extract protein composition by SDS-PAGE 
Peanut extract (PE) was isolated as an aqueous fraction from ground peanut in PBS by centrifugation 
steps and this extract’s protein composition was analyzed by SDS-PAGE. Column A was loaded with 74.27 
µg PE/slot, column B was loaded with 37.14 µg PE/slot, column C was loaded with 7.43 µg PE/slot and 
column D was loaded with molecular weight markers with their weights mentioned in the figure. 
 
Experimental design oral sensitization 
To ensure the use of immunologically naive animals with respect to peanut, 
pre-study blood samples were always tested for peanut protein specific antibodies. 
Then, rats were randomly allocated to their dosing regimens (n=8 per dosing regi-
men for experiment A), some reallocation was performed to ensure even starting 
weight distribution in all dosing regimens. For experiment A rats were exposed to 0, 
1 or 10 mg/ml PE in PBS by daily gavage, using a 18-gauge stainless steel animal 
feeding needle (1 ml/animal) during 6 weeks, with and without the use of the adju-
vant cholera toxin (CT; 1 µg/rat/day). In rats that were coexposed to CT daily CT 
gavage dosing started one week prior (day -7) to exposure to the allergen. 
 CT (azide free) was obtained from List Biological Laboratories, Inc. (Campbell, CA, 
USA). For experiment B the same sensitization procedure was used, without admini-
stration of an adjuvant. For experiment B dosing regimens 0 and 10 mg PE/day/rat 
consisted of 10 rats/ dosing regimen, while 20 rats were used for dosing regimen 1 
mg PE/rat/day. Blood samples were obtained from the tail vein at two-weekly inter-
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vals (day 14, 28 and 42 after start sensitization to PE). After coagulation for 1 h at 
room temperature, the blood samples were centrifuged (Heraeus Sepatech Biofuge 
13, Osterode, Germany) for 15 min. at 3000 G and 40C to obtain sera. The sera were 
stored at -800C until analyses for PE-specific IgE and IgG titres and RMCP-II levels by 
Enzyme Linked Immunosorbent Assay (ELISA). 
After the sensitization period (day 42), animals were not exposed for one week and 
were deprived of their food one day prior to sacrifice (day 49). At day 49, all rats 
were orally challenged by intragastric intubation with PE (2 mL of a 50 mg/mL solu-
tion). Thirty minutes after the oral challenge, the animals were sacrificed by exsan-
guination from the aorta under CO2/O2 anesthesia. Blood samples from the orbital 
plexus (0.5 ml/rat) collected in K3-EDTA tubes obtained from Terumo Europe N.V. 
(Leuven, Belgium) were used for the determination of differential cell types in 
blood. Also blood was taken by exsanguinations from the abdominal aorta and from 
this blood serum samples were prepared as described above. Spleens were re-
moved aseptically, weighed and single cell suspensions were prepared for cytokine 
analysis after ex-vivo re-stimulation with antigen. 
 
Experimental design intraperitoneal sensitization 
BN rats bred on a commercially available whey- and peanut-free rodent diet (LAD1; 
Special Diet Services, Witham, England) were sensitized by intraperitoneal (i.p.) 
injection of 0.5 ml of a 0.2 mg PE/ml solution in sterile PBS on days 0, 2, 4, 7, 9 and 
11. To potentiate the immune response, 0.2 ml of a 25 mg/ml alum adjuvant sus-
pension (Pierce) in sterile saline mixed with the 0.5 ml of PE-solution was injected 
on day 0. The animals were bled on day 28 by exsanguation from the abdominal 
aorta and serum was prepared as described above. Sera were used to determine 
IgG2a against Ara h1, Ara h2 and Ara h3. 
 
PE-DIG coupling 
Peanut protein-Digoxigenin (PE-DIG) coupling was established using a DIG-protein 
labeling kit obtained from Roche Diagnostics GmbH (Mannheim, Germany) accord-
ing to manufacturer’s instructions except for the following changes: 50 μL of a 20 
mg/mL digoxigenin-3-0-succinyl-ε-aminocaproic acid-N-hydroxy-succinimide ester 
(DIG-NHS) solution in DMSO was added to 1 mL of a 6 mg/mL solution of crude PE 
extract in PBS, from this point on the manufacturer’s instructions were followed. A 
1:2000 dilution of PE-DIG was used in the assay. 
 
Negative and positive control sera for Ig ELISAs 
Pooled serum, obtained from male F3 BN rats which were not exposed to peanut 
allergens, was used as negative control. Positive control sera were obtained by i.p. 
injections of female F3 BN rats with 0.5 ml of a 0.2 mg PE/ml solution in sterile PBS 
on days 0, 2, 4, 7, 9 and 11. To potentiate the immune response, 0.2 ml of a 40 
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mg/ml alum adjuvant suspension (Pierce) in sterile saline mixed with the 0.5 ml of 
PE-solution was injected on day 0. The animals were bled on day 28 by exsanguation 
from the abdominal aorta. Sera were prepared and stored as described above. 
These sera were pooled and used as positive control sera in the PE-specific Ig ELI-
SAs. 
 
PE- specific Ig ELISAs 
Positive and negative controls were incorporated in each plate of all Ig-ELISAs. After 
each incubation plates were washed six times with 300 μL PBS containing 0.1% 
Tween 20 using an ELISA washer (Auto plate washer ELX405R, Biotek Instruments 
Inc., Winooski, VT, USA). 
PE-specific IgE ELISA 
For detection of PE-specific IgE, a sandwich ELISA was performed. Microtitre plates 
(for all ELISAs: F96 Cert.Maxisorp no. 439454 Nunc-Immuno Plate, Nunc A/S, 
Roskilde, Denmark) were coated overnight at 4 °C with 100 μL/well of a 1.5 μg/mL 
dilution of mouse anti-rat IgE (MARE; Zymed, San Francisco, USA) in carbonate-
bicarbonate buffer (pH 9.6). Then, 200 μL/well of a postcoat solution (Tris Buffered 
Saline containing 1% bovine serum albumin (TBS-BSA, Sigma-Aldrich, St Louis, USA) 
was added and incubated 30 minutes at room temperature. Serial dilutions (starting 
at a 1:4 dilution) of rat serum (test sera and control sera) in standard diluent (post-
coat solution with 0.5% Tween 20) were added to the wells and incubated for 1h at 
room temperature. Next, 100 μL/well PE-DIG conjugate was added and incubated 
for 1h at 37 °C. Followed by the addition of 100 μL/well of a 625x dilution of 50U/mL 
anti-diogoxigenin-POD (poly) Fab Fragments (anti-DIG-POD) obtained from Roche 
Diagnostics GmbH in standard diluent. After incubation for 2h at 37 °C, the plates 
were incubated with TMB substrate and the enzyme reaction was stopped with 2 M 
H2SO4 and absorbance was read at 450 nm with an ELISA plate reader (Fluostar 
Galaxy, BMG Labtechnologies GmbH, Offenburg, Germany). The 2log titre in the 
samples was determined by using the average extinction in the plates’ negative 
control wells, to which three times the standard deviation was added as a cutoff. 
PE-specific IgG1 and IgG2a ELISA 
For detection of peanut-specific IgG1 and IgG2a, 96-wells microtitre plates were 
coated with 100 L/well of a 100 μg/mL solution of PE-extract in PBS. The plates 
were washed and blocked by addition of 200 μL/well postcoat solution. After 30 
minutes incubation at room temperature, the plates were washed and serial dilu-
tions (starting at a 1:128 dilution) of rat serum (test sera and control sera) in stan-
dard diluent were added to the wells and incubated for 1h at room temperature. 
After washing, 100 μL/well of an anti-IgG1 or anti-IgG2a horse radish peroxidase 
conjugate (Research Diagnostics Inc., Flanders, USA) in standard diluent was added 
(20000x diluted) and incubated for 1h at room temperature. Plates were washed 
again and 100 μL of TMB substrate solution was added. The color reaction was 
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stopped by adding 100 μL/well 2M H2SO4 and optical densities were read at 450 nm. 
Calculation of PE-specific IgG1 and IgG2a titres was the same as described for IgE 
ELISAs. 
To determine specific IgG2a antibodies against the purified allergens, plates were 
coated with 5 µg/ml Ara h1, Ara h2 or Ara h3 solution in carbonate buffer. After 
coating the protocol was similar as described above for the PE-specific IgG2a ELISA, 
with exception of the start dilution of the sera (1:8). The absorbance of 1:8 sera 
dilutions from control animals typically would not exceed an optic density (OD) at 
450 nm of 0.2; this was the case for all three purified peanut allergens. In order to 
discriminate between IgG2a high and low responders for the specific purified aller-
gens we set an arbitrary cut-off point for IgG2a high responders at an OD at 450 nm 
of at least 0.6 for 1:8 sera dilutions. 
 
Measurement of Rat mast cell protease II 
Rat mast cell protease II (RMCPII) concentrations were determined in day 42 and 49 
sera with a RMPCII ELISA kit (Moredun Scientific Limited, Penicuik, Midlothian, Scot-
land, UK) according to manufacturer’s instructions. 
 
Differential cell counting 
Blood samples, obtained on day 49 were diluted 1:1 in a solution of Bovine Serum 
Albumin (Fraction V, purity ≥ 96%; Sigma-Aldrich) in saline (40 g/L). The number of 
white blood cells (WBC), lymphocytes, eosinophils and basophils in the blood were 
counted with Bayer Advia 120 Hematology System (Bayer HealthCare, Diagnostics 
division, Tarrytown, NY, USA). 
 
Cell culture 
For in vitro restimulation of spleen cells, 50 mg/mL PE was filtrated using a syringe 
driven filter unit (Millipore Millex-HA 0.45 μm, Millipore, Billerica, USA) and diluted 
in RPMI 1640 + 25 mM Hepes + L-Glutamine obtained from Gibco BRL (Breda, the 
Netherlands) supplemented with 10% heat inactivated fetal calf serum (FCS) ob-
tained from Integro B.V. (Zaandam, The Netherlands) and 1% penicillin-
streptomycin (Gibco). This medium will be referred to as standard medium. Spleens 
were dissected at day 49 and collected in standard medium with 5% FCS. Single cell 
suspensions were prepared by pressing spleens through a 70 μm nylon cell strainer 
(Falcon, BD Biosciences, Franklin Lakes, USA) using a 5 mL Falcon syringe plunger. 
Cells were washed twice in 30 mL standard medium (1500 rpm, 10 minutes, 4 °C) 
and resuspended in 5 mL (spleen) or 2 mL (MLN) standard medium with 10% FCS 
and 7.5x10-5 M 2-mercaptoethanol (2-ME) obtained from SERVA (Heidelberg, Ger-
many). The concentration of the cell suspensions was adjusted to 4x106 cells/mL in 
standard medium with 10% FCS and 2-ME. Cell suspensions, were incubated with PE 
(0, 0.5 and 1 mg/ml) in cell cultures (4x105 cells/well) for 96 h. Cell cultures incu-
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bated for 48h with 3.33 µg/mL of the mitogen Concanavalin A (ConA; ICN Biomedi-
cals Inc., Irvine, USA) were used as positive controls. In the supernatants IFN-γ and 
IL-4 were determined by ELISA. 
 
Cytokine ELISAs 
IFN-γ 
A rat IFN-γ ELISA set (Rat IFN-γ BD OptEIA ELISA set; BD Biosciences, Erembodegem, 
Belgium) and Reagent set (IFN-γ BD OptEIA Reagent Set B, BD Biosciences) were 
used for detection of IFN-γ according to manufacturer’s instructions. Briefly: plates 
were coated overnight at 4 °C with anti-rat IFN-γ monoclonal antibody diluted 1:250 
in coating buffer (0.1 M Sodium Carbonate). The following day, plates were washed 
with 300 μL/repeat PBS containing 0.1% Tween 20 (Sigma-Aldrich) and blocked with 
200 μL/well assay diluent (PBS with 10% fetal bovine serum) for 1 h at room tem-
perature. After washing, samples and IFN-γ standards were added and incubated for 
2 h at room temperature. IFN-γ standards were added in duplo (start concentration 
= 2000 pg/mL) and diluted in assay diluent to a concentration of 7.81 pg/mL. Six 
wells per plate contained only assay diluent and were used as blanks. Plates were 
washed and incubated with 100 μL/well of a 1:250 dilution of biotinylated anti-rat 
IFN-γ monoclonal antibody in assay diluent for 1 h at room temperature. After 
washing, 100 μL/well of a 1:250 dilution of avidin-horseradish peroxidase conjugate 
in assay diluent was added and plates were incubated for 30 minutes at room tem-
perature. Plates were washed again and incubated with 100 μL/well of a substrate 
solution (containing TMB and hydrogen peroxide) for 30 minutes at room tempera-
ture. Then, the color reaction was stopped with stop solution (H2SO4) and absorb-
ance was measured at 450 nm using an ELISA plate reader (Fluostar Galaxy, BMG 
Labtechnologies GmbH). IFN-γ concentrations in samples were determined using 
the standard curve, corrected for deducted average absorbance of the blanks. 
IL-4 
IL-4 was measured using a rat IL-4 cytosets kit obtained from BioSource (Camarillo, 
CA, USA) according to the manufacturer’s instructions. Briefly: plates were coated 
overnight at 4 °C with 100 μL/well of a 1.25 μg/mL solution of rat IL-4 antibody in 
coating buffer (8.0 g NaCl, 1.42 g Na2HPO4 2H2O, 0.2 g KH2PO4 and 0.2 g KCl in 1L 
distilled water; all chemicals from Merck, Darmstadt, Germany). The plates were 
washed six times with 300 μL/repeat PBS containing 0.1% Tween 20 (Sigma-Aldrich). 
This was followed by the addition of 200 μL/well of TBS-BSA (Sigma-Aldrich). After 2 
h incubation at room temperature, the plates were washed six times. IL-4 standards 
were added in duplo at a start concentration of 1000 pg/mL and diluted in TBS-BSA 
containing 0.05% Tween 20 until a concentration of 3.7 pg/mL was reached. Super-
natants were added to the wells and were incubated for 90 minutes at room tem-
perature. After washing, 100 μL of a 0.05 μg/mL solution of rat IL-4 biotinylated 
antibody in TBS-BSA with 0.05% Tween 20 was added and incubated for 1h at room 
Thesis De Jonge V9.pdf   44 9-10-2009   11:37:06
 45 
temperature. Then, plates were washed again and 100 μL/well of a 0.15 μg/mL 
solution of streptavidin-horseradish peroxidase conjugate (in TBS-BSA with 0.05% 
Tween 20) was added. After incubation (45 minutes at room temperature), plates 
were washed and 100 μL of an enzyme substrate solution (see Ig ELISAs) was added. 
The plates were developed at room temperature for 30 minutes. Finally, 100 
μL/well 2M H2SO4 (Merck) was added and absorbance was measured at 450 nm 
using an ELISA plate reader (Fluostar Galaxy, BMG Labtechnologies GmbH). IL-4 
concentrations in samples were determined using the standard curve, corrected for 
deducted average absorbance of the blanks. 
 
Statistics 
Differences between peanut dosage groups in 2log IgE and IgG titres, RMCPII con-
centrations, and cytokine levels were analyzed using one-way ANOVA, with Bon-
ferroni as a post hoc test. The number of immune cells in blood was log-transformed 
prior to analysis, because these data did not meet the prerequisite of ANOVA that 
data should be normally distributed. 
In order to investigate the effect of the usage of CT the above mentioned one-way 
ANOVA was also performed in the CT-modulated group. Furthermore, the influence 
of an adjuvant on dose-response relationships between PE-exposure groups was 
analyzed by comparing data of the CT-coexposed group with data of the non-
adjuvated group. Differences between these two groups were analyzed using two-
way Analysis Of Variance (ANOVA) with Bonferroni for pairwise comparisons as post 
hoc test. Finally, the effect of the adjuvant was analyzed separately for each of the 
three PE dose levels (by splitting on PE-exposure) using a one-way ANOVA. This 
additional test was performed to investigate if CT influenced the outcome of an 
immunological parameter within a certain PE-exposure group. 
In all analyses, data were considered significantly different if p < 0.05.  
 
 
RESULTS 
To determine if the BN rats bred on a peanut- and soy-free diet for 3 generations 
could be orally sensitized to peanut without the use of an adjuvant we determined 
peanut protein-specific Ig responses, mast cell degranulation, number of eosino-
philic and basophilic granulocytes and cytokine production. 
 
PE-specific IgE, IgG1 and IgG2a titres 
Daily intragastric administration of 1 or 10 mg PE for 42 days, without the use of an adju-
vant, resulted in antigen-specific antibody responses in all rats. No IgE titres were detected 
in samples taken before sensitization. PE-specific IgE responses of rats orally exposed to PE 
increased with time. In the 10 mg/rat/day group they were found to increase at an earlier 
time point, and reached higher levels than in the 1 mg group (Fig. 2). 
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FIGURE 2. PE-specific IgE titres in time following oral exposure to peanut extract 
Groups of female rats (n=8 for each dosing regiment) bred for 3 generations on peanut- and soy-free 
feed received 0 (square), 1 (diamond) or 10 (triangle) mg/rat/day of peanut extract (PE) by daily oral 
gavage. Data are displayed as serum reciprocal IgE titres (average + S.E.M) in time. Day -7 is the pre-
dosing punction that has been tested to verify if the animals were naïve for PE. Closed lines represent the 
non-adjuvated groups, while interrupted lines represent CT-adjuvated groups (oral 1 µg CT/rat/day). 
a denotes the significant differences compared to the control group (0 mg PE and 0 mg PE + CT, respec-
tively) with p < 0.02 for the 10 mg PE group and p < 0.01 for 1 mg PE + CT group; b significantly different 
from the control group (0 mg PE and 0 mg PE + CT, respectively) with p < 0.01; c significantly different 
from the CT adjuvated group with p < 0.03. 
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FIGURE 3. PE-specific IgG2a titres in time following oral exposure to peanut extract 
Groups of female rats (n=8 for each dosing regiment) bred for 3 generations on peanut- and soy-free 
feed received 0 (square), 1 (diamond) or 10 (triangle) mg/rat/day of peanut extract (PE) by daily oral 
gavage. Data are displayed as serum reciprocal IgG2a titres (average + S.E.M) in time. Day -7 is the pre-
dosing punction that has been tested to verify if the animals were naïve for PE. Closed lines represent the 
non-adjuvated groups, while interrupted lines represent CT-adjuvated groups (oral 1 µg CT/rat/day). 
a on day 14 all PE exposed groups with and without CT adjuvation are significantly different (p < 0.01) 
compared to the control group (0 mg PE and 0 mg PE + CT, respectively); b on day 28 all PE exposed 
groups with and without CT adjuvation are significantly different (p < 0.01) compared to the control 
group (0 mg PE and 0 mg PE + CT, respectively), titres are also significantly higher in the 1 mg PE group 
compared to the 10 mg PE group with p < 0.03; c on day 42 all PE exposed groups with and without CT 
adjuvation are significantly different (p < 0.01) compared to the control group (0 mg PE and 0 mg PE + CT, 
respectively), titres are also significantly higher in the 1 mg PE group compared to the 10 mg PE group 
with p < 0.04. 
 
All animals that were sensitized to peanut for 42 days developed PE-specific IgG2a 
responses. Figure 3 shows that starting from day 14 significant differences in IgG2a 
titres between controls and both orally sensitized groups were seen. On day 28 and 
42, IgG2a titres were significantly higher in 1 mg group than in animals exposed to 
10 mg PE/day . 
Daily administration of PE resulted in the production PE-specific IgG1 antibodies in 
all rats. Figure 4 shows that from day 14 and onwards significant differences in IgG1 
titres between controls and both sensitized groups were seen. No differences in 
IgG1 were detected between animals in the 1 mg and 10 mg dose group. 
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FIGURE 4. PE-specific IgG1 titres in time following oral exposure to peanut extract 
Groups of female rats (n=8 for each dosing regiment) bred for 3 generations on peanut- and soy-free 
feed received 0 (square), 1 (diamond) or 10 (triangle) mg/rat/day of peanut extract (PE) by daily oral 
gavage. Data are displayed as serum reciprocal IgG1 titres (average + S.E.M) in time. Day -7 is the pre-
dosing punction that has been tested to verify if the animals were naïve for PE. Closed lines represent the 
non-adjuvated groups, while interrupted lines represent CT-adjuvated groups (oral 1 µg CT/rat/day). 
a titres are significantly higher (p < 0.01) than their control groups (0 mg PE and 0 mg PE + CT, respec-
tively) for all PE exposed groups with and without CT adjuvation. 
 
Rat mast cell protease-II 
To illustrate the clinical consequences of the PE-specific IgE antibody production, 
the mast cell product RMCP-II was also monitored. The RMCP-II responses before 
oral challenge (day 42) did not differ between PE-dosage groups. However, after 
oral challenge on day 49 all peanut-exposed groups had higher RMCP-II levels com-
pared to the 0 mg PE/rat/day group. This increase was significant for the 10 mg 
PE/rat/day group (Fig. 5). 
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FIGURE 5. RMCP-II release after oral challenge with peanut extract 
Groups of female rats (n=8 for each dosing regiment) bred for 3 generations on peanut- and soy-free 
feed received 0, 1 or 10 mg/rat/day of peanut extract (PE) by daily oral gavage. Data are displayed as 
serum RMCP-II levels (average + S.E.M) on day 49, 30 minutes after oral challenge with 100 mg PE/rat. 
Grey bars represent the non-adjuvated groups, while black bars represent the CT-adjuvated groups (oral 
1 µg CT/rat/day). 
a denotes significance (p < 0.02) compared to the 0 mg PE group control. 
 
Number of eosinophils and basophilic granulocytes in blood 
Another marker of the induction of allergy is the increase of eosinophilic and baso-
philic granulocytes in the blood collected at day 49 (Fig. 6). In rats that were ex-
posed to 10 mg PE daily, both basophils and eosinophils were increased. Exposure 
to 1 mg PE did not influence the number of basophils and eosinophils. 
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FIGURE 6. Numbers of eosinophilic and basophilic granulocytes 
Groups of female rats (n=8 for each dosing regiment) bred for 3 generations on peanut- and soy-free 
feed received 0, 1 or 10 mg/rat/day of peanut extract (PE) by daily oral gavage. Data are displayed as 
numbers of eosinophilic (A) or basophilic (B) granulocytes (average + S.E.M) in blood of day 49 (x109/L). 
Grey bars represent the non-adjuvated groups, while black bars represent the CT-adjuvated groups (oral 
1 µg CT/rat/day). 
 
Th2 and Th1 cytokines 
To gain insight in the Th2 and Th1 cytokines involved we determined IL-4 (Th2) and 
IFN-γ (Th1) in spleen cells stimulated ex vivo with PE. In many samples, IL-4 levels 
were below the detection limit (3.7 pg/mL) or only low concentrations were detect-
able (Fig. 7A). In the 1 mg PE/rat/day exposed group a non-significant increase in IL-
4 was seen. A significantly increased IFN-γ release (Fig. 7B) was detected in animals 
that were in vivo exposed to 1 mg PE/rat/day and 10 mg PE/rat/day. 
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FIGURE 7. IL-4 and IFN-γ levels in PE-restimulated spleen cells 
Groups of female rats (n=8 for each dosing regiment) bred for 3 generations on peanut- and soy-free 
feed received 0, 1 or 10 mg/rat/day of peanut extract (PE) by daily oral gavage. Spleens were dissected at 
day 49, single cell suspensions were prepared and these cells were incubated with PE in cell cultures 
(4x105 cells/culture) for 96 h. Data are displayed as supernatant IL-4 (A) or IFN-γ (B) levels (average + 
S.E.M). Grey bars represent the non-adjuvated groups, while black bars represent the CT-adjuvated 
groups (oral 1 µg CT/rat/day). Data of optimal PE-specific restimulation concentrations (1 mg PE/ml for 
IL-4 and 0.5 mg PE/ml for IFN-γ) for each cytokine are presented. 
a significantly different (p < 0.02) from the 0 mg PE group. 
 
The effect of extensive diet control 
We investigated the effect of the extensive diet intervention. Therefore, PE-specific 
IgE, IgG2a and IgG1 titres and RMCP-II responses in rats bred for 3 generations on 
peanut- and soy-free (3G PE+soy-free) feed were compared to that of rats directly 
obtained from an animal supplier that were bred and raised on a commercially 
available whey- and peanut-free (PE-free) diet. 
First we compared PE-specific IgE titres after 42 days of exposure to PE. The IgE 
titres of 3G PE+soy-free fed rats were higher than those of the PE-free fed rats. In 
the 3G PE+soy-free fed group 100% IgE responders were found after sensitization to 
both 1 and 10 mg PE. In contrast, in the PE-free fed group only 2/20 IgE responders 
were observed in the rats sensitized to 1 mg PE and no PE-specific IgE levels could 
be detected in the 10 mg group (Fig. 8). Next, we compared PE-specific IgG2a titres 
after 42 days of exposure to PE. In the rats fed 3G PE+soy-free all sensitized groups 
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showed 100% IgG2a responders, whereas in the rats fed PE–free, 17/20 of rats sen-
sitized to 1 mg PE, and 9/10 of rats sensitized to 10 mg PE showed positive reac-
tions. Additionally, IgG2a titres were also higher in the 3G PE+soy-free fed rats than 
those in the PE-free fed rats (Fig. 9). 
 
 
FIGURE 8. PE-specific IgE titres in both diet groups 
Comparison of rats bred and raised on peanut-free food with rats bred on peanut- and soy-free food for 
3 generations. Data are displayed as serum reciprocal IgE titres (average + S.E.M) on day 42. Grey bars 
represent the peanut-free bred group, while black bars represent the 3 generation peanut-and soy-free 
bred group. 
a statistically significant (p < 0.001) compared to the PE-free bred group exposed to the same amount of 
peanut. 
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FIGURE 9. PE-specific IgG2a titres in both diet groups 
Comparison of rats bred and raised on peanut-free food with rats bred on peanut- and soy-free food for 
3 generations. Data are displayed as serum reciprocal IgG2a titres (average + S.E.M) on day 42. Grey bars 
represent the peanut-free bred group, while black bars represent the 3 generation peanut-and soy-free 
bred group. 
a statistically significant (p < 0.001) compared to the PE-free bred group exposed to the same amount of 
peanut. 
 
Subsequently, we compared PE-specific IgG1 titres after 42 days of exposure to PE. 
All rats fed 3G PE+soy-free showed positive IgG1 titres while in the PE-free group 
19/20 rats reacted positively after sensitization to 1 mg PE, and 9/10 after sensitiza-
tion to 10 mg PE. In addition, the PE-specific IgG1 responses were higher in the 3G 
PE+soy-free group than those in the PE-free group (Fig. 10). 
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FIGURE 10. PE-specific IgG1 titres in both diet groups 
Comparison of rats bred and raised on peanut-free food with rats bred on peanut- and soy-free food for 
3 generations. Data are displayed as serum reciprocal IgG1 titres (average + S.E.M) on day 42. Grey bars 
represent the peanut-free bred group, while black bars represent the 3 generation peanut-and soy-free 
bred group. 
a statistically significant (p < 0.001) compared to the PE-free bred group exposed to the same amount of 
peanut. 
 
Finally, we studied the effect of diet on the RMCP-II responses 30 minutes after an 
oral PE challenge. An animal was considered a RMCP-II responder if the RMCP-II 
level after oral challenge exceeded 3 times the level prior to oral challenge. The 
percentage of animals of 3G PE+soy-free fed rats that showed a RMCP-II response 
was considerably higher than that of PE-free fed rats. Moreover, no RMCP-II re-
sponders could be detected in the 10 mg PE-free group (Fig. 11). 
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FIGURE 11. RMCP-II responders after oral challenge in both diet groups 
Comparison of rats bred and raised on peanut-free food with rats bred on peanut- and soy-free food for 
3 generations. Data are displayed as percentage of RMCP-II responders (average + S.E.M) 30 minutes 
after oral challenge with 100 mg of PE/rat. An animal is a RMCP-II responder if the RMCP-II level after 
oral challenge exceeds 3 times the level prior to oral challenge. Grey bars represent the peanut-free bred 
group, while black bars represent the 3 generation peanut-and soy-free bred group. 
a statistically significant (p < 0.001) compared to the PE-free bred group exposed to the same amount of 
peanut. 
 
The effect of the oral adjuvant cholera toxin 
Many animal models for food allergy apply an adjuvant to boost allergic responses. 
We investigated the effect of cholera toxin (CT) as an oral adjuvant in our model. 
In rats fed for 3 generations with peanut-and soy-free feed, daily adjuvation with 
cholera toxin resulted in higher PE-specific IgE titres in time compared to non-
adjuvated rats (Fig. 2). This difference was significant at day 14. Furthermore, IgE 
titres also occurred at an earlier time point in the adjuvated group. 
CT-adjuvation did not influence the development of PE-specific IgG2a titres as can 
be seen in Figure 3. A small but significant increase in IgG1 titres in CT exposed ani-
mals on day 28 was observed (Fig. 4). No influence of CT on RMCP-II levels was seen 
after oral challenge with 100 mg PE as is shown in Figure 5. We found CT to neither 
significantly influence the number of eosinophilic basophilic granulocytes in blood 
(Fig. 6) nor have an influence on cytokine levels (Fig. 7). 
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The effect of route of exposure on allergen recognition 
In order to compare the allergen recognition of different routes of exposure the 
purified peanut allergens Ara h1, Ara h2 and Ara h3 were used to determine IgG2a 
responses against these specific allergens in rats bred on peanut-free feed. From 
these allergen-specific responses we calculated the percentage of animals that gave 
high responses (at least 3 times that of a control) to these purified allergens. 
First, we looked at the IgG2a response against Ara h3 in i.p. or orally sensitized ani-
mals (1 and 10 mg/rat/day). We found no high responders against Ara h3 in i.p. 
sensitized animals whereas the animals sensitized orally with 1 mg or 10 mg showed 
50% and 30% Ara h3 specific IgG2a high responders, respectively. 
Next, we compared Ara h1 and Ara h2-specific IgG2a responses in the i.p. sensitized 
group with the highest responding orally sensitized group (1 mg/rat/day). From 
Table 1 it is clear that the i.p. and the orally sensitized groups show a similar per-
centage of IgG2a high responders against Ara h1, while the i.p. group shows a 
higher percentage of IgG2a high responders to Ara h2 (70%) as compared to the 
oral group (37.5%). 
 
TABLE 1. Specific IgG2a responses against Ara h1, Ara h2 and Ara h3 
 
Rats bred on peanut-free feed received 1 mg/rat/day of peanut extract (PE) by daily oral gavage (sera 
from day 42) and were compared with rats sensitized i.p. (0.5 ml of a 0.2 mg PE/ml solution in sterile PBS 
on days 0 (on this day potentiated with 0.2 ml of a 25 mg/ml alum), 2, 4, 7, 9 and 11; sera from day 28). 
Data are displayed as percentage of IgG2a high responders against the purified peanut proteins Ara h1, 
Ara h2 and Ara h3. Cut-off point for Ara h1, Ara h2 and Ara h3 high responders: optic density (O.D.) at 
450 nm >0.6 for 1:8 sera dilutions. 
a p < 0.01 vs i.p. sensitized group. 
 
 
DISCUSSION 
There is increasing interest in the development and evaluation of approaches for 
the safety assessment of novel foods, and in particular in methods for characteriza-
tion of allergenic potential. It is evident that considerable progress has been made 
in developing rodent models for the assessment of the allergenic potential of novel 
proteins but a lot of research remains to be done. Animal models have been sug-
gested for the identification of intrinsic hazard that is the inherent potential of a 
protein to cause allergic sensitization [60]. Since there are no validated animal 
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models available yet, further efforts are needed to evaluate and validate the sensi-
tivity, specificity, and reproducibility of these models. The approach described 
herein comprises systemic oral exposure of BN strain rats to protein allergens (in 
this experiment the peanut matrix) with responses measured as a function of aller-
gen-specific IgE, IgG1 and IgG2a antibody expression, allergen-specific degranula-
tion analyzed by RMCP-II levels in sera, enumeration of peripheral granulocytes and 
measurement of T-helper 1 (Th1) and T-helper 2 (Th2) cytokines after restimulation 
with the antigen in vitro. 
The herein described non-adjuvated BN model for food allergy shows 100% PE-
specific IgE, IgG2a and IgG1 responders in both oral dosing groups (1 and 10 mg 
PE/rat/day). Furthermore, the magnitude of the PE-specific IgE responses and the 
onset of positive responses were dose-related. Other allergy related parameters, 
such as RMCP-II, blood eosinophils and basophils were also increased in both dosing 
groups. Furthermore, Th1 (IFN-γ) cytokines were increased. Previous studies [61-66] 
have shown that food allergy in experimental animals is not strictly mediated by Th2 
responses, but that a mixed Th1/Th2 response is involved. Recent studies on airway 
hypersensitivity [67,68] suggest that the Th2 hypothesis is too simplistic and also in 
food allergy research the concept of an antigen-specific mixed Th1/Th2 response 
has gained ground [61-66]. Important to note is that it is not always possible in 
these models for food allergy to discriminate between the roles of the allergen and 
the adjuvant. A mixed Th1/Th2 response has also been demonstrated in humans. A 
polyisotypic peanut-specific humoral response was observed in peanut-allergic 
individuals, including elevated levels of serum IgG1, IgG4, and IgA [69]. Our data on 
peanut-specific immunoglobulins in BN rats are in accordance with these human 
data: both Th1 (IgG1) and Th2 (IgE and IgG2a) Igs were found after exposure to 
peanut. 
These data indicate that BN rats that were bred for 3 generations on a soy- and 
peanut-free diet could be orally sensitized to peanut without the use of an adjuvant. 
In addition, the measured specific antibodies were shown to be bioactive since clear 
challenge reactions could be observed in these animals, as demonstrated by ele-
vated levels of RMCP-II. In contrast, in rats that were bred on a peanut-free diet 
only a few rats responded with IgE. Thus, exposure to soy can render the animals 
tolerant for subsequent oral peanut exposure. This underlines that with proper diet 
restrictions oral models for food allergy can be a sensitive tool which is in accor-
dance with previous studies [32,33,40,70]. 
The adjuvant CT had only limited effects in this model. Adjuvation with CT enhanced 
the magnitude of IgE and to a lesser extent IgG1 but not of IgG2a, RMCP-II levels, 
numbers of granulocytes and cytokine levels. This indicates that in rats bred on a 
soy- and peanut-free diet, oral sensitization may already have been optimal or 
nearly optimal and CT could not increase the sensitivity of the model. 
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Since one of the most contentious issues regarding the development of various 
animal models of food allergy is that of the preferred route of exposure, we exam-
ined whether BN rats orally or i.p. exposed to peanut proteins would develop spe-
cific antibodies against the purified major allergens (Ara h1, Ara h2 and Ara h3). 
When comparing the allergen recognition of different routes of exposure we found 
that the response of i.p. and orally sensitized animals were comparable against one 
of the three tested purified allergens (Ara h1) but differed for the remaining two 
purified allergens (Ara h2 and Ara h3). The specific IgG2a response (Th2-mediated in 
rat) against Ara h2 in i.p. sensitized animals was twice that of orally sensitized ani-
mals. Moreover, the specific IgG2a response against Ara h3 was not found in the i.p. 
sensitized group but was found in 50% of the orally sensitized group. We could thus 
conclude that the route of exposure has an influence on the allergen recognition 
pattern: i.p. sensitization leads to the recognition of Ara h1 and Ara h2 and not Ara 
h3, while oral sensitization leads to the recognition of all three purified major aller-
gens. After oral exposure, proteins can be digested in the gastrointestinal tract, 
which may lead to presentation of different antigenic structures compared to i.p. 
exposure, without digestion. In contrast to i.p. dosing, oral dosing involves both oral 
mucosa and gut [71] and the accompanying mucosal immune systems, which may 
lead to induction of IgE responses to different allergens in orally compared to i.p. 
exposed rats. 
We showed that the profile of peanut allergens recognized by the immune system 
of the BN rat could be more comparable to the profile of allergens recognized by 
peanut allergic humans after oral compared to i.p. exposure of the BN rats to pea-
nut. These data support the preference for an oral model when dealing with food 
allergy since oral administration represents the most appropriate route of exposure 
for a method designed to identify potential food allergens. Furthermore, BN rats 
could discriminate between strong- (ovalbumin) weak- (bovine serum albumin) and 
non-allergenic (potato acid phophatase) proteins after oral exposure without the 
use of any adjuvants [16]. 
Other factors, including gender and age of animals, are also known to contribute to 
the sensitivity of oral allergy induction. Pilegaard and Madsen [14] demonstrated 
that sensitization of female BN rats to egg allergens offered a higher amount of IgE-
responders (38-75%) than did males (13-38%). Therefore we used female rats from 
the third generation of peanut- and soy-free bred rats (study A), while for study B 
male rats were used. This difference in sex, could to some extent contribute to the 
increased sensitivity of our extensive diet-controlled model. Another factor of im-
portance is age. With age the immune system matures which makes sensitization 
harder [72,73]. BN rats become less Th2-prone with age [74,75] and consequently 
less apt to sensitization. For this reason we used young rats (3-4 weeks at study 
initiation). 
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CONCLUSION 
Our study shows that extensive diet control can greatly increase sensitivity of BN 
rats to oral sensitization to peanut. The non-adjuvated oral model as described 
displayed maximum PE-specific IgE, IgG2a and IgG1 responders. The extensive diet 
control enhanced the sensitivity by such extent that even the potent oral adjuvant 
CT could enhance the allergic response to a limited extent. Furthermore, we dem-
onstrated by comparing the specific IgG2a response against several purified peanut 
allergens of i.p. and orally sensitized animals that the allergen recognition patterns 
differ between different routes of exposure with only oral exposed animals recog-
nizing all tested major allergens. Taken together, these data demonstrate that for 
food allergy the preferred model would be (A) oral and (B) if possible without the 
use of an adjuvant. Our model in BN rats unites these preferred characteristics. 
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Chapter 3  
Bis(tributyltin)oxide (TBTO) decreases 
the food allergic response against peanut 
and ovalbumin in Brown Norway rats 
 
 
 
 
Published in Toxicology 239, 68-76 (2007).
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ABSTRACT 
Other factors than the allergen itself may be of importance in the development of 
food allergy. This report describes the influence of the immunosuppressive com-
pound bis(tributyltin)oxide (TBTO), present in the food chain, on the development 
of food allergy to peanut or ovalbumin in Brown Norway (BN) rats. To study these 
effects BN rats were sensitized to either 1 or 10 mg peanut or ovalbumin by daily 
oral gavage and the TBTO-groups were fed a diet containing 80 mg TBTO per kg 
diet. 
Co-exposure to TBTO not only resulted in decreased general immunologic parame-
ters such as weights of mesenteric lymph nodes and Peyer’s patches, lymphocyte 
proliferation rates in splenocytes, but also on allergic parameters. In the peanut 
allergen-model TBTO decreased allergen-specific Th2 cytokine production by spleen 
cells, number of eosinophilic and basophilic granulocytes in the blood and produc-
tion of mast cell protease II after oral food challenge. In the ovalbumin allergen-
model TBTO decreased the number of eosinophilic and basophilic granulocytes, 
allergen-specific IgE and production of mast cell protease II after oral food chal-
lenge. 
The data imply that in the process of risk assessment of food allergy attention 
should be given to immunomodulating compounds present in the diet. 
 
 
INTRODUCTION 
Considerable progress has been made in the development of rodent models for the 
assessment of allergenic potential of food proteins (de Jonge et al. 2007; Dearman 
et al. 2000; Dearman and Kimber 2001; Knippels et al. 1998). So far, animal models 
are being proposed for hazard identification of potential allergenicity of (novel) 
foods. A next step may be to use animal models for risk assessment of allergens. 
This manuscript describes the effect of immunomodulating compounds in food on 
the development of allergic responses, as such influences may possibly be needed 
to incorporate in the eventual process of risk assessment. 
As an example of an immunomodulatory compound that could influence the food 
allergic response we studied bis(tributyltin)oxide (TBTO; C24H54OSn2). TBTO is pre-
sent in the food chain (Aluoch and Whalen 2005; Ikeda et al. 2001; Sekizawa 1998; 
WHO-IPCS 1999). In several studies with laboratory animals, both short term and 
long term, it has been demonstrated that TBTO is an immunotoxic chemical (Aluoch 
and Whalen 2005; Ikeda et al. 2001; Sekizawa 1998; WHO-IPCS 1999). Immunosup-
pression by TBTO in rats is characterized by a direct action of TBTO on cortical thy-
mocytes, resulting in suppressed T-cell dependent immune responses. Vos et al. 
(Vos et al. 1984; Vos et al. 1990) found TBTO to reduce ovalbumin (OVA)-induced 
Delayed Type Hypersensitivity (DTH) reactions in rats. TBTO also decreased innate 
immune responses, such as Natural Killer (NK) cell (Aluoch and Whalen 2005; Dudi-
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mah et al. 2006) and macrophage activity (Vandebriel et al. 1998; Vos et al. 1984). 
In host resistance models TBTO suppressed resistance to the infectious agents Lis-
teria monocytogenes (Vos et al. 1990) and Trichinella (T.) spiralis (Vos et al. 1984). In 
the T. spiralis model TBTO suppressed serum T. Spiralis-specific IgE titres (Vos et al. 
1984). 
TBTO has not only immunosuppressive effects as has been shown in a study in rats. 
In a study by Smialowicz et al. (1990) TBTO exposure enhanced the plaque forming 
cell (PFC) responses to sheep erythrocytes, which was attributed to effects on the 
suppressor (OX8-positive) T-lymphocyte population. In contrast, in a study by Van 
Loveren et al. (1991) it was found that TBTO decreased IgM-responses to sheep 
erythrocytes. These opposite results may relate to the different study design and 
the use of different dosages of TBTO, however both studies clearly show that TBTO 
has an influence on humoral responses to T-cell dependent antigens. 
Food allergic processes are highly T-cell dependent, and regulation of T-cell re-
sponses play an important role in IgE-synthesis, further substantiating a possible 
effect of TBTO on food allergy. From its effects on specific IgE responses to parasites 
and its effect on T-cells, one may speculate that TBTO could also influence the food 
allergic reaction to food proteins, which is largely dependent on IgE responses. We 
have addressed this hypothesis in a Brown Norway (BN) rat model for food allergy, 
sensitized with ovalbumin (Knippels et al. 1998) or peanut allergen (de Jonge et al. 
2007). 
 
 
MATERIALS AND METHODS 
Animals 
Oral sensitization was studied in young Brown Norway (BN) rats. In the first study 
(experiment A) Brown Norway (BN Rij:Hsd) rats obtained from Harlan Netherlands 
B.V. (Horst, the Netherlands) were used. These rats were bred and raised on a pea-
nut and soy protein-free diet (since soy and peanut are cross-reactive legumes 
(Beardslee et al. 2000; Eigenmann et al. 1996)) obtained from Harlan Netherlands 
B.V (2016S Teklad Global 16% Protein Rodent Diet) at our institute (de Jonge et al. 
2007). In this experiment, female rats of the third generation (F3) and onwards 
were used and fed the peanut and soy protein-free diet during the experiments. 
In the second study (experiment B) female BN rats obtained from Harlan Nether-
lands B.V. (Horst, the Netherlands) were directly used. These rats were kept on a 
hen’s egg white-free diet obtained from Harlan Netherlands B.V (2018S Teklad 
Global 18% Protein Rodent Diet) at our institute and were bred by Harlan on the 
same diet. 
At study initiation rats were 3-4 weeks old. The rats were housed in an animal room 
maintained at 23 ± 30C, with a light/dark cycle of 14 h/10 h, and a relative humidity 
of 30-70% during the experiment and for at least 7 days prior to study initiation. The 
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animals were housed in stainless-steel wire (Macrolon III) cages in groups of two 
and had free access to food and tap-water. Approval from the Institutional Animal 
Ethics Committee was obtained for all experimental procedures involving animals. 
 
Preparation of peanut extract 
Lightly blanched (100°C) peanuts (Arachis Hypogaea) from the USA Runner cultivar 
were kindly provided by IMKO Gelria (Doetinchem, The Netherlands) and were 
stored at 4°C until use. Peanut extract (PE) was prepared according to the method 
described by Koppelman et al. (Koppelman et al. 2003) with some minor modifica-
tions that are described in our previous publication (de Jonge et al. 2007). To verify 
whether the PE contained the major allergens (Ara h1, Ara h2 and Ara h3) SDS-PAGE 
was performed essentially according to Laemlli (Laemmli 1970) using a BioRad Mini 
Protean II system (BioRad, Hercules, CA) with 15% acrylamide gels (15 cm × 10 cm) 
and the method applied has been described in detail previously (de Jonge et al. 
2007). 
 
Preparation of TBTO diet 
Bis(tributyltin)oxide (TBTO) was purchased from Sigma-Aldrich Chemie GmbH 
(Steinheim, Germany). Prior to mixing the diets and TBTO, the diets were ground, in 
order to allow even distribution of 80 mg TBTO/kg in the diet. The TBTO-diets were 
prepared at the facilities of the Toxicology and Applied Pharmacology Department 
of TNO Quality of Life (Zeist, The Netherlands). 
 
Endotoxin content 
The endotoxin content of the PE (33.6 mg/ml in PBS) and OVA (10 mg/ml in PBS) 
was assessed chromatographically by quantitative limulus amebocyte (LAL) assay 
according to the manufacturer’s instructions (Cambrex BioSciences, Wokingham, 
UK). The applied method has been described in detail in our previous publication 
(de Jonge et al. 2007). All the PE samples had endotoxin levels < 0.01 EU/ml. These 
endotoxin levels are considered very low. All the OVA samples had endotoxin levels 
of 640 EU/ml (6.4 ng/mg). These endotoxin levels for OVA were considered accept-
able. 
 
Experimental design oral sensitization 
To ensure that animals were immunologically naive with respect to peanut (experi-
ment A) or OVA (experiment B), pre-study blood samples were always tested for 
allergen specific antibodies. Rats were randomly allocated to their dosing regimens 
(n=8 per dosing regimen). Some reallocation was performed to ensure even starting 
weight distribution in all dosing regimens. Rats were exposed to 1 ml of 0, 1 or 10 
mg/ml PE in PBS (experiment A) or to 0.5 ml of 0, 2 or 20 mg/ml OVA in milliQ (ex-
periment B) by daily oral gavage, using a 18-gauge stainless steel animal feeding 
Thesis De Jonge V9.pdf   66 9-10-2009   11:37:07
 67 
needle for the duration of 6 weeks. The TBTO-groups were also exposed to the 
immunosuppressant (TBTO; 80 mg/kg diet) in their diets. Feeding with TBTO-diet 
started one week prior (day -7) to exposure to the allergen. 
 Blood samples were obtained from the tail vein at two-weekly intervals (day 14, 28 
and 42 after start sensitization to PE or OVA). After coagulation for 1 h at room 
temperature, the blood samples were centrifuged (Heraeus Sepatech Biofuge 13, 
Osterode, Germany) for 15 min. at 3000 G and 40C to obtain sera. The sera were 
stored at -800C until analyses for allergen-specific IgE and IgG antibodies and RMCPII 
levels by Enzyme Linked Immunosorbent Assay (ELISA). 
Sensitized rats were orally challenged with a high dose of allergen followed by the 
determination of the level of rat mast cell protease II (RMCPII) in the serum. This 
protease is selectively expressed by intestinal mucosal mast cells in the rat and is a 
specific marker for mast cell activation that can be measured in serum (Stenton et 
al. 1998). After 42 days of daily oral exposure to the PE-dosages, rats did not receive 
allergen and TBTO for one week and were deprived of their food one day prior to 
sacrifice (day 49). At day 49, all rats were orally challenged by intragastric intubation 
with PE (2 mL of a 50 mg/mL solution) or OVA (1 mL of 100 mg/ml solution). Blood 
samples for hematology were taken from the orbital plexus (0.5 ml/rat) directly 
after oral challenge and were collected in K3-EDTA tubes obtained from Terumo 
Europe N.V. (Leuven, Belgium) to prevent clotting. Thirty minutes after the oral 
challenge, the animals were sacrificed by exsanguination from the aorta under 
CO2/O2 anesthesia. Serum samples were prepared as described above. Spleens, 
mesenteric lymph nodes (MLNs) and Peyer’s patches (PP) were removed aseptically 
and weighed. A total of 10 PP/rat were removed from the ileum (starting from the 
cecum). 
 
Ex vivo stimulation of spleen cells: allergen-specific cell proliferation and cytokine 
production 
Single cell suspensions were prepared under aseptic conditions by pressing the 
spleen through a 70 μm nylon cell strainer (Falcon, Franklin Lakes, USA). Cells were 
washed twice and resuspended in 5 mL standard medium (RPMI 1640 + 25 mM 
Hepes + L-Glutamine) obtained from Gibco BRL (Breda, the Netherlands) supple-
mented with 10% heat inactivated fetal calf serum (FCS) obtained from Integro B.V. 
(Zaandam, The Netherlands) and 1% penicillin-streptomycin (Gibco) with 7.5x10-5 M 
2-mercaptoethanol (2-ME) obtained from SERVA (Heidelberg, Germany). Cell num-
ber was determined with a Coulter Counter (Z2, Coulter Electronics, Mijdrecht, The 
Netherlands). Cell viability was determined by the Trypan blue cytotoxicity test. The 
concentration of the cell suspensions was adjusted to 4x106 viable cells/ml. 
For cell proliferation, 100 μL of the cell suspension was added per well in triplicate. 
Cells were incubated for 96 h with 2 mg/ml PE and [3H]-Thymidine was added for 
the last 18-20 h. 
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For cytokine measurements, 100 μl of the cell suspension was added to the well and 
incubated with 1 mg/ml PE for 96 h. In the supernatants, IL-2, IL-4, IL-5, IL-10, IL-13 
and IFN-γ were measured using a rat cytokine LINCOplex kit obtained from NU-
CLILAB B.V. (Ede, The Netherlands) according to the manufacturer’s instructions. 
Cytokine measurements were performed on a Luminex® (Biorad Life Science, Her-
cules, CA, USA) and Luminex software was used to calculate the amount of cyto-
kines (in pg/ml supernatant). 
 
PE-DIG and OVA-DIG coupling 
Peanut extract-Digoxigenin (PE-DIG) and ovalbumin-Digoxigenin (OVA-DIG) coupling 
was established using a DIG-protein labeling kit obtained from Roche Diagnostics 
GmbH (Mannheim, Germany) according to manufacturer’s instructions except for 
the following changes: 50 μL of a 20 mg/mL digoxigenin-3-0-succinyl-ε-aminocaproic 
acid-N-hydroxy-succinimide ester (DIG-NHS) solution in DMSO was added to 1 mL of 
a 6 mg/mL solution of crude PE in PBS or OVA in PBS. From this point on the manu-
facturer’s instructions were followed. A 1:2000 dilution of PE-DIG or OVA-DIG was 
used in the assay. 
 
Negative and positive control sera for Ig ELISAs 
Pooled serum, obtained from male F3 BN rats which were not exposed to peanut 
allergens, was used as negative control for both experiment A and experiment B. 
Positive control sera were obtained by sensitizing female BN rats i.p. . At day 0 rats 
were injected with a solution that contained 500 μl of 0.2 mg/ml PE or OVA mixed 
with 200 μl alum adjuvant suspension (Pierce) in sterile saline. On day 2, 4, 7, 9 and 
11 rats were injected ip with 500 μl 0.2 mg PE or OVA/ml solution in sterile PBS. The 
animals were sacrificed on day 28 by exsanguination from the abdominal aorta. Sera 
were prepared and stored as described above. 
 
PE- and OVA-specific IgE, IgG1 and IgG2a ELISAs 
PE-specific IgE, IgG1 and IgG2a ELISAs were performed as described earlier (de 
Jonge et al. 2007). OVA-specific IgE, IgG1 and IgG2a ELISAs were done following the 
same protocol, but for the IgE ELISA an OVA-DIG conjugate was used. 
 
Measurement of rat mast cell protease II (RMCPII) 
RMCPII concentrations were determined in day 42 and 49 sera with a RMCPII ELISA 
kit (Moredun Scientific Limited, Penicuik, Midlothian, Scotland, UK) according to 
manufacturer’s instructions. 
 
Differential cell counting 
Blood samples, obtained on day 49 were diluted 1:1 in a solution of Bovine Serum 
Albumin (Fraction V, purity ≥ 96%; Sigma-Aldrich) in saline (40 g/L). The number of 
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white blood cells (WBC), and differential cell counting was performed using Bayer 
Advia 120 Hematology System (Bayer HealthCare, Diagnostics division, Tarrytown, 
NY, USA). 
 
Statistics 
We tested the hypothesis that TBTO decreases parameters of food allergy. 
The overall difference between the control groups and TBTO-treated groups regard-
ing the immune parameters tested were assessed with a two-way analysis of vari-
ance (ANOVA) with Bonferroni for pairwise comparisons as post hoc test. The re-
sults from the PE and OVA experiments were analyzed separately. To determine if 
TBTO decreased an allergic parameter within a dosing group of either OVA or PE a 
one-way ANOVA with Bonferroni as post hoc test was done. 
The number of immune cells in blood was log-transformed prior to analysis, be-
cause these data did not meet the prerequisite of ANOVA that data should be nor-
mally distributed. In all analyses, data were considered significantly different if p < 
0.05 (one-sided). 
 
 
RESULTS 
The effect of TBTO on relative weight of PP and MLN 
Daily oral exposure to 1 mg PE resulted in a significant increase of the relative 
weight of the PPs (Figure 1A). TBTO decreased the weight of PPs significantly. If 
separate allergen dose groups were evaluated, the decrease was significant in the 
groups exposed to 1 and 10 mg PE. Relative weights of MLNs were not affected by 
exposure to PE. Overall, TBTO significantly reduced MLN weight, but this difference 
was not statistically significant when separate allergen dose groups were analyzed 
(Fig. 1B). 
Generally, in the model with OVA similar observations were done (Figure 2). In con-
trast to the model with PE, TBTO decreased the MLN weight in all separate dose 
groups (Figure 2B). 
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FIGURE 1. Lymph node weights in the PE-model 
Groups of female rats (n=8 for each dosing regiment) received 0, 1 or 10 mg/rat/day of PE by daily oral 
gavage. MLNs and PP were dissected at day 49. Data are displayed as percentages of the body weight 
(B.W.) for PP (A) and MLN (B) (average + S.E.M). Grey bars represent the groups that received the control 
diet and striped grey bars represent the groups that received the TBTO diet (80 mg TBTO/kg diet). 
TBTO significantly decreased the relative weight of the MLN (p = 0.012) and of the PP (p = 0.001). 
a effects of TBTO on relative PP weight were significant when separate allergen dose groups were ana-
lyzed: p = 0.023 (1 mg PE + TBTO compared to 1 mg PE) and p = 0.016 (10 mg PE + TBTO compared to 10 
mg PE). 
 
Thesis De Jonge V9.pdf   70 9-10-2009   11:37:07
 71 
(b)
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.1
0 1 10
OVA (mg/rat/day)
P
P
 w
ei
gh
t (
%
 o
f B
.W
.)
a
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
0.2
0 1 10
OVA (mg/rat/day)
M
LN
 w
ei
gh
t (
%
 o
f B
.W
.)
b
b b
 
FIGURE 2. Lymph node weights in the OVA-model 
Groups of female rats (n=8 for each dosing regiment) received 0, 1 or 10 mg/rat/day of OVA by daily oral 
gavage. MLNs and PP were dissected at day 49. Data are displayed as percentages of the body weight 
(B.W.) for PP (A) and MLN (B) (average + S.E.M). Black bars represent the groups that received the con-
trol diet and striped black bars represent the groups that received the TBTO diet (80 mg TBTO/kg diet). 
TBTO significantly decreased the relative weight of the MLN (p = 0.001) and of the PP (p = 0.011). 
a effects of TBTO on relative PP weight were significant when separate allergen dose groups were ana-
lyzed: p = 0.019 (10 mg OVA + TBTO compared to 10 mg OVA). 
b effects of TBTO on relative MLN weight were significant when separate allergen dose groups were 
analyzed: p = 0.041 (0 mg OVA + TBTO compared to 0 mg OVA), p = 0.044 (1 mg OVA + TBTO compared to 
1 mg OVA) and p = 0.002 (10 mg OVA + TBTO compared to 10 mg OVA). 
 
The effect of TBTO on PE-specific lymphocyte cell proliferation in the spleen 
Figure 3 shows that TBTO suppressed PE-specific proliferation of splenocytes. When 
separate dose groups were evaluated, this decrease was significant only in rats 
sensitized with 1 mg PE. 
 
The effect of TBTO on PE-specific cytokine levels in spleen supernatant 
The production of cytokines by spleen cells cultured ex vivo with PE is shown in 
Table 1. IL-2 production was not influenced by PE, but IL-2 levels were significantly 
(a)
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lower in TBTO exposed animals (p = 0.007). When evaluating the dose groups sepa-
rately, this decrease was significant in the 0 and 10 mg PE groups (p = 0.028 and p = 
0.044 respectively). In sensitized rats, IL-4, IL-5, IL-10, IL-13 and IFN-γ were in-
creased. Overall, TBTO decreased IL-4 (p = 0.036), IL-5 (p = 0.016), and IL-13 (p = 
0.014). When single dose groups were analyzed IL-13 levels were significantly de-
creased in rats exposed to 10 mg PE (p = 0.036). 
 
TABLE 1. PE-specific cytokine production by spleen cells  
 
 
PE (mg/rat/day) 
All cytokines (pg/ml) Modulator 0 1 10 
None 131.58 ± 20.26 103.90 ± 18.23 109.53 ± 12.40 IL-2a 
TBTO 82.16 ± 12.26b 86.41 ± 16.47 79.66 ± 10.55b 
None 3.41 ± 1.88 5.19 ± 3.38 8.72 ± 5.46 IL-4a 
TBTO 1.75 ± 0.62 0.00 ± 0.00 4.44 ± 2.30 
None 0.00 ± 0.00 30.40 ± 18.49 17.16 ± 11.16 IL-5a 
TBTO 0.87 ± 0.87 1.61 ± 1.61 1.09 ± 1.09 
None 275.22 ± 31.94 422.34 ± 96.40 393.83 ± 90.78 IL-10 
TBTO 285.43 ± 39.25 305.43 ± 28.66 330.09 ± 30.18 
None 285.45 ± 71.63 1203.59 ± 616.05 547.16 ± 137.98 IL-13a 
TBTO 192.53 ± 62.32 220.75 ± 60.23 286.20 ± 31.90b 
None 190.13 ± 52.36 513.24 ± 131.02 554.96 ± 76.70 IFN-γ 
TBTO 218.01 ± 39.47 379.00 ± 63.85 636.40 ± 121.39 
Groups of female rats (n=8 for each dosing regiment) received 0, 1 or 10 mg/rat/day of peanut extract 
(PE) by daily oral gavage. Spleens were dissected at day 49, single cell suspensions were prepared and 
incubated (4x105 cells/well) with PE (1 mg/ml) for 96 h. IL-2, IL-4, IL-5, IL-10, IL-13 and IFN-γ production 
were measured in supernatants and are expressed as pg/ml supernatant (average + S.E.M). 
a TBTO decreased cytokine levels of IL-2 (p = 0.007), IL-4 (p = 0.036), IL-5 (p = 0.016) and IL-13 (p = 0.014); 
b significantly different from non-immune-modulated group with p = 0.028 (IL-2; 0 mg PE + TBTO com-
pared with 0 mg PE), p = 0.044 (IL-2; 10 mg PE + TBTO compared with 10 mg PE), p = 0.036 (IL-13; 10 mg 
PE + TBTO compared with 10 mg PE). 
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FIGURE 3. PE-specific proliferation of spleen cells 
Groups of female rats (n=8 for each dosing regiment) received 0, 1 or 10 mg PE/rat/day by daily oral 
gavage. Spleens were dissected at day 49, single cell suspensions were prepared and 4x105 cells/well 
were incubated with 2 mg/ml PE for 96 h. Lymphocyte proliferation in spleen cells is expressed in cpm 
(average + S.E.M). Black bars represent the groups that received the control diet and striped black bars 
represent the groups that received the TBTO diet (80 mg TBTO/kg diet). 
TBTO significantly decreased cell proliferation with p = 0.003. 
a effects of TBTO on cell proliferation were significant when separate allergen dose groups were ana-
lyzed: p = 0.001 (1 mg PE + TBTO compared to 1 mg PE). 
 
The effect of TBTO on allergen-specific antibodies 
TBTO did not affect OVA-specific IgG1 and IgG2a serum levels (data not shown). 
With the allergen PE no effects of TBTO on these antibodies were observed either, 
except a small but significant decrease of PE-specific IgG1 serum levels at day 28 (p 
= 0.043; data not shown). 
With the allergen PE we observed a rather modest increase of specific IgE antibod-
ies in sensitized rats after 28 days of daily oral exposure, on which TBTO did not 
have an effect (Figure 4A). With the allergen OVA the specific IgE responses after 28 
days of oral exposure were higher and significantly affected by TBTO. When evaluat-
ing this in the separate dose groups, the effect of TBTO was significant in the 1 and 
10 mg OVA groups (Fig. 4B). 
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FIGURE 4. PE- and OVA-specific IgE titres following 28 days of oral exposure 
Groups of female rats (n=8 for each dosing regiment) received 0, 1 or 10 mg/rat/day of PE or OVA by 
daily oral gavage. Data are displayed as serum reciprocal antigen-specific IgE titres (average + S.E.M) on 
day 28 in the PE-model (A) or in the OVA-model (B). Grey bars represent the groups that received the 
control diet and striped grey bars represent the groups that received the TBTO in the PE allergen-model. 
For the OVA allergen-model: black bars represent the groups that received the control diet and striped 
black bars represent the groups that received the TBTO diet (80 mg TBTO/kg diet). 
TBTO decreased OVA-specific IgE levels (p = 0.008). 
a effects of TBTO on OVA-specific IgE levels were significant when separate allergen dose groups were 
analyzed: p = 0.034 (1 mg OVA + TBTO compared to 1 mg OVA) and p = 0.038 (10 mg OVA + TBTO com-
pared to 10 mg OVA). 
 
The effect of TBTO on eosinophilic and basophilic granulocytes in the blood 
The numbers of white blood cells, lymphocytes, and neutrophilic granulocytes in the 
circulation were decreased after TBTO exposure in both allergen models (data not 
shown). Also the number of eosinophilic granulocytes was decreased by TBTO in 
both allergen-models (Fig. 5). When evaluating the separate dose groups the effect 
of TBTO was signficant in the 0 en 10 mg PE group. In the OVA model the effect of 
TBTO on eosinophils was only significant in the 1 mg OVA group, but approached 
significance (p = 0.052) in the 10 mg OVA/rat/day group. 
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FIGURE 5. Numbers of eosinophilic granulocytes 
Groups of female rats (n=8 for each dosing regiment) received 0, 1 or 10 mg/rat/day of PE or OVA by 
daily oral gavage. Data are displayed for the PE-study (A) and for the OVA-study (B) as numbers of eosi-
nophilic granulocytes (average + S.E.M) in blood of day 49 (x109/L). Grey bars represent the groups that 
received the control diet and striped grey bars represent the groups that received the TBTO in the PE 
allergen-model. For the OVA allergen-model: black bars represent the groups that received the control 
diet and striped black bars represent the groups that received the TBTO diet (80 mg TBTO/kg diet). 
TBTO decreased number of eosinophilic granulocytes significantly in the the PE allergen-model (p = 
0.032) and the OVA allergen-model (p = 0.003). 
a effects of TBTO on eosiniophilic granulocytes were significant when separate allergen dose groups were 
analyzed: p = 0.049 (0 mg PE + TBTO compared to 0 mg PE), p = 0.001 (10 mg PE + TBTO compared to 10 
mg PE) and p = 0.015 (1 mg OVA + TBTO compared to 1 mg OVA). 
 
Figure 6 shows that the numbers of basophilic granulocytes in the blood were in-
creased in rats sensitized with 10 mg PE or 1 mg OVA. TBTO significantly decreased 
the number of basophilic granulocytes only in those two dose groups. 
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FIGURE 6. Numbers of basophilic granulocytes 
Groups of female rats (n=8 for each dosing regiment) received 0, 1 or 10 mg/rat/day of PE or OVA by 
daily oral gavage. Data are displayed for the PE-study (A) and for the OVA-study (B) as numbers of baso-
philic granulocytes (average + S.E.M) in blood of day 49 (x109/L). Grey bars represent the groups that 
received the control diet and striped grey bars represent the groups that received the TBTO in the PE 
allergen-model. For the OVA allergen-model: black bars represent the groups that received the control 
diet and striped black bars represent the groups that received the TBTO diet (80 mg TBTO/kg diet). 
a effects of TBTO on basophilic granulocytes were significant when separate allergen dose groups were 
analyzed: p = 0.007 (10 mg PE + TBTO compared to 10 mg PE) and p = 0.030 (1 mg OVA + TBTO compared 
to 1 mg OVA). 
 
The effect of TBTO on mast cell degranulation after oral challenge with the allergen 
RMCPII levels increased after oral challenge with the allergens PE and OVA (Figure 
7). Exposure to TBTO significantly decreased the amount of PE-induced RMCPII in 
serum. These effects were especially evident in the 1 mg PE and OVA group. 
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FIGURE 7. RMCPII release after oral challenge 
Groups of female rats (n=8 for each dosing regiment) received 0, 1 or 10 mg/rat/day of PE or OVA by 
daily oral gavage. Data are displayed in the PE allergen-model (A) and in the OVA allergen-model (B) as 
serum RMCPII levels (average + S.E.M) on day 49, 30 minutes after oral challenge with 100 mg PE or 
OVA/rat. Grey bars represent the groups that received the control diet and striped grey bars represent 
the groups that received the TBTO in the PE allergen-model. For the OVA allergen-model: black bars 
represent the groups that received the control diet and striped black bars represent the groups that 
received the TBTO diet (80 mg TBTO/kg diet). 
TBTO decreased release of RMCPII significantly in the PE allergen-model (p = 0.007) and in the OVA 
allergen-model (p = 0.003). 
a effects of TBTO on RMCPII were significant when separate allergen dose groups were analyzed: p = 
0.031 ( mg PE + TBTO compared to 0 mg PE), p = 0.041 (1 mg PE + TBTO compared to 1 mg PE) and p = 
0.016 (1 mg OVA + TBTO compared to 1 mg OVA). 
 
 
DISCUSSION 
The chemical TBTO that is present in the food chain is a known immunosuppressive 
compound. In several studies in experimental animals it has been demonstrated 
that the thymus is a target organ of TBTO, and that one of the main immune effects 
of TBTO is the suppression of T cell dependent immune responses (Raffray and 
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Cohen 1991; Vos et al. 1984; WHO-IPCS 1999). In a host resistance model it has 
been shown that TBTO decreased resistance against T. Spiralis and also decreased 
specific IgE serum levels (Vos et al. 1984). This effect of TBTO has led to the hy-
pothesis that this chemical could also influence food allergic responses which are 
IgE dependent. 
The effects of TBTO were investigated in a model for food allergy in BN rats using 
two allergens: PE and OVA. TBTO suppressed the weight of PP and MLN, confirming 
previous reports (Funahashi et al. 1980; Krajnc et al. 1984). In studies investigating 
the immune effects of TBTO, various dosages of TBTO have been applied. The dose 
applied in our study is based on earlier research conducted by our igroup (Krajnc et 
al. 1984; van Loveren et al. 1990; Vandebriel et al. 1998). Immunotoxic effects of 
TBTO are dose-dependent. In a study in rats (Verdier et al. 1991) no treatment-
related effects were noted on IgM responses to immunization with sheep erythro-
cytes and delayed type hypersensitivity responses to bovine serum albumin at dos-
ages of 0, 0.5, 2, 5, or 50 mg TBTO/kg of diet, whereas thymic atrophy and impaired 
clearance of L. monocytogenes were noted only at a dietary concentration of 50 
mg/kg. Several other studies (Krajnc et al. 1984; Verdier et al. 1991; Vos et al. 1984; 
Vos et al. 1990) have described effects of TBTO on the T-cell dependent immune 
response, including IgE-production, at concentrations as low as 5 mg TBTO/kg food. 
In our study we used 80 mg TBTO/kg of feed, a dose that is similar or somewhat 
higher than the dosages used by Verdier et al. (Verdier et al. 1991), Krajnc et al. 
(Krajnc et al. 1984) and Vos et al. (Vos et al. 1984; Vos et al. 1990) and our results 
are therefore in line with these findings of effects on T-cell activity. 
Our study shows that TBTO also suppressed allergen specific parameters. In rats 
sensitized to either peanut or ovalbumin, TBTO decreased the number of eosino-
phils and basophils and mast cell degranulation was also suppressed. The produc-
tion of the Th2 cytokines IL-4, IL-5 and IL-13 by spleen cells ex vivo stimulated with 
PE were suppressed by TBTO. TBTO did not significantly affect IL-10 and IFN-γ, al-
though these cytokines were slightly decreased in the 1 mg PE group. Hence, TBTO 
predominantly affected Th2 cytokines and not Th1 and regulatory T cell (Treg) asso-
ciated cytokines. The effect on IL-5, a cytokine that is important for the influx of 
eosinophils, is in line with the observed suppression of blood eosinophils. The de-
crease of IL-4 and IL-13, which play a role in IgE production, contrasts the absence of 
decreased PE-specific IgE levels after TBTO exposure. In rats sensitized to OVA, spe-
cific IgE levels were significantly decreased by TBTO. 
In our study we found that TBTO predominantly suppressed Th2-associated cyto-
kines and not Th1- and Treg-associated cytokines. TBTO did not have an effect on 
DTH in rats exposed to doses of TBTO ranging from 1.25 – 15 mg TBTO/kg B.W./day 
(Smialowicz et al. 1990) or 0.5 – 50 mg TBTO/kg feed/day (Verdier et al. 1991). This 
is in contrast with the decrease in Th1/Th2 ratio as found in a C56Bl/6 mice model 
(van den Berg et al. 2005) induced by the maximum tolerated dose of TBTO. This 
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difference could be due to dose-dependent effects of TBTO on the immune system 
and the use of different animal models in their and our study designs. 
With OVA we observed specific IgE levels to be significantly decreased. It is difficult 
to explain the discrepancy between the effect of TBTO on PE- and on OVA-specific 
IgE levels, especially since other immune parameters in both allergen models were 
similarly affected by TBTO. Another discrepancy is the fact that in the PE experiment 
TBTO had no effect on specific IgE levels, yet decreased the mast cell RMCPII re-
lease. This latter finding may indicate a direct, IgE-independent effect of TBTO on 
mast cells. It is important to note that several differences exist between the two 
allergen models: e.g. different breeding for multiple generations on different diets 
(Knippels et al. 1999; Pilegaard and Madsen 2004), different allergens and different 
purity of allergens (OVA is a purified protein, while PE is the aequous extract of the 
peanut matrix) and different affinities for proteins (de Jonge et al. 2007; Knippels 
and Penninks 2005; Knippels et al. 1998; Penninks and Knippels 2001). Furthermore 
the allergic response is not identical in both experiments. Administration of OVA at 
a dose of 1 mg induces higher IgE levels than at a dose of 10 mg, whereas in the 
case of PE IgE increases dose dependently. Also, the specific IgE response is consid-
erably lower in PE-sensitized rats, than in OVA-sensitized rats. This difference might 
explain the observed differences in effects of TBTO on IgE. Possibly, TBTO can more 
easily modulate vigorous IgE responses, than more subtle IgE responses. TBTO sup-
pressed the release of RMCPII by mast cells after an oral challenge with both aller-
gens. This parameter is clinically relevant (Stenton et al. 1998) and this indicates 
that TBTO directly suppressed the allergic response. These data imply that it is im-
portant to investigate multiple parameters at multiple immunological levels in a 
food allergy model, rather than primarily focusing on a single immune parameter. 
In conclusion TBTO suppressed allergy-specific parameters. This complements ear-
lier findings of immunosuppression by TBTO, exemplified by delayed-type hypersen-
sitivity responses, decreased innate immune responses (NK activity and macrophage 
activity (Aluoch and Whalen 2005; Dudimah et al. 2006; Vandebriel et al. 1998; Vos 
et al. 1984)) and may be interpreted as a general suppression of immune respon-
siveness, rather than a selective modulation of Th1 or Th2 mediated immune re-
sponses. The data imply that immunomodulatory components present in food may 
have an impact on the expression of food allergy, and that such components need 
to be considered if an eventual risk assessment of food allergens is to be made. 
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Chapter 4  
Lactobacillus casei Shirota does not 
decrease the food allergic response to 
peanut extract in Brown Norway rats 
 
 
 
Published in Toxicology 249, 140-5 (2008). 
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ABSTRACT 
Probiotics are claimed to beneficially affect the immune system and their involve-
ment in allergy prevention is being investigated extensively. However, the efficacy 
of probiotics in allergy prevention remains controversial. We investigated whether 
the probiotic Lactobacillus casei Shirota (LcS) could modulate the food allergic re-
sponse against peanut extract (PE) in Brown Norway (BN) rats. For this purpose BN 
rats were sensitized to PE (0, 1 and 10 mg/rat/d) by daily oral gavage and the LcS-
groups were additionally orally dosed with 1*109 Colony Forming Units LcS/rat/d. 
LcS administration had minor effects in animals that were not sensitized. LcS in-
creased Th1- (PE-specific IgG1), whereas the Th1/Th2 ratio based on PE-specific 
IgG1/PE-specific IgG2a shifted towards Th2 dominance in rats sensitized to PE in the 
presence of LcS as compared to rats that were sensitized to PE only. LcS stimulated 
PE-specific IgG2a; but for PE-specific IgE the effect was less clear; whereas there was 
no overall effect, 2 rats did not show detectable specific IgE antibodies, whereas the 
remainder showed significantly increased levels. LcS also resulted in increased 
numbers of basophilic granulocytes in blood. Furthermore, LcS increased levels of 
both Th1- (IFN-γ) and Th2- (IL-4) related cytokines in PE stimulated spleen and mes-
enteric lymph node (MLN) cells, but predominantly IL-4 levels in the supernatants of 
both spleens and MLNs. 
Our study does not support the hypothesis that LcS down-regulates food allergic 
responses in a BN rat model for food allergy to peanut. 
 
 
INTRODUCTION 
The increase of allergies over the last decennia has highlighted the need to develop 
preventive strategies. Growing concern about the adverse immunological conse-
quences of increasing hygiene in the developed world has fueled the interest in the 
role of microbial products such as probiotics as tools to prevent and/or treat allergic 
diseases. The intake of lactic acid bacteria with Th1 stimulating properties is thought 
to be potentially beneficial in reducing allergic symptoms in atopic individuals. 
Immune effects of Lactobacillus casei Shirota (LcS) have been demonstrated in ro-
dent models (Baken et al. 2006; de Waard et al. 2001; Ezendam and van Loveren 
2008; Matsuzaki and Chin 2000; Matsuzaki et al. 1998). Shida et al. (Shida et al. 
2002) have shown that LcS reduced serum ovalbumin (OVA)-specific IgE and IgG1 
responses and diminished systemic anaphylaxis in a mouse model for food allergy. 
In this model, LcS skewed the immune response towards Th1 immunity, thereby 
reducing the Th2-mediated allergic responses. LcS stimulated IFN-γ production by 
mouse splenocytes in vivo and in vitro, possibly via macrophage-activation and IL-12 
production and subsequent enhancement of Th1 cell functions (Kato et al. 1999). 
Effects of LcS have also been studied in a rat model for Th1-mediated autoimmunity 
(experimental autoimmune encephalomyelitis (EAE)) and LcS aggravated clinical 
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symptoms indicating that stimulation of Th1 immunity can also induce unwanted 
effects (Baken et al. 2006; Ezendam and van Loveren 2008). Taken together these 
data suggest that immunomodulatory effects of LcS can lead to both beneficial as 
well as adverse effects. 
Effects of probiotics on Th1-mediated immunity is only one of the mechanisms that 
have been proposed to explain the beneficial effects of probiotics on allergic re-
sponses. Other mechanisms, such as stimulation of regulatory T cells (Tregs), which 
suppress both Th1- and Th2-associated responses (Prioult et al. 2004; Rook et al. 
2004) and a decrease in intestinal permeability (Bongaerts and Severijnen 2005; 
Rosenfeldt et al. 2004) have also been suggested. The precise mechanisms by which 
probiotics may influence allergic responses are still unknown and data on efficacy in 
human studies are limited. In humans, the effects of probiotics on prevention or 
alleviation of atopic eczema have been studied most extensively. Administration of 
probiotics reduced symptoms in infants who suffered from IgE mediated atopic 
eczema (Rosenfeldt et al. 2003; Sistek et al. 2006; Viljanen et al. 2005). In addition, 
probiotics reduced the prevalence of atopic eczema in infants that received the 
probiotic Lactobacillus GG in the first six months of their lives (Kalliomaki et al. 
2001; Kalliomaki et al. 2003). However, in other studies (Brouwer et al. 2006; Gru-
ber et al. 2007) no effects on symptoms of atopic eczema were found. Remarkably, 
in a study with atopic infants that received the probiotic L. acidophilus during the 
first six months of their lives, no effects on prevalence of atopic eczema was found, 
but sensitization to several allergens was increased (Taylor et al. 2007). 
These studies in humans demonstrate that probiotics can have beneficial effects on 
atopic eczema, but that some probiotics can also induce unintended immunostimu-
lation. These differences can probably be explained by the strain-dependent effects 
of probiotics. To investigate the effects of a probiotic with Th1 stimulating proper-
ties on allergic responses, the effects of LcS were studied in a rat model for peanut 
allergy. 
 
 
EXPERIMENTAL METHODS 
Animals 
Oral sensitization was studied in young Brown Norway (BN) rats. Brown Norway (BN 
Rij:Hsd) rats obtained from Harlan Netherlands B.V. (Horst, the Netherlands) were 
used. These rats are bred by Harlan on their basal diet (2018 Teklad Global 18% 
Protein Rodent Diet), which does contain soy-products as a protein source. At our 
institute these rats were bred and raised on a peanut and soy protein-free diet 
(since soy and peanut are cross-reactive legumes (Beardslee et al. 2000; de Jonge et 
al. 2007; Eigenmann et al. 1996)) obtained from Harlan Netherlands B.V (2016S 
Teklad Global 16% Protein Rodent Diet). In this experiment, female rats of the third 
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generation (F3) and onwards were used and fed the peanut and soy protein-free 
diet during the experiments. At study initiation, rats were 3-4 weeks old. 
The rats were housed in an animal room maintai 
ned at 23 ± 30C, with a light/dark cycle of 14 h/10 h, and a relative humidity of 30-
70% during the experiment and for at least 7 d prior to study initiation. The animals 
were housed in stainless-steel wire (Macrolon III) cages in groups of two and had 
free access to food and tap-water. Approval from the Institutional Animal Ethics 
Committee was obtained for all experimental procedures involving animals. 
 
Preparation of peanut extract 
Lightly blanched (100°C) peanuts (Arachis Hypogaea) from the USA Runner cultivar 
were kindly provided by IMKO Gelria (Doetinchem, The Netherlands) and were 
stored at 4°C until use. Peanut extract was prepared according to the method de-
scribed by Koppelman et al. (Koppelman et al. 2003) with some previously described 
minor modifications (de Jonge et al. 2007). To verify whether the peanut extract 
contained the major allergens (Ara h1, Ara h2 and Ara h3) SDS-PAGE was performed 
essentially according to Laemlli (Laemmli 1970) using a BioRad Mini Protean II sys-
tem (BioRad, Hercules, CA) with 15% acrylamide gels (15 cm × 10 cm) using a previ-
ously described method (de Jonge et al. 2007). 
 
Probiotic preparation 
Lactobacillus casei Shirota strain (LcS) was cultured for 72 hours at 30°C under an-
aerobic conditions in Man Rogosa Sharpe (MRS) broth (52.5 g MRS (Merck, Darm-
stadt, Germany)/L distilled water). Thereafter, bacteria were washed twice with 
saline (0.9% NaCl) and resuspended in saline to a final concentration of 10*109 Col-
ony Forming Units (CFU)/ml (allowing doses of 100 μl/rat/d) and stored at 4 °C prior 
to use. The number and viability of the lactobacilli were determined by aerobic 
culturing on MRS plates (Tritium Microbiologie B.V., Veldhoven, The Netherlands) 
for 72 hours. Rats were dosed with LcS averaging between 1-2*109 CFU of LcS/rat/d. 
Every week, 100 μl of 10-7, 10-8 and 10-9 suspensions of bacteria in saline were 
plated in duplicate on MRS containing agar plates (Tritium Microbiologie B.V., Veld-
hoven, The Netherlands). After 72 h of cultivation, the number of colonies on each 
plate was counted in order to check the concentration of bacteria in the suspension 
used for co-exposure of animals. There was some variation between weeks but 
always 1 to 2*109 CFU per daily dose per rat was applied. 
 
Endotoxin content 
The endotoxin content of the PE (33.6 mg PE/ml in PBS) was assessed chromato-
graphically by quantitative limulus amebocyte (LAL) assay according to the manufac-
turer’s instructions (Cambrex BioSciences, Wokingham, UK) using the method de-
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scribed previously (de Jonge et al. 2007). Endotoxin content in all PE samples was 1 
pg or 0.01 Endotoxin Units (EU)/ml. 
 
Experimental design oral sensitization 
To ensure the use of immunologically naive animals with respect to peanut, 
pre-study blood samples were tested for peanut-specific antibodies. Rats (8 per 
experimental group) were then randomly allocated to their dosing regimens), fol-
lowed by additional reallocation to ensure even starting weight distribution in all 
dosing groups. Rats were exposed to 1 ml of 0, 1 or 10 mg PE /ml PBS by daily oral 
gavage, using an 18-gauge stainless steel animal feeding needle during the first 42 d 
of the study. In addition, the LcS-groups were also exposed by oral gavage of the 
probiotic (LcS; 1*109 CFU/rat/d) and the groups that were not exposed to LcS were 
given saline by oral gavage by the same dosing regimen as the LcS-groups. 
In rats that received LcS, oral dosing with LcS started one week prior (d -7) to expo-
sure to the allergen and was maintained for 49 d. 
 After commencement of the sensitization, blood samples were obtained from the 
tail vein at two-weekly intervals (d 14, 28 and 42 after start sensitization to PE). 
After coagulation for 1 h at room temperature, the serum samples were centrifuged 
(Heraeus Sepatech Biofuge 13, Osterode, Germany) for 15 min. at 3000 G and 40C to 
obtain sera. The sera were stored at -800C until analyses for allergen-specific IgE and 
IgG titers and RMCPII levels by ELISA. 
After the sensitization period (d 42), animals were no longer exposed to allergen or 
LcS and one d prior to sacrifice rats were deprived of their food (d 49). At d 49, all 
rats were orally challenged by intragastric intubation with PE (2 ml of a 50 mg/ml 
solution). Blood samples for hematology were taken from the orbital plexus (0.5 
ml/rat) directly after oral challenge and were collected in K3-EDTA tubes (Terumo 
Europe N.V., Leuven, Belgium) to prevent clotting. Thirty min after the oral chal-
lenge, the animals were sacrificed by exsanguination from the abdominal aorta 
under CO2/O2 anesthesia and serum samples were prepared from this blood as 
described above. Spleens and mesenteric lymph nodes (MLNs) were removed asep-
tically, weighed and single cell suspensions were prepared for cytokine analysis in 
the supernatant of spleen and MLN cells after ex-vivo re-stimulation with PE. 
 
Ex vivo stimulation of spleen cells: allergen-specific cytokine production 
Single cell suspensions were prepared under aseptic conditions by pressing the 
spleens or MLNs through a 70 μm nylon cell strainer (Falcon, Franklin Lakes, USA). 
Cells were washed twice and resuspended in 5 mL standard medium (RPMI 1640, 25 
mM Hepes concentration, L-Glutamine) obtained from Gibco BRL (Breda, the Neth-
erlands) supplemented with 10% heat inactivated fetal calf serum (FCS) obtained 
from Integro B.V. (Zaandam, The Netherlands) and 1% penicillin-streptomycin 
(Gibco) with 7.5x10-5 M 2-mercaptoethanol (2-ME) (SERVA, Heidelberg, Germany). 
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Cell number was determined using a Coulter Counter (Z2, Coulter Electronics, Mi-
jdrecht, The Netherlands). Cell viability was determined by the Trypan blue cytotox-
icity test. The concentration of the cell suspensions was adjusted to 4x106 viable 
cells/ml. 
For cytokine measurements, 100 μl of the cell suspension was added to the well of 
96-wells microtitre plates (Greiner tissue culture plate U-shape, no. 650180; 
Greiner, Frickenhausen, Germany) and incubated with 1 (for IL-4) and 0.5 (for IFN-γ) 
mg/ml PE for 96 h. IFN-γ present in the supernatants was measured by ELISA (Rat 
IFN-γ BD OptEIA ELISA set; BD Biosciences, Erembodegem, Belgium) and Reagent set 
(IFN-γ BD OptEIA Reagent Set B, BD Biosciences) according to the manufacturer’s 
instructions. IL-4 was measured using a rat IL-4 cytoset kit obtained from BioSource 
(Camarillo, CA, USA) as described previously (de Jonge et al. 2007). 
 
PE-DIG coupling 
Peanut protein-Digoxigenin (PE-DIG) coupling was established using a DIG-protein 
labeling kit obtained from Roche Diagnostics GmbH (Mannheim, Germany) accord-
ing to manufacturer’s instructions except for the following changes: 50 μl of a 20 
mg/ml digoxigenin-3-0-succinyl-ε-aminocaproic acid-N-hydroxy-succinimide ester 
(DIG-NHS) solution in DMSO was added to 1 ml of a 6 mg/ml solution of crude PE 
extract in PBS, from this point on the manufacturer’s instructions were followed. A 
1:2000 dilution of PE-DIG was used in the assay. 
 
Negative and positive control sera for Ig ELISAs 
Pooled serum, obtained from male F3 BN rats that were not exposed to peanut 
allergens, was used as the negative control. Positive control sera were obtained by 
sensitizing female F3 BN rats i.p. At d 0 rats were injected with a solution containing 
0.5 ml of a 0.2 mg PE/ml solution in sterile PBS mixed with 0.2 ml of a 40 mg/ml 
alum adjuvant suspension (Pierce) in sterile saline. On d 2, 4, 7, 9 and 11 rats were 
injected i.p. with 0.5 ml of a 0.2 mg PE/ml solution in sterile PBS. The animals were 
bled on d 28 by exsanguation from the abdominal aorta. Sera were prepared and 
stored as described above. These sera were pooled and used as positive control sera 
in the PE-specific Ig ELISAs. 
PE-specific Ig ELISAs 
Positive and negative controls were incorporated on each plate of all Ig-ELISA’s. 
After each incubation plates were washed six times with 300 μl PBS containing 0.1% 
Tween 20 using an ELISA washer (Auto plate washer ELX405R, Biotek Instruments 
Inc., Winooski, VT, USA). 
 
PE-specific IgE ELISA 
For detection of PE-specific IgE, a sandwich ELISA was performed as described ear-
lier (de Jonge et al. 2007). 
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PE specific IgG1 and IgG2a ELISA 
For detection of PE-specific IgG1 and IgG2a, 96-wells microtitre plates were coated 
with 100 μL/well of a 100 μg/ml solution of PE in PBS the remainder of the proce-
dure was similar to that described before (de Jonge et al. 2007). 
To determine the effect of LcS on the Th1/Th2 balance, differences (value LcS 
treated groups divided by the value of the non-treated groups) in IgG1 levels (as 
fraction of their plate’s positive control) of sensitized animals (d 42) were divided by 
the differences in corresponding IgG2a levels (as fraction of their plate’s positive 
control). 
 
Measurement of rat mast cell protease II (RMCPII) 
RMCPII concentrations were determined in d 42 and 49 sera with a RMCPII ELISA kit 
(Moredun Scientific Limited, Penicuik, Midlothian, Scotland, UK) according to the 
manufacturer’s instructions. 
 
Differential cell counts 
Blood samples, obtained on d 49 were diluted 1:1 in a saline solution (40 g/L) con-
taining Bovine Serum Albumin (Fraction V, purity ≥ 96%; Sigma-Aldrich). The num-
ber of white blood cells (WBC), and differential cell counting was performed using a 
Bayer Advia 120 Hematology System (Bayer HealthCare, Diagnostics division, Tarry-
town, NY, USA). 
 
Statistics 
All experimental groups comprised 8 rats. Statistical treatment of results was proc-
essed with SPSS version 13.0 (SPSS Inc., Chicago, Illinois, USA). 
The overall difference between the control groups and LcS-treated groups regarding 
the immune parameters tested were assessed with a two-way ANOVA with Bon-
ferroni for pairwise comparisons as post hoc test. To determine if LcS influenced the 
outcome of an allergic parameter within a dosing group of PE a one-way ANOVA 
with Bonferroni as post hoc test was done. 
Data for the IgG1/IgG2a ratio’s and the number of immune cells in blood were log-
transformed prior to analysis, because these data did not meet the prerequisite of 
ANOVA that data should be normally distributed. In all analyses, data were consid-
ered significantly different if P<0.05 (two-sided). 
 
 
RESULTS 
The effect of LcS on PE-specific IgE 
In two out of 8 rats that received 10 mg PE together with LcS, PE-specific IgE titres 
could not be detected at 14 d. However, mean values of PE-specific in this group, 
calculated after excluding these two rats, showed increased values in both the 1 and 
Thesis De Jonge V9.pdf   89 9-10-2009   11:37:09
 90 
10 mg PE group (Fig. 1A). This increase was significant (P=0.026) when all dosing 
groups were compared with rats that were not treated with LcS. If separate allergen 
dosages were evaluated, this increase was not significant. On d 42 no significant 
effect of LcS on the IgE response was found (Fig. 1B). 
 
 
FIGURE 1. PE- specific IgE titers following 14 and 42 d of oral exposure to peanut 
Groups of female rats (n=8 for each dosing regimen) received 0, 1 or 10 mg/rat/d of peanut extract (PE). 
Data are displayed as serum reciprocal antigen-specific IgE titers (average + S.E.M) on d 14 (A) or on d 42 
(B). Grey bars represent the non-treated groups and striped grey bars represent the Lactobacillus casei 
Shirota (LcS)-treated groups (1*109 CFU of LcS/rat/d). 
LcS significantly increased the overall difference in PE-specific IgE levels at d 14 (P=0.026). 
The effect of LcS on PE-specific IgG2a and IgG1 
Sensitization with 1 or 10 mg PE, resulted in increased PE-specific IgG1 and IgG2a serum levels at d 14, 
28, 42 and 49. LcS significantly further increased PE-specific IgG1 levels at d 14 (P=0.019) and d 49 
(P=0.019) at the level of overall difference between LcS-treated and non-treated groups. If separate 
allergen dosages were evaluated, the increase of IgG1 levels was significant in the 10 mg PE/rat/d at d 14 
(P=0.030), d 42 (P=0.044) and d 49 (P=0.044) (Table 1A). 
LcS also significantly further increased PE-specific IgG2a levels at d 42 (P=0.009) at the level of overall 
difference between LcS-treated and non-treated groups. If separate allergen dosages were evaluated, 
the increase of IgG2a levels was significant in the 10 mg PE/rat/d at d 14 (P=0.021) and d 42 (P=0.019) 
(Table 1B). 
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TABLE 1. PE-specific IgG1 and IgG2a titers in time 
TABLE 1A. PE-specific IgG1 titers in time 
PE (mg/rat/d) 0 0 + LcS 1 1 + LcS 10 10 + LcS 
       
d 14 0.00 + 0.00 0.00 + 0.00 11.60 + 1.10 14.00 + 1.04 14.11 + 0.46 16.25a + 0.80 
d 28 0.00 + 0.00 0.88 + 0.88 17.38 + 0.66 17.00 + 0.87 17.25 + 0.53 18.86 + 0.60 
d 42 1.38 + 1.38 3.50 + 1.77 17.29 + 0.36 18.13 + 0.64 17.13 + 0.52 19.17a + 0.79 
d 49 1.38 + 1.38 3.38 + 1.68 17.29 + 0.84 18.25 + 0.53 17.25 + 0.86 20.00a + 0.82 
 
TABLE 1B. PE-specific IgG2a titers in time 
PE (mg/rat/d) 0 0 + LcS 1 1 + LcS 10 10 + LcS 
       
d 14 0.88 + 0.88 0.00 + 0.00 10.60 + 1.00 11.88 + 0.64 11.89 + 0.48 13.63a + 0.46 
d 28 0.00 + 0.00 1.13 + 1.13 15.25 + 0.62 15.13 + 0.44 13.50 + 0.42 14.86 + 0.59 
d 42 0.00 + 0.00 2.63 + 1.72 15.57 + 0.57 16.50 + 0.42 13.88 + 0.52 16.33a + 0.80 
d 49 0.00 + 0.00 3.00 + 1.97 16.29 + 0.61 16.63 + 0.53 15.00 + 0.50 16.33 + 0.84 
Groups of female rats (n=8 for each dosing regimen) received 0, 1 or 10 mg/rat/d of peanut extract (PE). 
Data are displayed as serum reciprocal antigen-specific IgG1 titers (average + S.E.M) in time (A) and serum 
reciprocal antigen-specific IgG2a titers (average + S.E.M) in time (B). The tables display the non-treated 
groups and the Lactobacillus casei Shirota (LcS)-treated groups (1*109 CFU of LcS/rat/d) in a direct compari-
son. 
LcS significantly increased the overall difference in PE-specific IgG1 (d 14: P=0.019; d 49: P=0.046) and IgG2a 
levels (d 42: P=0.009). 
a effects of LcS on PE-specific IgG1 or IgG2a levels were significant when separate allergen dose groups were 
analyzed: P=0.030 (d 14 IgG1; 10 mg PE + LcS compared to 10 mg PE), P=0.044 (d 42 IgG1; 10 mg PE + LcS 
compared to 10 mg PE), P=0.044 (d 49 IgG1; 10 mg PE + LcS compared to 10 mg PE), P=0.021 (d 14 IgG2a; 10 
mg PE + LcS compared to 10 mg PE) and P=0.019 (d 42 IgG2a; 10 mg PE + LcS compared to 10 mg PE). 
 
To determine the effects of LcS on the Th1/Th2 ratio, the ratio of the increase of PE-
specific IgG1 over the increase of PE-specific IgG2a on d 42 was calculated. In rats 
that daily received 10 mg PE a significant shift towards Th2 dominance due to LcS 
treatment was found on d 14, and in rats that received 1 mg PE such a significant 
shift was noted at d 28.The greatest shift in this ratio was found on d 42, where LcS 
significantly shifted the Th1/Th2 ratio towards Th2 in both sensitized groups (Figure 
2). At d 49 this effect had disappeared. 
 
The effect of LcS on white blood cells, basophilic granulocytes and rat mast cell pro-
tease-II 
The numbers of basophilic granulocytes were significantly increased (P=0.017) by 
LcS in the 1 mg PE group as compared to it’s untreated control (Fig. 3). The numbers 
of lymphocytes, neutrophils, monocytes and eosinophilic granulocytes were not 
affected by LcS compared to the non-treated groups (data not shown). 
Sensitization with 1 or 10 mg PE, resulted in a dose-dependent increased of PE-
mediated RMCPII release (Fig. 4). Modulation with LcS did not significantly alter the 
increase in release of RMCPII. 
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FIGURE 2. PE-specific IgG1/IgG2a ratio’s in time 
Groups of female rats (n=8 for each dosing regimen) received 0, 1 or 10 mg/rat/d of peanut extract (PE). To 
determine the effect of LcS on the Th1/Th2 balance, differences (value LcS treated groups divided by the 
value of the non-treated groups) in IgG1 levels of sensitized animals (d 42) were divided by the differences in 
corresponding IgG2a levels. Data are displayed as IgG1/IgG2a ratio’s (average + S.E.M.) in time. Grey bars 
represent the ratio of the non-treated groups and striped grey bars represent the ratio of the Lactobacillus 
casei Shirota (LcS)-treated groups (1*109 CFU of LcS/rat/d), the d at which the ratio was calculated is dis-
played within each bar. 
LcS significantly increased the overall difference in PE-specific IgG1/IgG2a ratio at d 42 (P=0.018);  a effects of LcS 
on the PE-specific IgG1/IgG2a ratio were significant when separate allergen dose groups were analyzed: 
P=0.003 (d 14; 10 mg PE + LcS compared to 10 mg PE), P=0.039 (d 28; 1 mg PE + LcS compared to 1 mg PE), 
P=0.003 (d 42; 1 mg PE + LcS compared to 1 mg PE) and P=0.028 (d 42; 10 mg PE + LcS compared to 10 mg PE). 
 
 
FIGURE 3. Numbers of basophilic granulocytes 
Groups of female rats (n=8 for each dosing regimen) received 0, 1 or 10 mg/rat/d of peanut extract (PE). 
Data are displayed as numbers of basophilic granulocytes (average + S.E.M) in blood of d 49 (x109/L). Grey 
bars represent the non-treated groups and striped grey bars represent the Lactobacillus casei Shirota (LcS)-
treated groups (1*109 CFU of LcS/rat/d);  a effects of LcS on basophilic granulocytes were significant when 
separate allergen dose groups were analyzed: P=0.017 (1 mg PE + LcS compared to 1 mg PE). 
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FIGURE 4. RMCPII release after oral challenge 
Groups of female rats (n=8 for each dosing regimen) received 0, 1 or 10 mg/rat/d of peanut extract (PE). 
Data are displayed as serum rat mast cell protease II (RMCPII) levels (average + S.E.M) on d 49, 30 min 
after oral challenge with 100 mg PE/rat. Grey bars represent the non-treated groups and striped grey 
bars represent the Lactobacillus casei Shirota (LcS)-treated groups (1*109 CFU of LcS/rat/d). 
 
 
The effect of LcS on cytokine levels in supernatants of PE-stimulated spleen and MLN 
cells 
MLN and spleen cells from PE-sensitized rats showed modest antigen-specific pro-
liferative responses after in vitro culture with PE for 96 hr. In addition, restimulation 
of spleen lymphocytes with PE resulted in increased IFN-γ levels in both the 1 mg 
(P=0.013) and 10 mg PE (P=0.017) groups. LcS did not affect IFN-γ levels in either 
antigen-specific stimulated spleen or MLN cells (data not shown). 
Figure 5 shows IL-4 levels in supernatants of cell suspensions of spleen (Fig. 5A) and 
MLN (Fig 5B) cells that were ex vivo restimulated with PE for 96 hours. LcS signifi-
cantly increased IL-4 levels further at the level of overall difference between LcS-
treated and non-treated groups in the supernatants of both spleen and MLN cells. 
In rats that were dosed with 1 or 10 mg PE, without LcS, IL-4 levels were not signifi-
cantly affected. In the 1 mg PE group, LcS significantly increased IL-4 levels in cell 
suspensions of spleen (P=0.010) and MLN cells (P=0.014). In the 10 mg PE group, LcS 
did not affect IL-4 production. 
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FIGURE 5. IL-4 levels in PE-restimulated spleen and MLN cells 
Groups of female rats (n=8 for each dosing regimen) received 0, 1 or 10 mg/rat/d of peanut extract (PE). 
Spleens and mesenteric lymph nodes (MLNs) were dissected at d 49 and their cells were incubated with 
PE (1 mg/ml) in cell cultures (4x105 cells/culture). Data are displayed as IL-4 levels (average + S.E.M) in the 
supernatants of spleen (A) or MLN (B) cultures. Grey bars represent the non-treated groups and striped 
grey bars represent the Lactobacillus casei Shirota (LcS)-treated groups (1*109 CFU of LcS/rat/d). 
LcS significantly increased the overall difference in IL-4 levels in the supernatants of spleen cells 
(P=0.003) and of MLN cells (P=0.006). 
a effects of LcS on IL-4 levels were significant when separate allergen dose groups were analyzed: P=0.010 
(spleen; 1 mg PE + LcS compared to 1 mg PE) and P=0.014 (MLN; 1 mg PE + LcS compared to 1 mg PE). 
 
 
DISCUSSION 
We investigated whether the probiotic strain Lactobacillus casei Shirota (LcS) could 
influence the food allergic response against peanut extract (PE) in a BN rat model 
for food allergy. The most pronounced effects of LcS were found on allergen-specific 
cytokine production. The Th2- related cytokine IL-4 was increased by LcS and this 
increase was found in the supernatants of both spleen and MLN cultures. IFN-γ was 
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also non-significantly increased in the supernatants of both spleen and MLN cul-
tures of the control animals. This indicates that LcS had an effect on IFN-γ that was 
independent of the PE-response, which has been described earlier (Ezendam and 
van Loveren 2008). The most pronounced effect of LcS noted in this study was on IL-
4 production in rats that were dosed with 1 mg PE. In contrast, in rats that received 
1 or 10 mg PE, IFN-γ production was not affected by LcS. It is remarkable that the 
effect of LcS on IL-4 was only observed in the 1 mg PE group. This is possibly due to 
the timing of the experiment: IL-4 was measured after 96 hours of culturing, which 
might be too late for the 10 mg PE group. 
Effects of LcS on PE-specific IgE levels were only observed after 14 days of exposure. 
In the 1 mg PE group, LcS increased specific IgE levels further. In the 10 mg PE 
group, however, two rats did not respond with specific IgE levels, whereas the mean 
values of the other six rats were increased compared to the rats that did not receive 
LcS. At day 42, the levels of IgE were similar in rats that did or did not not receive 
LcS. Taken together, our data do not show statistically decreased IgE titres as a 
result of LcS treatment. This is in contrast to what has been previously published 
(Matsuzaki and Chin 2000; Matsuzaki et al. 1998; Shida et al. 2002), but in accord to 
other studies that failed to demonstrate suppressive effects of LcS on specific IgE 
levels (Ezendam and van Loveren 2008). It should be noted that these latter obser-
vations were not done in oral sensitization models, but rather in intraperitoneal or 
respiratory sensitization models. 
Both PE-specific IgG1 and IgG2a antibody titres were increased by LcS during the 
course of the experiment. This increase was directed more towards Th2, which is 
accordance with the observed effects on cytokine production. In contrast to what 
was hypothesized, based on the notion that if LcS would suppress allergic re-
sponses, LcS could also suppress the food allergic response, our results indicate that 
LcS increased the levels of PE-specific IgE, IgG1 and IgG2a, although IgE was only 
affected early after exposure to PE. Enhancement of the immune system by LcS was 
also illustrated by an increase of the number of basophils. LcS did not affect mast 
cell degranulation, as measured by the release of RCMP-II. This parameter is consid-
ered to be clinically relevant, since mediators released from mast cells cause clinical 
symptoms in allergic patients. 
From our experimental data, we can conclude that LcS stimulates certain responses 
in this experimental model for peanut allergy, rather than suppressing the food 
allergic response. Our study does therefore not support the hypothesis that probiot-
ics have a protective role in the prevention of allergic responses in our BN rat model 
for food allergy against peanut. It is important to note that effects of probiotics are 
highly dependent on the species and strain used, and further depend on viability, 
dose and time (Broekaert and Walker 2006; de Waard et al. 2003; Kalliomaki and 
Isolauri 2004). Hence, although our study does not demonstrate an inhibitory effect 
of LcS on the food allergic response, this does not necessarily imply that other pro-
Thesis De Jonge V9.pdf   95 9-10-2009   11:37:09
 96 
biotic strains would not have such effects. Furthermore, in other studies LcS has 
been shown to decrease IgE responses against OVA (Shida et al. 1998; Shida et al. 
2002), which could imply that the effects of a probiotic strain are also dependent on 
the experimental model used. 
At present, evidence for efficacy of probiotics on allergy prevention in humans is 
scarce. Although there are some promising results on prevention and alleviation of 
atopic eczema in infants (Kalliomaki et al. 2001; Kalliomaki et al. 2003; Rosenfeldt et 
al. 2003; Sistek et al. 2006; Viljanen et al. 2005), at the moment no effects on atopic 
manifestations that occur later in life, e.g. asthma, have been reported. More im-
portantly, a recent study has demonstrated that L. plantarus enhanced sensitization 
to food and respiratory allergens in infants that received this probiotic in the first six 
months of their lives (Taylor et al. 2007). It is unknown if the observed increase in 
sensitization will also lead to an increased development of clinical effects in these 
infants. Additionally, a recent review, in which twelve randomized clinical trails 
were included, has demonstrated that probiotics significantly reduce infant eczema. 
However, when the analysis was restricted to studies on IgE-dependent atopic ec-
zema the reduction in eczema was no longer significant. In addition, it was shown 
that no benefits were reported for any other allergic disease or hypersensitivity 
outcome (Osborn and Sinn 2007). Recently, it has been shown that probiotics might 
beneficially affect rhinitis induced by Japanese cedar pollen. In a randomized dou-
ble-blind, placebo-controlled study LcS did not prevent allergic symptoms, but after 
subgroup analysis it was shown that in patients with moderate-to-severe nasal 
symptom scores, LcS delayed the occurrence of allergic symptoms (Tamura et al. 
2007). Hence, currently there is insufficient evidence from human studies for the 
efficacy of probiotics in prevention of either allergic diseases or food hypersensitiv-
ity. 
More research is needed to substantiate efficacy of probiotics in allergy prevention. 
Experimental animal models for allergy are useful to select probiotics which could 
be effective in allergy prevention and can provide more insight in the mechanisms 
involved. Efficacy and safety, however, should both be demonstrated in humans. 
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ABSTRACT 
New techniques are needed to broaden the understanding of the food allergic re-
sponse. The capacity of peanut extract to influence gene expression profiles was 
investigated in a Brown Norway rat model for food allergy. 
Brown Norway rats were sensitized to peanut extract (0, 1 and 10 mg/rat/d) by daily 
oral gavage and were dissected after 3, 7 or 14 days of exposure. RNA extracted 
from mesenteric lymph nodes of individual rats were hybridized against a common 
reference pool on Agilent whole rat genome (4*44k) arrays. The raw data were 
normalized and statistically analyzed using the statistical program R. A False Discov-
ery Rate of 10% and a Fold Ratio of -1.5 ≤ Fold Ratio or Fold Ratio ≥ 1.5 between the 
experimental groups and their respective control groups were applied. Differentially 
expressed genes were clustered into a heatmap. Functional annotation and Gene-
Ontology term enrichment were examined. Furthermore, the involvement of the 
differentially expressed genes in specific cellular pathways was investigated with 
MetaCore. 
Gene expression changes, which were both dose- and time-dependent, were de-
tected after sensitization to peanut. A total of 64 genes were differentially ex-
pressed, of which 60 were up-regulated and four were down-regulated. These 
changes were related to the regulation of immunological processes, most notably 
increased cell division. 
The findings indicate that responses to peanut include proliferation of immunologi-
cally relevant tissues, which can be identified by analysis of gene expression pro-
files. This may lay a basis for further research into possibilities for discrimination of 
allergenic from non-allergenic proteins. 
 
 
INTRODUCTION 
About 2% of the adult population and 6-8% of children below the age of 3 are af-
fected by a food allergy (Burks and Ballmer-Weber 2006; Untersmayr and Jensen-
Jarolim 2006), which sometimes results in fatal reactions (anaphylactic shock) (Si-
cherer 2002). It is often difficult to predict whether foods that so far were not sub-
stantially consumed (novel foods) may be allergenic, and this problem may further 
increase due to the production of genetically modified food resulting in the intro-
duction of new potentially allergenic proteins (Taylor 2006). 
Animal models, although not yet validated, have been proposed for assessing the 
potential allergenicity of novel foods. In such models, specific IgE synthesis as well 
as other features such as mast cell mediator release, are indicators of allergenicity 
of the products to which the animals are exposed. 
The publication of the sequence of the human genome has resulted in a dramatic 
increase in knowledge in the field of genomics (Gatzidou et al. 2007) and as a con-
sequence, during the past two decades great advances have been achieved in mo-
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lecular biology. One of the most recent techniques accountable for these advances 
is the microarray technique. DNA microarrays permit the quantitative measurement 
of the expression levels of thousands of individual genes in different biological sam-
ples at the same time. Another benefit of this technique is that it allows for moni-
toring of early parameters of biological effects. Several studies have shown that it is 
possible to detect changes in the gene expression profile after exposure to immu-
nomodulating agents, both in vivo (Ezendam et al. 2004) and in vitro (Schoeters et 
al. 2007). Schoeters et al. (Schoeters et al. 2007) compared the gene expression 
profiles of dendritic cells (DCs) exposed to contact allergens and irritants. They 
found 25 genes that were altered in response to contact allergens, but not to the 
irritants. Most of these genes could be linked to the immune response and/or to 
their expression in DCs. So far no studies have been performed that assessed the 
expression profile in food allergy. We aimed to test whether effects on the gene 
expression profile could be found in an in vivo setting of food allergy. 
In the study described below, the effects of oral exposure to peanut extract (PE) on 
gene expression was investigated in a Brown Norway (BN) rat model for food al-
lergy. PE is known to produce food allergic reactions in humans and rats. PE is the 
whole aqueous peanut extract and consists of several peanut allergens in the aque-
ous peanut matrix. Changes in expression of immunologically relevant and other 
genes that would be detected in this experimental setting could yield additional 
insight into the mechanisms of responses to proteins, including food allergens, and 
could eventually help to provide early markers of food allergy. 
 
 
METHODS 
Animals 
PE sensitization was studied in young Brown Norway (BN) rats. In this study Brown 
Norway (BN Rij:Hsd) rats obtained from Harlan Netherlands B.V. (Horst, the Nether-
lands) were used. These rats were bred and raised on a peanut and soy protein-free 
diet (because soy and peanut are cross-reactive legumes) obtained from Harlan 
Netherlands B.V. (2016S Teklad Global 16% Protein Rodent Diet) at our institute 
Female rats of the third generation (F3) and onwards were used and fed the peanut 
and soy protein-free diet during the experiment. At study initiation, the rats were 3-
4 weeks old. The rats were housed in an animal room maintained at 23 ± 3˚C, with a 
light/dark cycle of 14 h/10 h, and a relative humidity of 30-70% during the experi-
ment and for at least 7 days prior to study initiation. The animals were housed in 
stainless-steel wire (Macrolon III) cages in groups of two and had free access to food 
and tap-water. The guidelines described in the Dutch “Experiments on Animals” Act 
(1997), which can be found online 
(http://www.vet.uu.nl/nca/userfiles/other/The_Dutch_Experiments_on_Animals_A
ct.pdf), were applied for the care and use of the animals. Approval from the Institu-
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tional Animal Ethics Committee was obtained for all experimental procedures in-
volving animals. 
 
PE sensitization 
To ensure that animals were immunologically naive with respect to peanut, pre-
study blood samples were always tested for allergen specific antibodies. Rats were 
randomly allocated to their dosing regimens (n=8 per dosing regimen). Some reallo-
cation was performed to ensure even starting weight distribution in all dosing regi-
mens. Rats were exposed to 1 ml of 0, 1 or 10 mg/ml PE in PBS by daily po gavage, 
using a 18-gauge stainless steel animal feeding needle for the duration of 3, 7, or 14 
days for the microarrays and 42 days followed by 7 days of rest (no PE sensitization) 
for the mesenteric lymph node (MLN) proliferation assay. After exposure the rats 
were sacrificed by exsanguination from the aorta under CO2/O2 anesthesia. The 
MLNs were removed aseptically and stored at -80°C for RNA isolation. For the pro-
liferation assay single cell suspensions were prepared from fresh MLNs for prolifera-
tion analysis of MLN cells after ex-vivo re-stimulation with PE. 
 
PE-specific IgE, IgG1 and IgG2a ELISAs 
PE-specific IgE, IgG1, IgG2a levels were measured to examine whether the animals 
were adequately sensitized. PE-specific IgE, IgG1 and IgG2a Enzyme-Linked Immu-
noSorbent Assay (ELISAs) were performed as described earlier (de Jonge et al. 
2007b). Serum samples were collected at sacrifice at day 3, 7 and 14. 
 
Ex vivo stimulation of spleen cells: allergen-specific cell proliferation 
Assessment of PE-specific proliferation was done to assess if the rats animals were 
adequately sensitized. Single cell suspensions were prepared under aseptic condi-
tions by pressing the MLN through a 70 μm nylon cell strainer (Falcon, Franklin 
Lakes, USA). Cells were washed twice and resuspended in 5 mL standard medium 
(RPMI 1640 + 25 mM Hepes + L-Glutamine) obtained from Gibco BRL (Breda, the 
Netherlands) supplemented with 10% heat inactivated fetal calf serum (FCS) ob-
tained from Integro B.V. (Zaandam, The Netherlands) and 1% penicillin-
streptomycin (Gibco) with 7.5x10-5 M 2-mercaptoethanol (2-ME) obtained from 
SERVA (Heidelberg, Germany). Cell number was determined with a Coulter Counter 
(Z2, Coulter Electronics, Mijdrecht, The Netherlands). Cell viability was determined 
by the Trypan blue cytotoxicity test. The concentration of the cell suspensions was 
adjusted to 1x106 viable cells/ml. 
For cell proliferation, 100 μL of the cell suspension was added per well in triplicate. 
Cells were incubated for 96 h with 2 mg/ml PE and [3H]-Thymidine was added for 
the last 18-20 h. The optimal time point to assess lymphocyte proliferation was 
established in previously performed studies and 96 hours was the most optimal 
time point. 
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RNA isolation 
The RNA of the MLNs was isolated using the RNeasy Lipid Tissue midi kits (Qiagen, 
Maryland, USA) according to the manufacturers’ instructions. To start the proce-
dure, the frozen MLNs were first finely crushed using a pestle and mortar cooled 
with liquid nitrogen, after which the crushed tissue was transmitted into 5 mL Qia-
zol Lysis Reagent (Qiagen) and homogenized to allow immediate lysis after thawing. 
The quantity of RNA in each sample was determined spectrophotometrically (DU 
800-spectrophotometer, Beckman Coulter, Fullerton, CA, USA) and RNA integrity 
was assessed using a Bioanalyzer 2100 (Agilent Technologies, Breda, the Nether-
lands). The RNA samples were stored at -80ºC until used. A common reference pool 
was prepared by mixing 0.33 µg of RNA of all samples to be analyzed. 
 
RNA amplification and labeling 
First, 0.5 µg total RNA (volume: 3.25 µL) of each sample and 1 µg RNA (volume: 6.5 
µL) of the common reference pool was used for the labelling with Cyanine fluoro-
phores (Cy3 and Cy5; Agilent Technologies) using the Low RNA Input Linear Amplifi-
cation kit (Agilent Technologies) according to the manufacturers’ instruction, with 
some adjustments. To the samples, 2.5 µL T7-primer, 4.25 µL cDNA mastermix and 
15 µL transcription mastermix were added per reaction; to the refence pool, 5 µL 
T7-primer, 8.5 µL cDNA mastermix and 30 µL transcription mastermix were added 
per reaction. Briefly, the total RNA was reverse transcribed into cDNA using T7-
primers and MMLV reverse transcriptase. This cDNA was transcribed into cRNA, 
during which the fluorophores were incorporated into the RNA; Cy3 was incorpo-
rated into the common reference pool and Cy5 was incorporated into the samples. 
Next, the cDNA was purified using the RNeasy Mini kit (Qiagen) according to the 
manufacturer’s instructions and the incorporation rate of the fluorophores into the 
cRNA was determined spectrophotometrically. Only samples with a dye-
incorporation rate of ≥ 7 pmol/µg cRNA were considered suitable for further proc-
essing. 
 
Hybridization 
The labeled cRNA was prepared for hybridization using a Gene Expression Hybridiza-
tion Kit (Agilent Technologies), according to manufactures’ instructions. A mix of 
equal amounts of cRNA from the samples and the common reference pool was 
hybridized to slides from the Whole Rat Genome (4x44k) Oligo Microarray Kit 
(Agilent Technologies). This technique is also known as a two dye microarray; one 
dye for the individual samples and the other dye for the pooled reference sample, 
whereby the pooled reference sample allows for standardized comparison of indi-
vidual samples. In total, 23 array slides with each four samples/ slide were gener-
ated. The arrays were hybridized for 17 hours at 65 °C in a hybridization oven 
(Agilent technologies). After washing the slides with the Gene Expression Wash 
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Buffer kit (Agilent Technologies) according to the manufacturer’s protocol, the 
slides were dipped in Stabilization and Drying Solution (Agilent) (2:1 diluted with 
acetonitrile) to protect the slides from environmental ozone and dried with N2 . 
 
Scanning 
Immediately after washing, the arrays were scanned (GenePix 4000B) with a scan 
precision of 5 µm which generated separate Cy3 and Cy5 images. The photomulti-
plier tube (PMT)-gain for Cy5 was set at 623 nm and the PMT-gain for Cy3 was set at 
450 nm. Imagene software was used to determine Cy3 and Cy5 signal intensities for 
each separate spot and the background noise. Quality control was performed on the 
raw data: first, the scans were visually inspected in Imagene followed by analyses of 
the raw data using a specifically designed Excel-file application. In this application 
the raw data were visualized as a scatter plot and an M/A-plot as well as a normal 
probability plot to assess signal distribution. 
 
Data analysis 
The raw data were normalized using the statistical program R (www.r-project.org), 
in three steps: (1) natural log-transformation, (2) quantile normalization of all scans 
and (3) correction of the sample spot signal for differences in the corresponding 
reference spot signal between arrays. For additional quality control, these normal-
ized data were visualized by Principle Component Analysis (PCA). Next, statistical 
analysis of the data took place; in R significance of differences in gene expression 
between the experimental groups was calculated with one-way ANOVA. A False 
Discovery Rate (FDR) of 10% and a Fold Ratio (FR) of -1.5 ≤ FR or FR ≥ 1.5 between 
the experimental groups and their respective control groups were applied. 
Differentially expressed genes were clustered into a heatmap using GeneMaths 
(Applied Maths, St-Martens-Latem, Belgium). Functional annotation and GeneOn-
tology (GO) term enrichment (www.geneontology.org) were examined with the 
DAVID/EASE program (david.abcc.ncifcrf.gov/). MetaCoreTM (GeneGo, San Diego, 
CA) was used to identify and visualize the involvement of the differentially ex-
pressed genes in specific cellular pathways, and this was related to the total amount 
of genes involved in the particular pathway and in all the available pathways com-
bined. 
 
Statistics of ex vivo proliferation assay 
To determine if PE altered the ex vivo proliferation of MLNs within a dosing group of 
PE a one-way ANOVA with Bonferroni as post hoc test was done. Differences were 
considered significant if p < 0.05 (two-sided). 
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RESULTS 
Antigen-specific antibodies 
The animals were naïve at the level of antigen-specific antibodies before study ini-
tiation. At day 3 PE-specific IgE, IgG1 and IgG2a were not detectable in both dosing 
groups. At day 7, increased levels of PE-specific IgG2a and IgG1 levels were detected 
in the 10 mg PE group. At this time-point PE-specific IgE levels were not detectable 
(data not shown). At day 14, PE-specific IgG1 (Fig. 1C) and IgG2a titres (Fig. 1B) are 
detectable in both dosing groups. PE-specific IgE titres are detectable in 4 of the 8 
rats in the 1 mg PE group and in 6 of the 8 rats in the 10 mg PE group (fig. 1A). 
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FIGURE 1. PE-specific IgE, IgG2a and IgG1 titers after 14 days of exposure to PE. 
Groups of female rats (n=8 for each dosing regiment) received 0, 1 or 10 mg PE/rat/day by daily oral 
gavage. PE-specific Ig titers (2log) are shown at day 14: (A) displays PE-specific IgE titers, (B) displays PE-
specific IgG2a titers and (C) displays PE-specific IgG1 titers. 
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PE-specific lymphocyte cell proliferation of MLN cells 
Figure 2 shows that in vivo dosing with 10 mg PE/rat/day group increased the PE-
specific ex vivo proliferation, as compared to the 0 mg PE/rat/day group of MLN 
cells. This change was not significant, due to variability especially in the 10 mg pea-
nut/rat/day group, but a strong dose-response correlation was found (R2 of 0.9999). 
 
 
FIGURE 2. PE-specific proliferation of MLN cells 
Groups of female rats (n=8 for each dosing regiment) received 0, 1 or 10 mg PE/rat/day by daily oral 
gavage. MLNs were dissected at day 49, single cell suspensions were prepared and 1x105 cells/well were 
incubated with 1 mg/ml PE for 96 h. In earlier studies were we performed time series analysis we found 
96 h of restimulation with PE to be the optimal time point for lymphocyte proliferation. Lymphocyte 
proliferation of MLN cells is expressed in cpm (*105) per organ. 
a y = 0.5923x + 6.7682 with a R2 of 0.9999 define the trendline of the dose response between ex vivo PE-
specific proliferation of MLN cells and in vivo PE-dosing. 
 
Gene expression profiles 
Gene expression data of the three groups exposed to 1 mg PE/rat/day and the three 
groups exposed to 10 mg PE/rat/day were compared to the data of their time-
matched controls by one-way ANOVA. An apparent time-effect was seen, as well as 
a clear dose-response relationship. Differential gene expression was most pro-
nounced on day 7 for both the 1 mg and the 10 mg PE/rat/day group. The groups 
exposed to 10 mg PE/rat/day showed a stronger effect on all three days than the 
groups exposed to 1 mg PE/rat/day. On day 7 in the 10 mg PE/rat/day exposure 
group 60 genes were differentially expressed with a Fold Ratio of > 1.5; on day 7 in 
the 1 mg PE/rat/day exposure group 12 genes were differentially expressed with a 
Fold Ratio of > 1.5. In total, 64 genes were differentially expressed with a Fold Ratio 
of > 1.5 in one or more of the groups exposed to PE, of which there were 50 unique 
identifiable genes. 
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Table I shows these genes with the FRs for the different exposure groups. In this 
table the genes are itemized into three groups: (Table I A) cell cycle genes, (Table I 
B) immunological genes and (Table I C) other genes. Figure 3 shows the clustering of 
these regulated genes. GO term enrichment analysis showed that cluster A, which 
consists of consistently up-regulated genes for both dosing regimens, was signifi-
cantly enriched for cell cycle-related and immunological genes. In addition, Meta-
Core analysis of the differentially regulated genes resulted in the identification of 
several pathways in which the proteins coded by these genes were implicated. The 
six most regulated pathways identified by MetaCore were involved in cell cycle, 
confirming the GO-term enrichment analysis. These pathways were (number of 
genes regulated of the total genes included in this pathway during analysis are 
placed between brackets): role anaphase-promoting complex (APC) in cell cycle 
regulation (8 of 53), nucleocytoplasmic transport of cyclin-dependent kinase 
(CDK)/cyclins (4 of 22), cell cycle (generic schema; 4 of 26), the metaphase check-
point (4 of 36), ataxia telangiectasia mutated (ATM)/ ataxia telangiectasia and 
RAD3-related (ATR) regulation of G2/M checkpoint (3 of 29) and chromosome con-
densation in prometaphase (3 of 33). Figure 4 shows the highest ranking pathway 
obtained by MetaCore analysis. It represents the role of the APC in cell cycle regula-
tion and illustrates the expression changes for cell cycle related genes. The genes 
involved in the six most significant pathways were: Cdk1 (cyclin-dependent kinase; 
cdc2a: cell division cycle 2a), cyclin A, cyclin E and SPBC24 (Spbc24), which were up-
regulated at day 7 in BN rats exposed to 1 mg PE/rat/day or 10 mg PE/rat/day; and 
cyclin B1, MAD2 (mitotic arrest deficient; Mad2l1), Cks1 (Cdc kinase subunit 1; 
RGD1561797), geminin, BUB1 (budding uninhibited by benzimidazoles 1 homolog, 
beta; Bub1) and BUBR1 (Bub1b) which were up regulated at day 7 after exposure to 
10 mg PE/rat/day, but not after exposure to 1 mg PE/rat/day. All these genes were 
proliferation related. 
 
No immunological pathways based on sufficient numbers of regulated genes were 
found using MetaCore analysis, but several individual immunologically relevant 
genes were regulated by PE in the food allergy model: adenosine deaminase (ADA), 
immunoglobulin light chain variable region (Ig), IgG1, Igj, tumor necrosis factor re-
ceptor (TNFR) superfamily, member 17 (Tnfrsf17), Siva and tumor rejection antigen 
gp96 (Tra1). These genes were all up-regulated in the exposure group receiving 10 
mg PE/rat/day at day 7, Tra1 was also up-regulated in the 1 mg PE/rat/day group at 
day 7. 
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TABLE I: Individually regulated genes in a rat model for peanut allergy 
A: Cell cycle genes 
Accession  
number 
Symbol Gene name FR 
1mg PE/rat/day 10mg PE/rat/day  
3d 7d 14d 3d 7d 14d 
XM_215849 Bub1_predicte
d 
budding uninhibi-
ted by benzimida-
zoles 1 homolog (S. 
cerevisiae) (pre-
dicted) 
-1.03 1.49 1.07 -1.03 2.07A 1.10 
NM_053702 Ccna2 cyclin A2 1.13 1.51A 1.07 1.18 1.92A 1.05 
NM_171991 Ccnb1 cyclin B1 -1.10 1.49 -1.01 -1.06 1.85A 1.05 
NM_019296 Cdc2a cell division cycle 2 
homolog A (S. 
pombe) 
-1.10 1.69A 1.11 -1.08 2.6A 1.07 
XM_214152 Cdkn3_predict
ed 
cyclin-dependent 
kinase inhibitor 3 
(predicted) 
-1.07 1.69A 1.00 -1.04 2.7A 1.19 
XM_218601 E2f8 E2F transcription 
factor 8 
1.01 1.41 1.14 -1.05 1.94A 1.21 
XM_214477 Gmnn_predict
ed 
geminin (pre-
dicted) 
-1.05 1.47 -1.00 -1.11 1.67A 1.05 
XM_216161 Mad2l1_predic
ted 
MAD2 (mitotic 
arrest deficient, 
homolog)-like 1 
(yeast) (predicted) 
-1.13 1.29 1.02 -1.08 1.59A 1.10 
NM_022381 Pcna proliferating cell 
nuclear antigen 
-1.05 1.48 1.02 1.05 1.6A -1.00 
XM_236477 Ttk_predicted Ttk protein kinase 
(predicted) 
-1.03 1.44 1.07 -1.00 1.91A 1.06 
XM_213891 
 
Aspm_predicte
d 
 
asp (abnormal 
spindle)-like, 
microcephaly 
associated (Droso-
phila) (predicted) 
-1.08 1.42 -1.04 -1.08 1.89A 1.07 
XM_342494 
 
Bub1b 
 
budding uninhibi-
ted by benzimida-
zoles 1 homolog, 
beta (S. cerevisiae) 
1.00 1.33 1.16 1.01 1.59A 1.12 
XM_001077331 Ccne1 cyclin E -1.03 1.54A 1.07 1.02 2.23A 1.13 
XM_226624 Ell2 elongation factor 
RNA polymerase II 
2 
1.06 1.14 1.02 1.04 2.02A 1.18 
XM_226624 Ell2 elongation factor 
RNA polymerase II 
2 
1.09 1.15 -1.14 1.18 1.67A 1.08 
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XM_341592 
 
Kif20a_predict
ed 
 
kinesin family 
member 20A 
(predicted) 
-1.11 1.47 1.03 -1.16 1.97A 1.12 
NM_001025740 
 
Rrm2_mapped 
 
ribonucleotide 
reductase M2 
1.00 1.50A -1.01 -1.01 2.93A 1.19 
NM_001025740 
 
Rrm2_mapped 
 
ribonucleotide 
reductase M2 
-1.03 1.40 1.01 1.03 2.06A 1.18 
BG153336 
 
Smarcb1 
 
SWI/SNF related, 
matrix associated, 
actin dependent 
regulator of chro-
matin, subfamily b, 
member 1 
-1.02 1.16 1.01 -1.04 1.75A 1.21 
XM_215471 
 
Solt_predicted 
 
SoxLZ/Sox6 leucine 
zipper binding 
protein in testis 
(predicted) 
1.10 1.42 1.02 1.06 1.93A 1.00 
XM_343359 
 
Spbc24_predic
ted 
 
spindle pole body 
component 24 
homolog (S. cere-
visiae) (predicted) 
1.01 1.62A 1.02 -1.01 2.06A -1.04 
 
B: Immunological genes 
Accession  
number 
Symbol Gene name FR 
1mg PE/rat/day 10mg PE/rat/day  
3d 7d 14d 3d 7d 14d 
Immunological genes 
NM_130399 Ada adenosine  
deaminase 
1.00 1.18 -1.01 -1.02 1.95A 1.09 
NM_130399 Ada adenosine  
deaminase 
-1.00 1.33 -1.02 -1.04 1.99A 1.18 
XM_344042 Ig similar to immu-
noglobulin light 
chain variable 
region (predicted) 
1.00 1.04 -1.06 -1.02 1.86A 1.05 
XM_344042 Ig similar to immu-
noglobulin light 
chain variable 
region (predicted) 
-1.02 1.13 1.00 -1.05 1.87A 1.21 
XM_573321 LOC498113 similar to This CDS 
feature is included 
to show the trans-
lation of the corre-
sponding V_region. 
Presently transla-
tion qualifiers on 
V_region features 
are illegal 
1.02 1.81A 1.36 1.11 5.21A 1.88A 
TC548855 IgG1 immunoglobulin G1 1.06 1.09 1.21 -1.10 2.11A 1.64A 
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XM_341195 Igj immunoglobulin 
joining chain 
-1.06 1.49 -1.07 -1.03 2.65A 1.07 
S82585 Igj immunoglobulin 
joining chain 
1.01 1.58A -1.05 -1.03 2.84A 1.12 
XM_213211 Tnfrsf17_predi
cted 
tumor necrosis 
factor receptor 
superfamily, mem-
ber 17 (predicted) 
1.07 1.78A -1.01 1.06 3.79A 1.20 
XM_343117 
 
Siva_predicted Siva_predicted -1.04 1.23 1.00 1.02 1.55A 1.10 
NM_001012197 
 
Tra1_predicted 
 
tumor rejection 
antigen gp96 
(predicted) 
-1.02 1.17 -1.09 -1.10 2.46A 1.03 
 
C: Other genes 
Accession  
number 
Symbol Gene name FR 
1mg PE/rat/day 10mg PE/rat/day  
3d 7d 14d 3d 7d 14d 
XM_236614 Ar-
met_predicted 
arginine-rich, 
mutated in early 
stage tumors 
(predicted) 
-1.05 1.13 1.05 -1.04 1.90A 1.13 
XM_236614 Ar-
met_predicted 
arginine-rich, 
mutated in early 
stage tumors 
(predicted) 
-1.03 1.13 1.01 -1.02 1.94A 1.13 
XM_343189 
 
Ckap4_predicte
d 
 
cytoskeleton-
associated protein 
4 (predicted) 
1.08 1.16 -1.04 1.06 2.31A 1.05 
NM_053886 Lman1 lectin, mannose-
binding, 1 
1.04 1.14 -1.02 1.04 1.78A 1.19 
NM_053886 Lman1 lectin, mannose-
binding, 1 
-1.07 1.17 -1.02 1.02 1.67A 1.13 
NM_153628 
 
Sec11l3 
 
Sec11-like 3 (S. 
cerevisiae) 
-1.05 1.32 -1.05 -1.04 2.17A 1.20 
NM_001008891 
 
Ssr1 
 
signal sequence 
receptor, alpha 
-1.08 1.22 -1.14 1.06 2.09A 1.16 
NM_001008334 
 
Tmem97 
 
transmembrane 
protein 97 
1.08 1.31 -1.37 -1.00 3.24A 1.43 
NM_181084 
 
Trp53inp1 
 
transformation 
related protein 53 
inducible nuclear 
protein 1 
-1.02 1.17 -1.02 -1.03 1.70A -1.01 
XM_225257 
 
Txndc5_predict
ed 
thioredoxin do-
main containing 5 
(predicted) 
1.04 1.28 -1.04 1.11 2.02A 1.09 
NM_001034952 Pqlc3 
 
 
PQ loop repeat 
containing 3 
-1.04 1.18 1.05 1.05 1.85A 1.12 
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NM_053849 
 
Pdia4 
 
protein disulfide 
isomerase family 
A, member 4 
1.07 1.13 -1.05 -1.00 2.21A 1.01 
NM_001024240 RGD1310251 similar to RIKEN 
cDNA 
2010001M09 
-1.06 1.55A 1.02 -1.08 3.90A 1.33 
XM_001058771 
 
LOC681870 
 
hypothetical 
protein 
LOC681870 
 
-1.14 1.55A 1.05 -1.03 1.88A -1.01 
NM_001025683 
 
 
RGD1311946 
 
 
similar to RIKEN 
cDNA 
1810055G02 
-1.02 1.19 -1.04 -1.10 1.81A 1.10 
 
 
 
XM_579997 
 
 
 
RGD1561797_pr
edicted 
 
RGD1561797 
(predicted) 
-1.08 1.37 1.05 -1.04 1.77A 1.18 
 
 
NM_001014041 
 
 
LOC310721 
 
 
similar to 
4930431B09Rik 
protein 
-1.04 1.13 -1.11 1.01 1.75A 1.14 
 
 
XM_001058844 LOC680782 similar to signal 
peptidase com-
plex subunit 3 
homolog 
-1.05 1.13 -1.01 -1.01 1.75A 1.06 
AY310157 
 
RGD1311563 
 
similar to Oligo-
saccharyl trans-
ferase 3 CG7748-
PA 
1.02 1.14 -1.01 -1.01 1.63 -1.06 
NM_198776 
 
 
 
 
MGC72973 
 
 
 
 
beta-glo -1.22 1.24 -
1.55A
-
1.78A 
1.32 -1.07 
 
 
 
 
NM_001013853 
 
 
LOC287167 
 
globin, alpha -1.28 1.08 -
1.51A
-
1.68A 
1.14 -1.05 
 
 
X53003 
 
 
Acaca 
 
acetyl-coenzyme 
A carboxylase 
alpha 
1.02 -1.14 -1.26 1.04 -1.23 -1.63A 
 
 
NM_012543 
 
 
Dbp 
 
D site albumin 
promoter binding 
protein 
-1.07 -1.22 1.15 1.14 -1.48 1.54A 
 
 
NM_017297 Kcnj5 potassium in-
wardly-rectifying 
channel, subfam-
ily J, member 5 
-1.08 -1.33 1.00 -1.10 -
1.64A 
1.03 
Gene expression data are displayed as the Fold Ratio (FR) of the individual genes at the three time points: 
days (d) 3, 7 or 14. 
A Differentially expressed genes 
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FIGURE 3. Hierarchial clustering of genes regulated by PE 
Gene expression data are displayed as a clustered heat map (in LN-scale ranging from -2 to +2). The color 
bar and the corresponding Fold Ratio indicate gene expression: red represents up-regulation, green 
down-regulation and yellow no difference. Cluster A consists of consistently up-regulated genes for both 
dosing regimens and cluster B consists of less consistent regulated genes. 
 
ADA is an enzyme that catalyzes the deamination of adenosine and deoxyadenosine 
to inosine and deoxyinosine, respectively. ADA is required for the maturation and 
function of lymphocytes, especially T lymphocytes in which its main biologic activity 
is detected (Mishra et al. 2005), and for the maturation of human blood monocytes 
to macrophages. 
Tnfrsf17 is a member of the TNFR superfamily that is important for B cell develop-
ment. It is preferentially expressed in mature B lymphocytes, especially that of B 
memory cells (Treml et al. 2006), and autoimmune response. Several TNF Receptor-
Associated Factors are able to bind to Tnfrsf17 hereby transducing cell-signals for 
cell survival and proliferation (Hatzoglou et al. 2000). 
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FIGURE 4. Effect of PE on role of anaphase-promoting complex (APC) in cell cycle 
regulation 
Expression changes of several cell cycle-related genes are displayed in a pathway. The red (up-regulation) 
and green (down-regulation) bars represent the raw gene expression data. For each regulated gene, from 
left to right the first three bars and the last three bars represent days 3, 7 and 14 of the 1 mg PE and the 
10 mg PE groups, respectively. A legend of symbols can be found online 
(http://www.genego.com/files/MC legend.pdf). 
 
 
Siva (apoptosis-inducing factor) plays an important role in the apoptotic pathway of 
thymocytes. Association of Siva with members of the TNFR family, sends pro-
apoptotic signals into the cell. It negatively regulates the nuclear factor-kappa B (NF-
κB) activity, which has anti-apoptotic properties. Hereby, Siva promotes the activa-
tion-induced cell death, resulting in the down-regulation of immune responses, 
which is essential for T-cell homeostasis (Gudi et al. 2006). 
Tra1, also known as heat shock protein gp96, has protective functions during cellu-
lar stress and plays an important role in the maintenance of protein homeostasis. 
Furthermore, gp96 exerts potent stimulatory activity on both innate and adaptive 
immunity. Gp96 is especially involved in the immune response to tumor antigens by 
chaperoning tumor antigen-derived immunogenic peptides and deliver them to 
antigen-presenting cells for specific T cell stimulation. Gp96 also mediates the matu-
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ration of DCs by up-regulating the expression of MHC class II and co-stimulatory 
molecules (Rivoltini et al. 2003; Zhang et al. 2006). 
 
 
DISCUSSION AND CONLUSIONS 
We investigated the immunologic response to PE at the level of gene expression in a 
BN rat model for food allergy. This peanut model has been tested for various con-
ventional immune parameters (de Jonge et al. 2007a; de Jonge et al. 2007b). In an 
earlier study (de Jonge et al. 2007b) we used PE in combination with the adjuvant 
cholera toxin as a positive control, and found that careful breeding for multiple 
generations on feed that excluded the protein of interest (PE) and cross-reactive 
proteins (soy) resulted in strong allergic responses in non-adjuvated animals that 
were similar to animals that were adjuvated with cholera toxin. In the current article 
we repeat earlier results, indicating that oral exposure to PE leads to specific anti-
body responses and specific lymphocyte proliferative responses, and in addition 
that oral exposure to PE results in gene expression profiles in the MLN that were 
associated with cell division and immunological processes. 
Gene expression profiles demonstrate a dose-response relationship, exposure to 10 
mg PE induced a more pronounced differential expression than exposure to 1 mg 
PE. In previous experiments it has been shown that PE-specific IgE levels (de Jonge 
et al. 2007a) and the number of eosinophilic and basophilic granulocytes (de Jonge 
et al. 2007b) were higher in the BN rats exposed to 10 mg PE compared to those 
exposed to 1 mg PE. In addition, the ex vivo proliferation rates of the MLNs of BN 
rats exposed to 10 mg PE were also higher than those of the 1 mg PE group. 
Besides a dose-dependent effect, a time-dependent effect was also demonstrated. In 
both the 1 and 10 mg PE groups, the strongest differential gene expression was shown 
on day 7. This might be explained by the observation that the T cell response after the 
encounter with an antigen peaks after seven days (Haring and Harty 2006). Further-
more, analysis of Ig levels by ELISA showed that the PE-specific 2log IgG2a and IgG1 
titers after PE-sensitization were higher on day 14 than on day 7. It should be men-
tioned that days 3 and 7 are in fact too early to detect specific IgE responses, and even 
day 14 is not optimal (de Jonge et al. 2007b). The early response in the MLN can be 
explained by the fact that the MLN is an immunologic organ that is at the frontline of 
the gut-associated immune response, whereas the production of food allergen-
specific antibodies by B-cells takes place at a later moment in the response. Further-
more, changes in gene expression precede biological changes. Lastly, some regulation 
or some degree of oral tolerance could have occured on day 14. 
In the MLN, several genes involved in immunological processes were found to be 
upregulated. Increased expression of genes encoding for the immunoglobulin com-
ponents Ig (the variable light region) and Igj (the joining segment) are in accordance 
with the observed increased levels of PE-specific IgG1 in serum. Also, recent studies 
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indicate that free light chains, not assembled into an immunoglobulin, are involved 
in the pathogenesis of allergies (Redegeld et al. 2004). Several genes, ADA, Tnfrs17 
and Siva, known to be involved in lymphocyte functioning (Mishra et al, 2005, Trem 
et al 2006, Hatzoglou et al 2000, Gudi et al, 2006) were found to be upregulated by 
PE. Gp96, is involved in innate and adaptive immune response (Rivoltinie et al 2003, 
Zhang et al 2006). 
Besides genes directly involved in immunological processes, a large number of cell 
cycle-related genes was affected by PE and the most regulated pathways were all 
involved in cell proliferation. In accordance with this are the dose-dependent effects 
of PE on lymphocyte proliferation in the MLN. In this conventional assay high vari-
ability was observed. This might indicate a higher sensitivity of investigating numer-
ous genes by the microarray technique as compared to conventional testing of cell 
proliferation.  
The genes that we found stimulated in the current experiment could be involved in 
the allergic response against peanut, although it cannot be excluded that other 
antigen-specific immune responses, including oral tolerance, are also associated 
with regulation of these genes. That the genes found in this experiment are indica-
tive of an immunological response of rats to an orally applied protein extract (in this 
case PE) is supported by the fact that almost all regulated genes were involved in 
cell proliferation or general immunological processes, but these genes do not dis-
criminate between different types of immunity, i.e. do not specifically indicate al-
lergy. The only gene which was upregulated and which is strongly associated with 
allergy, was the gene encoding for IgG1 (Faquim-Mauro et al. 1999; Knippels et al. 
1998). Further research is needed to determine whether the effect at the gene 
expression level found in our BN rat model was limited to an immunologic response, 
or could also be indicative of an allergic response. Subsequent studies should there-
fore include immunologically active, but non-allergenic proteins alongside known 
allergens such as peanut. 
To date, no other studies have been conducted that determined the gene expres-
sion profiles in food allergy models. However, microarray data of respiratory allergy 
studies are available. Benson et al. (Benson et al. 2006) performed a network-based 
analysis of DNA microarray data from allergen-challenged CD4(+) T cells from pa-
tients with seasonal allergic rhinitis. They found a strong upregulation of expression 
of TNFRSF4, one of the genes of the TNF superfamily, which is involved in regulation 
of apoptosis and Th2 proliferation. Interestingly, in our study we found the 
TNFRSF17 gene of the same superfamily to be up-regulated most strongly of all 
immunologic genes (Table I). Although both studies differ: (a) one is a study into 
respiratory allergy, the other study is that of a food allergic model, (b) different 
species were studied and (c) Benson et al. (Benson et al. 2006) studied allergen-
specific T cells, whereas we studied a pool of MLN cells. With both studies in mind 
one could further substantiate the claim that the proliferation of allergen-
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challenged Th2 cells is associated with an increase in TNFRSF-family signaling. How-
ever, an association of TNFRSF17 with Th2 responses has not been made to date. In 
addition, in a mouse model for experimental asthma, gene expression profiling of 
lung tissue was performed (Zimmermann et al. 2003). We compared the regulated 
genes of this study with the results of our study and found overlap, especially at the 
levels of immunological genes (11 overlapping genes) and cell cycle genes (19 over-
lapping genes). This corroborates that both immunological and cell cycle genes are 
involved in allergen response reactions. 
Gene expression profiles assessed in this food allergy model were compared to 
previous immunotoxicogenomics studies in rodents performed at the National Insti-
tute of Public Health and the Environment results. For this, Numerical Overlap 
Analysis of GenericGene Groups (NOAGGG) analysis, developed in house, was used. 
It was demonstrated that exposure to both hexachlorobenzene (HCB) (Ezendam et 
al. 2004) and bis(tri-n-butyltin)oxide (TBTO) (Baken et al. 2007a) affected several 
genes implicated in the cell cycle and some of the genes induced by these com-
pounds overlap with genes that were upregulated in the food allergy model. TBTO 
which is a known immunosuppressive chemical, downregulated genes involved in 
cell proliferation (Baken et al. 2007a), whereas HCB, a pollutant known to stimulate 
the immune system, upregulated cell cycle genes (Ezendam et al. 2004). Hence, 
when we compare gene expression profiles of known immunotoxic compounds with 
PE, it appears that a common target of immunosuppressive as well as immu-
nostimulatory compounds is the cell cycle. 
In conclusion, gene expression changes related to the regulation of immunological 
processes, most notably increased cell division were detected after oral exposure to 
peanut. This finding confirms that in the response to a foreign protein proliferation 
of immunologically relevant tissues is of great importance, and that such effects can 
be detected by analysis of gene expression profiles. Further studies using other food 
allergens, and proteins that are capable of inducing immune responses yet fail to 
induce food allergic sensitization, will likely shed more light on specific genes and 
pathways indicative of food allergens and might thus be of value for both the 
mechanistic insight in the food allergic process as well as potential predictive 
screening purposes for potential allergens. 
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Chapter 6  
Summary and general discussion 
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MAIN FINDINGS 
Food allergy is a puzzling problem of our modern era due to its relatively high preva-
lence, its potentially fatal symptoms and its impact on social life. Furthermore, our 
continuously advancing food chain may be further supplemented by the rise of the 
use of genetically modified organisms, which may introduce new potentially aller-
genic proteins. Risk assessment of food allergens is still in its infancy mainly because 
of the fact that the most sensitive patients are not enrolled in challenge studies to 
assess threshold levels for elicitation. In addition, several factors have an effect on 
the prevalence of food allergy, and might thus be included in the risk assessment of 
food allergy, the most important being genetic factors and environmental factors. 
Currently no validated animal models to study food allergy are available. Not only 
may such animal models aid in helping understanding how environmental factors 
impact the expression of food allergy, they may also be of value for identification of 
novel food allergens. In this thesis the further development of an experimental 
rodent model for food allergy is described, and the model is applied to investigate 
effects of immunomodulatory compounds on food allergy. Furthermore, gene ex-
pression profiles as a novel tool to be applied in food allergy research were studied 
in this model. The main findings of this thesis can be summarized as: 
• Brown Norway (BN) rats showed allergic sensitization to peanut allergens after 
ingestion via the oral route, but only when the rats were bred on a peanut- and 
soy-free diet (Chapter 2). Soy proteins and peanut proteins show cross-
reactivity, e.g. preexposure to soy influences the status of sensitization and/or 
lead to tolerance when subsequently exposed to peanut. 
• The most renowned allergens contained in peanut are three sugar-protein 
molecules named ‘Ara h1’, ‘Ara h2’ and ‘Ara h3’. Rats orally sensitized to peanut 
extract (PE) recognized all tested major peanut allergens; Ara h1-3 whereas in-
traperitoneally (i.p). sensitized rats only recognized Ara h1 and Ara h2 (Chapter 
2). Indicating the importance of the route of exposure in allergen recognition. In 
contrast to i.p. dosing, oral dosing involves both oral mucosa and gut and the 
accompanying mucosal immune systems, which may lead to induction of IgE re-
sponses and/or oral tolerance to different allergens in orally compared to i.p. 
exposed rats. 
• Cholera toxin (CT) enhanced allergic sensitization to a limited extent (Chapter 
2). 
• The immunosuppressant bis(tributyltin)oxide (TBTO) suppressed food allergy 
against both peanut and ovalbumin (an allergen present in hen’s egg white) on 
multiple levels in the food allergic response (Chapter 3) 
• The bacterial strain Lactobacillus casei Shirota (LcS), claimed to have an impact 
on food allergy, failed to suppress the food allergic response to peanut in our 
model. Moreover, LcS shifted the Th1/Th2 ratio towards Th2 dominance both at 
the level of cytokine production and immunoglobulin production (Chapter 4). 
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• Chapter 5 described for the first time the effect of oral exposure to peanut on 
the level of gene expression and it was shown that gene expression changes 
were both dose- and time-dependent. The most important pathway (in this con-
text a set of related responses within a specific process (e.g. cell proliferation)), 
that was regulated after oral administration, was that of cell division. In addi-
tion, immunological processes were activated. 
 
 
RODENT FOOD ALLERGY MODELS: ISSUES TO CONSIDER 
In order to successfully assess the effect of both allergens and (potential) immuno-
modulation by food constituents or food contaminants on the allergic response, we 
investigated a range of conventional parameters at multiple levels of the food aller-
gic process. It was apparent from our studies that in our experimental model for 
food allergy, this range of parameters at multiple levels of the food allergic process 
helped in the interpretation of the effect of these interventions. Complimentary to 
these conventional parameters, this thesis also investigated other novel parameters 
that could potentially be used as biomarkers for food allergy. The application possi-
bilities of animal models for food allergy may lie in investigations of effects of envi-
ronmental factors and food components on food allergic processes, as well as in the 
identification of allergenic activities of a new food to which no a priori exposure in 
the population is apparent. In the development of animal models of food allergy 
several issues need to be considered: 
 
Species and strain 
Various animal models for food allergy are presently in use including models in 
mice, rats, dogs and swines (Dearman and Kimber, 2009). We will briefly discuss the 
two most popular species in this research: mice and rats. 
The species most commonly favoured with respect to animal model development 
for food allergy is the mouse. This is largely driven by the availability of various im-
munological and molecular reagents, including transgenic animals in which particu-
lar genes of interest have been over expressed or deleted. A major advantage for 
studies involving IgE antibody responses is the availability of inbred and congenic 
high IgE responder mouse strains, such as the high IgE responder BALB/c strain 
(Dearman and Kimber, 2007; Mori et al., 1990; Yamanishi et al., 2003) and the 
C3H/HeJ strain (Li et al., 1999; van Wijk et al., 2004). As such, these strains have 
analogy with the susceptible (atopic) human phenotype that has a propensity to 
develop IgE-mediated disease, facilitating the identification of potentially allergenic 
proteins. Mice are most often dosed i.p. for sensitization to the allergen with or 
without the use of an adjuvant, an alternative that is also regularly applied are mice 
dosed orally for sensitization to the allergen in the presence of an adjuvant. 
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Other rodent species, particularly the BN rat have been the experimental model of 
choice for many investigators (Akiyama et al., 2001; de Jonge et al., 2007; Jia et al., 
2005; Knippels and Penninks, 2002; Knippels et al., 1998b; Pilegaard and Madsen, 
2004). The BN rat is a high-immunoglobulin (particularly IgE) responder rat strain 
that to a certain degree resembles atopic humans in their genetic predisposition to 
react with an overproduction of IgE to antigens. In addition, clinical reactions, in-
cluding increased gut permeability and changes in blood pressure and respiratory 
function, were observed in BN rats after an oral challenge (Knippels et al., 1999b) 
and the profile of allergens recognized by the immune system of the BN rat ap-
peared comparable with the profile of allergens recognized by allergic patients 
(Knippels and Penninks, 2003). One of the advantages of this model is that these 
rats can be sensitized orally in the absence of an adjuvant (Akiyama et al., 2001; de 
Jonge et al., 2007; Jia et al., 2005; Knippels and Penninks, 2002; Knippels et al., 
1998b; Pilegaard and Madsen, 2004). Furthermore, this rat, due to its size, offers 
the possibility to monitor within individual animals the kinetics of specific serum 
antibody (IgE and IgG) responses. Moreover, rats, unlike mice, are routinely used in 
toxicity studies, which may also lead to an easier integration process of food allergy 
assessment studies in rat models into the current line of safety studies. 
 
Dietary exposure to the allergen or cross-reactive proteins 
An important aspect that should be considered with regard to the development of a 
food allergy model is uncontrolled dietary pre-exposure of the test animals and 
their parental generations to the allergen under investigation. Exposure of the pa-
rental generation to the antigen under investigation influences the outcome of oral 
sensitization studies with the offspring, at least two generations of animals should 
be bred on a diet free of the antigen under investigation. For instance: Knippels et 
al. (Knippels et al., 1998a) described that soy-specific IgG antibodies could not be 
detected after two generations bred on soy-free diet. Animal feed may contain 
proteins that are identical to the proteins that will be tested, or may share cross 
reactivity with these proteins. It is evident that previous exposure of the test ani-
mals to proteins that will be the focus of the investigation will have an impact on 
the status of sensitization and/or lead to tolerance. This thesis shows that exclusion 
of such proteins in the diet of the test animals for a number of generations is a pre-
requisite for a proper function of the model (Chapter 2). This underlines the impor-
tance of diet restrictions in oral models for food allergy as has been shown previ-
ously (Knippels et al, 1998a, Brix et al. 2005, Christensen et al 2003, 2004). 
 
Route of exposure 
Exposure to food allergens in humans is predominantly by oral consumption of 
allergens present in food. After oral exposure, proteins can be digested in the gas-
trointestinal tract, which may subsequently lead to presentation of different anti-
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genic structures to the mucosal immune system. Some models involve i.p. sensitiza-
tion, but as oral administration represents the most appropriate route of exposure 
for a method designed to identify potential food allergens, oral models for food 
allergy are preferred. This rationale is supported by experimental data. Chapter 2 
showed that although the responses of animals that were either i.p. or orally sensi-
tized to peanut to one of the three tested purified peanut allergens (Ara h1) were 
comparable, the responses differed for the remaining two purified allergens (Ara h2 
and Ara h3). The specific IgG2a response (Th2-mediated in rat) against Ara h2 in i.p. 
sensitized animals was twice that of orally sensitized animals. Moreover, the specific 
IgG2a response against Ara h3 was not found in the i.p. sensitized group but was 
found in 50% of the orally sensitized group. After oral exposure, proteins can be 
digested in the gastrointestinal tract, which may lead to presentation of different 
antigenic structures compared to i.p. exposure, without digestion. In contrast to i.p. 
dosing, oral dosing involves both oral mucosa and gut (Madsen and Pilegaard, 2003) 
and the accompanying mucosal immune systems, which may lead to induction of 
IgE responses to different allergens in orally compared to i.p. exposed rats. The data 
as presented in Chapter 2 indicate that oral sensitization in comparison to i.p. sensi-
tization of BN rats better reflects the responses as observed in peanut allergic pa-
tients where specific IgE responses against Ara h1-3 are observed (Koppelman et al., 
2004). 
 
Adjuvation 
Most animal models used in food allergy research, both pertaining to i.p. and oral 
models, incorporate the use of an adjuvant for successful sensitization to the pro-
tein under investigation. Adjuvant is applied to boost the allergic responses to aller-
gens that may have a low intrinsic allergenic potential. Drawbacks might be that 
such adjuvants may add to the complexity of the model, and renders the mode of 
sensitization probably different from how humans are sensitized. Inclusion of an 
adjuvant may increase sensitivity, but this may go at the cost of selectivity. The BN 
rat model is one of the few experimental models for food allergy that allows for oral 
sensitization, without the use of an adjuvant. Furthermore, BN rats can discriminate 
between strong- (ovalbumin), weak- (bovine serum albumin) and non-allergenic 
(potato acid phosphatase) proteins after oral exposure without the use of any adju-
vants (Jia et al., 2005). Moreover, the orally sensitized BN rat as a model for food 
allergy can result in 100% IgE-responders, even without the use of an adjuvant, if 
preconditions such as allergen free diets are carefully met (Chapter 2). 
 
 
Other factors 
Other factors, including gender and age of animals, are also known to contribute to 
the sensitivity of oral allergy induction. Pilegaard and Madsen (Pilegaard and 
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Madsen, 2004) demonstrated that sensitization of female BN rats to egg allergens 
offered a higher amount of IgE-responders (38-75%) than did males (13-38%). With 
age the immune system matures which makes sensitization more difficult. BN rats 
become less Th2-prone with age (Ide et al., 1999; van der Meide et al., 1995) and 
consequently less apt to sensitization (Ide et al., 1999; Pauwels et al., 1979). For this 
reasons we used female rats that were 3-4 weeks of age at study initiation. 
Finally, the matrix in which the protein is presented is of importance for determin-
ing the allergenicity of the protein in an experimental model for food allergy (van 
Wijk et al., 2005), since some food constituents have the potential to modulate 
allergic responses to allergens. 
 
Ideally, test animals should, next to sensitization as measured by allergen-specific 
IgE responses, show clinical reactions with respect to organ sensitivities that reflect 
responses seen in humans upon a challenge with the allergen. The model should be 
relatively easy to conduct and reproducible in time and different laboratories 
(Penninks and Knippels, 2001). Although all these criteria (i.e. oral exposure, no 
requirement for the use of an adjuvant, clinical manifestations, reproducibility and 
ease to perform) are difficult to attain in one model, the oral food allergy model 
developed in BN rats and presented in this thesis might provide a suitable model to 
study the allergenicity of food proteins in humans. This notion is also supported in 
publications describing studies in BN rats (Atkinson et al., 1996; Atkinson and Miller, 
1994; Jia et al., 2004; Jia et al., 2005; Knippels et al., 1999a; Knippels and Penninks, 
2002; Knippels et al., 1999b; Knippels et al., 1998b; Knippels et al., 1999c; Knippels 
et al., 2000; Ogawa et al., 2003; Pilegaard and Madsen, 2004). 
 
 
LIMITATIONS OF THE BROWN NORWAY RAT AS AN EXPERIMENTAL MODEL FOR 
FOOD ALLERGY 
Although our BN rat food allergy model has many advantages as an experimental 
model, it also has some drawbacks. 
These drawbacks for the assessment of risks include: 
1. the BN rat is an inbred strain of rats: although the high Coefficient of Inbreeding 
increases the likeliness that one BN rat’s immune reaction resembles that of 
another (and thus decreases the number of animals needed in each group), the 
drawback is that as a model it has not the wide genetic diversion as seen in 
atopic humans; 
2. absence of anaphylactic reactions: the absence of anaphylactic reactions in BN 
rats differs with the strong anaphylactic reactions that occur in humans. This 
difference between BN rats and atopic patients is of special relevance since 
anaphylaxis is both life-threatening and greatly contributing to the suffering of 
food allergic patients; 
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3. single gender: the use of female BN rats as applied in our further development 
of the BN rat food allergy model, increased the sensitivity to the antigens of in-
terest (and thus decreases the number of animals needed in each group), but 
also does not resemble the human situation in which atopic patients are repre-
sented by both genders; and 
4. possible underestimation of the effect of immunostimulants: Chapter 2 de-
scribed that the adjuvant CT was not capable of substantially increasing the se-
verity of the allergic response to peanut proteins, this could imply that this 
model might be suboptimal to address the effect of immunostimulants on the 
food allergic response. 
 
 
UTILITY OF A FOOD ALLERGY MODEL IN BN RATS 
The first rule of toxicology is that all substances produce an effect, but it is the dose 
that decides whether the effects are adverse or beneficial (Paracelcus (1493-1541); 
“Dosis sola facit veneum” (only the dose determines whether something is poison-
ous)). As indicated above, besides the dose, also other factors, including environ-
mental factors or other components in the food than the allergens themselves, 
determine the outcome of the food allergy. There is a difference between hazards 
(the potential to cause adverse effects) and risks (the actual risk that these adverse 
effects do occur). In food allergy validated animal models for food allergy could be 
used, besides for hazard identification, also for risk assessment, especially to probe 
factors influencing risk, such as environmental factors or food components other 
than the allergen itself. 
 
 
Immunodulatory effects investigated with the BN rat food allergy model 
The effects of three different immunomodulators were studied in this thesis. In 
Chapter 2 effects of the mucosal adjuvant CT was studied. For this purpose BN rats 
were sensitized to peanut by daily oral gavage and the CT-groups were simultane-
ously with the peanut dosing also exposed to a daily oral dosing of CT. The adjuvant 
CT had only limited effects in this model. Adjuvation with CT enhanced the magni-
tude of IgE and to a lesser extent IgG1 but not of IgG2a, rat mast cell protease 2 
(RMCPII) levels, numbers of granulocytes and cytokine levels. This indicates that in 
rats bred on a soy- and peanut-free diet, oral sensitization may already have been 
nearly optimal and CT could not greatly increase the sensitivity of the model. 
Chapter 3 described the influence of the immunosuppressive compound TBTO, 
present in the food chain, on the development of food allergy to peanut or ovalbu-
min in BN rats. To study these effects BN rats were sensitized to either peanut or 
ovalbumin by daily oral gavage and the TBTO-groups were fed a diet containing 
TBTO. Co-exposure to TBTO not only resulted in decreased general immunologic 
Thesis De Jonge V9.pdf   127 9-10-2009   11:37:11
 128 
parameters, but also had a suppressing effect on allergic parameters. TBTO de-
creased allergen-specific Th2 cytokine production by spleen cells, allergen-specific 
IgE, number of eosinophilic and basophilic granulocytes in the blood and production 
of mast cell protease II after oral food challenge. 
After investigating such different immunomodulating effects on the food allergic 
response in our model, i.e. the effects of the immunosuppressant (TBTO) and those 
of the immunostimulant (CT), we tested the effect of Lactobacillus casei Shirota 
(LcS) on the food allergic process against peanut (Chapter 4). Figure 1 gives a simpli-
fied overview of the interactions of the immunomodulators CT and TBTO with the 
immune system, and also depicts where Lactobacillus casei Shirota (LcS) has an 
impact. We hypothesized an immunosuppressive effect of this bacterial strain that 
is proposed to have probiotic (probiotica – literally “for life”) activity. Unexpectedly, 
we did not find LcS to suppress the food allergic response against peanut. More-
over, in our peanut allergy model (Chapter 4) it was found that LcS shifted the 
Th1/Th2 ratio towards Th2 dominance on both the level of cytokine production and 
immunoglobulin production. The most pronounced effect of LcS noted in this study 
was on IL-4 production by spleen and mesenteric lymph node (MLN) cells. LcS was 
also capable of stimulating early peanut extract (PE)-specific IgE-levels and PE-
specific IgG levels. This is in contrast to three studies on food allergy in rodents that 
describe decreased IgE levels (Matsuzaki and Chin, 2000; Matsuzaki et al., 1998; 
Shida et al., 2002), LcS has also been described to decrease IgE levels produced by in 
vitro restimulated splenocytes from OVA-primed mice (Shida et al., 1998). In a respi-
ratory allergy model LcS did not reduce IgE levels (Ezendam and van Loveren, 2008). 
 
What does this mean for the situation in humans? First, it should be noted that 
effects of probiotics depend on viability, dose, time, length of treatment, mode of 
treatment, prenatal exposure and strain (Broekaert and Walker, 2006; de Waard et 
al., 2003; Kalliomaki and Isolauri, 2004; Prescott et al., 2005; Savilahti et al., 2008). 
Furthermore, it has been shown that the effects of bacterial strains on the immune 
system depend on the immunological state of an individual (Pelto et al., 1998; 
Roessler et al., 2007). Pelto et al. (Pelto et al., 1998) have shown that Lactobacillus 
GG (LGG)-supplementation resulted in an increased expression of phagocytosis 
receptors in healthy subjects, whereas LGG-supplementation resulted in suppressed 
expression of these receptors in milk-hypersensitive subjects. Roessler et al. 
(Roessler et al., 2007) claimed to have shown that probiotic activity differently 
modulates peripheral immune parameters, in healthy volunteers and adults with 
atopic dermatitis. Probably, the underlying mechanism is partly associated with the 
existing differences in the composition and stability of the microbiota. Hence, dif-
ferent environmental conditions influence the host–bacterial crosstalk by compet-
ing for epithelial attachment sites. Possibly, different pathways of bacterial–
enterocyte crosstalk may induce different immune responses in healthy subjects 
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and allergic patients (Christensen et al., 2002; Perdigon et al., 2000; Roessler et al., 
2007). 
Studies in humans (Abrahamsson et al., 2007; Brouwer et al., 2006; Gruber et al., 
2007; Kalliomaki et al., 2001; Kalliomaki et al., 2003; Osborn and Sinn, 2007; 
Rosenfeldt et al., 2003; Savilahti et al., 2008; Sistek et al., 2006; Taylor et al., 2007; 
Viljanen et al., 2005) demonstrate that bacterial strains can have beneficial effects 
on allergies and may be considered probiotic, but that some probiotics can also 
induce unintended immunostimulation (Taylor et al., 2007). 
It is evident that more research is needed to substantiate efficacy of bacterial 
strains meant as probiotics in allergy prevention. It could very well be that certain 
bacterial strains can be beneficial for human health in some disorders, while having 
adverse effects in others. Therefore the search for specific bacterial strains that 
decrease the onset and/or severity of food allergic responses remains crucial since 
not all probiotic strains exhibit the same properties and might even increase the 
onset and/or severity of food allergic responses. 
Experimental animal models for allergy are useful as a first selection tool in order to 
select bacterial strains which could be effective in allergy prevention and can also 
provide more insight in the mechanisms involved. Subsequently, both efficacy and 
safety of these selected bacterial strains should be demonstrated in humans. 
 
Novel biomarkers: gene expression profiles 
A validated animal model could be important for identification of potential aller-
genic proteins in foods to which no prior exposure is apparent (hazard identifica-
tion). In addition to classical measures of allergic sensitization, novel markers such 
as food allergy specific genes, for example, could in the future be of potential use as 
additional tools to screen for potential allergens in novel foods (Chapter 5). There is 
an ongoing discussion concerning the ethical use of experimental animal models 
and a need for alternatives for animal models is eminent. In the search for alterna-
tives to experimental animal models three categories (three R’s) are considered: 
Reduction, Refinement and Replacement (Russell and Burch, 1959). Reduction re-
fers to methods to reduce or minimize the number of animals used in experiments 
to acquire necessary information. Refinement refers to improved experimental 
techniques that eliminate or reduce animal stress and discomfort. Replacement 
refers to methods that allow a research goal to be achieved without conducting 
experiments on animals. In the context of this thesis, investigating gene expression 
profiles may especially be seen as a further refinement within the current model, by 
providing additional information on effects that may help to characterize allergic 
responses. All chapters of this thesis clearly indicate that in our experimental mod-
els for food allergy it is a necessity to investigate parameters at multiple levels of 
the food allergic process (some of these parameters are included in Figure 1). 
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In Chapter 5 of this thesis the effects of oral administration of peanut on gene ex-
pression profiles in the mesenteric lymph nodes (MLNs) was investigated, with the 
aim to potentially find new biomarkers that could be of use to better predict aller-
genicity of food allergens (hazard identification). A second aim is obviously to 
broaden our knowledge base of the food allergic response (mechanistic research). 
Gene expression profiles were altered after three days of exposure to peanut, which 
was the earliest time-point included in these experiments. Furthermore, optimal 
regulation of gene expression was found after seven days of daily dosing with pea-
nut, and this regulatory effect on gene expression was greatly diminished after 14 
days of dosing to peanut. It is noteworthy that conventional parameters are often 
only (strongly) regulated at relatively late time-points: PE-specific IgE was optimal 
after 42 days of oral dosing with PE. 
Peanut induced regulation of genes that were involved in cell proliferation or gen-
eral immunological processes. However, the genes involved in immunological 
proceses were not specific to the degree that they allowed us to discriminate be-
tween different types of immunity, i.e. these genes did not specifically indicate 
allergy. Further studies that strengthen this initial concept are needed to determine 
whether the effect at the gene expression level found in our BN rat model was lim-
ited to an immunologic response, or could also be indicative of an allergic response. 
Subsequent studies should therefore include immunologically active, but non-
allergenic proteins alongside known allergens such as peanut. Such additional re-
search will likely shed more light on specific genes and pathways indicative of food 
allergens and might thus be of value for both the mechanistic insight in the food 
allergic process as well as potential predictive screening purposes for potential al-
lergens. 
Further anticipating on the future possibilities, gene expression profiles could in a 
later phase be a very interesting tool to help elucidating the driving forces behind 
the phenomenon that some animals and humans do develop allergy after exposure 
to an allergen while some animals and humans do not. We expect that assessing the 
discrepancy in the involvement of genes and pathways between these two immu-
nological outcomes could play a key role in answering this question and thereby 
greatly increasing our knowledge on this topic. This knowledge in turn could help in 
the prevention and treatment of food allergy and could also supply us with some 
directions for different outcomes after exposure to allergens in other types of al-
lergy/ allergy in general. 
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FIGURE 1. The effect of the (potential) immunomodulators: cholera toxin (CT), 
bis(tributyltin)oxide (TBTO) and Lactobacillus casei Shirota (LcS) on parameters at 
various levels of the food allergic response to peanut.  
Each immunomodulator’s effect are displayed by arrows that indicate at which level they potentially 
modulate the food allergic response. Moreover, the direction of the effect at the aforementioned levels 
in the food allergic response are indicated by ‘-’ (inhibition), ‘+’ (stimulation) or ‘++’ (very strong stimula-
tion). 
RMCPII is the abbreviation of “rat mast cell protease 2”, which is a mast cell release product that can be 
released by degranulation after repeated exposure to the sensitized allergen. 
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HOOFDBEVINDINGEN 
Voedselallergie is een probleem in de samenleving vanwege haar relatief hoge pre-
valentie, haar potentieel fatale symptomen en haar impact op het sociale leven. In 
het ontstaan van voedselallergie spelen verschillende factoren een rol, waarvan de 
meest belangrijke genetische en omgevingsfactoren zijn. Daarnaast is het mogelijk 
dat consumenten blootgesteld worden aan nieuwe allergenen, die aan de voedsel-
keten kunnen worden toegevoegd door ontwikkelingen op het gebied van de voe-
ding, zoals genetisch gemodificeerde voeding. Op dit moment is de risico-evaluatie 
op dit gebied nog in ontwikkeling en zijn er nog geen gevalideerde diermodellen 
voorhanden om voedselallergie te bestuderen. Dergelijke diermodellen helpen niet 
alleen om de invloed van externe factoren op de ontwikkeling van voedselallergie 
beter te begrijpen, maar kunnen ook van nut zijn bij de identificatie van nieuwe 
voedselallergenen in bijvoorbeeld genetisch gemodificeerde voeding. 
In dit proefschrift wordt de verdere ontwikkeling van een experimenteel diermodel 
voor voedselallergie beschreven. Dit model werd gebruikt om de effecten van im-
munomodulerende bestanddelen zoals aanwezig kunnen zijn in voeding op de 
voedselallergische respons te bepalen. Tevens is dit model toegepast om vast te 
stellen of door middel van het bepalen van genexpressie profielen nieuwe biomar-
kers konden worden gedetecteerd. 
 
De hoofdbevindingen van dit proefschrift kunnen worden samengevat als: 
• Na orale inname van pinda extract (PE) waren Brown Norway (BN) ratten aller-
gisch gesensibiliseerd, mits de ratten 3 generaties gevoed werden op een pinda- 
en soja-vrij dieet (Hoofdstuk 2). Soja eiwitten en pinda eiwitten vertonen kruis-
reactiviteit, en blootstelling aan soja kan tolerantie veroorzaken tegen zowel so-
ja als pinda en als zodanig pinda sensibilisatie beïnvloeden. 
• De meest notoire allergenen die in pinda’s voorkomen zijn drie suikereiwit mo-
leculen genaamd ‘Ara h1’, ‘Ara h2’ en ‘Ara h3’. Ratten die oraal gesensibiliseerd 
werden met PE herkenden de belangrijke pinda allergenen: Ara h1-3, terwijl in-
traperitoneaal (i.p.) gesensibiliseerde ratten alleen Ara h1 en Ara h2 herkenden 
(Hoofdstuk 2). Deze vinding onderstreept het belang van de blootstellingsroute 
in de herkenning van allergenen. In tegenstelling tot i.p. dosering, leidt orale 
dosering tot blootstelling van zowel de orale mucosa als de darm mucosa inclu-
sief de bijbehorende immuunsystemen, wat mogelijk in de inductie van IgE res-
ponsen en/of orale tolerantie tegen verschillende eiwitten resulteert in oraal 
blootgestelde ratten ten opzichte van ratten die i.p. blootgesteld zijn. 
• Cholera toxine (CT) versterkte de allergische sensibilisatie slechts in beperkte 
mate. 
• De immunosuppressieve stof bis(tributyltin)oxide (TBTO) onderdrukte voedsel-
allergie gericht tegen zowel pinda als ovalbumine (een allergeen aanwezig in 
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kippeneiwit) en deed dit op meerdere niveaus van de voedselallergische res-
pons (Hoofdstuk 3) 
• De bacteriële stam Lactobacillus casei Shirota (LcS), waarvan geclaimd wordt 
dat deze een effect op allergie heeft, had geen effect op de allergische respons 
geïnduceerd door pinda. De hypothese was dat LcS de Th1/Th2 balans richting 
Th1 dominantie zou schuiven en zo de Th2-gemedieerde allergische respons zou 
dempen. Echter, LcS induceerde een Th2 dominantie, zowel op het niveau van 
cytokine productie als op het niveau van immunoglobuline productie (Hoofd-
stuk 4). 
• Hoofdstuk 5 beschrijft de effecten van orale blootstelling aan PE op genexpres-
sie profielen. Na inname van PE werden tijds- en dosisafhankelijke veranderin-
gen in genexpressie gevonden. De belangrijkste gereguleerde “pathway” (in de-
ze context een verzameling van aan elkaar gelieerde responsen binnen een be-
paald proces) was die van de celdeling. Daarnaast werden ook immunologische 
processen geactiveerd. 
 
 
KNAAGDIERMODELLEN VOOR VOEDSELALLERGIE: RELEVANTE FACTOREN 
De effecten van (potentiële) immunomodulerende bestanddelen van en contami-
nanten uit voeding op de pinda-allergische respons zijn onderzocht door middel van 
bepaling van een spectrum aan conventionele parameters in het BN model. De 
resultaten van deze studies tonen aan dat het bepalen van meerdere parameters op 
verschillende niveaus van de voedselallergische respons waarde toevoegt aan de 
interpretatie van het effect. Diermodellen voor voedselallergie kunnen gebruikt 
worden in onderzoek naar de effecten van immuunmodulerende verbindingen, bij 
het bestuderen van mechanismen en voor het identificeren van potentiële allerge-
nen in bijvoorbeeld genetisch gemodificeerde voeding. 
 
Keuze van het diermodel: species en stam 
Verschillende diermodellen voor voedselallergie zijn op dit moment in gebruik, 
inclusief modellen in muizen, ratten, honden en zwijnen (Dearman and Kimber, 
2009). We bespreken hier kort de twee meest populaire diersoorten die in deze 
onderzoekstak worden gebruikt: knaagdiermodellen in de muis en in de rat. 
De muis is de diersoort, die op dit moment het meest wordt toegepast met betrek-
king tot de ontwikkeling van een diermodel voor voedselallergie. Deze voorkeur 
wordt voornamelijk gevoed door de beschikbaarheid van verscheidene immunologi-
sche en moleculaire reagentia, inclusief transgene dieren waarin bepaalde interes-
sante genen tot overexpressie gebracht zijn, danwel buiten werking zijn gesteld. Een 
belangrijk voordeel in studies naar IgE-antilichaam responsen is de beschikbaarheid 
van inteelt en congene hoge IgE reagerende muizenstammen, zoals de hoge IgE 
reagerende BALB/c stam (Dearman and Kimber, 2007; Mori et al., 1990; Yamanishi 
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et al., 2003) en de C3H/HeJ strain (Li et al., 1999; van Wijk et al., 2004). Als zodanig 
hebben deze stammen analogie met het ontvankelijke (atopische) menselijke feno-
type dat de inclinatie heeft om IgE-gemedieerde ziekte te ontwikkelen, en facilite-
ren zodoende de identificatie van potentiële allergene eiwitten. Om muizen te sen-
sibiliseren wordt over het algemeen i.p. dosering toegepast, al dan niet in de aan-
wezigheid van een adjuvant. Een andere methode die veel wordt toegepast is oraal 
doseren met het allergeen en een adjuvant. 
Naast muizen worden ook ratten gebruikt als experimenteel model en dat vooral de 
BN rat (Akiyama et al., 2001; de Jonge et al., 2007; Jia et al., 2005; Knippels and 
Penninks, 2002; Knippels et al., 1998b; Pilegaard and Madsen, 2004). De BN rat 
heeft als specifieke eigenschap dat Th2 responsen makkelijk op te wekken zijn en 
dat hij grote hoeveelheden antilichamen, vooral IgE, kan aanmaken. Na het oraal 
toedienen van voedselallergenen worden reacties waargenomen, zoals toename in 
de darmpermeabiliteit en veranderingen in bloeddruk en respiratoire functie (Knip-
pels et al., 1999b), die ook humaan klinisch relevant zijn. Het profiel aan allergenen 
dat herkend wordt door BN ratten lijkt vergelijkbaar met het profiel dat door allergi-
sche patiënten wordt herkend (Knippels and Penninks, 2003). BN ratten kunnen 
oraal worden gesensibiliseerd zonder gebruik te maken van adjuvantia (Akiyama et 
al., 2001; de Jonge et al., 2007; Jia et al., 2005; Knippels and Penninks, 2002; Knip-
pels et al., 1998b; Pilegaard and Madsen, 2004). Een bijkomend voordeel is dat 
ratten door hun grootte makkelijk te gebruiken zijn voor kinetiekstudies, zoals het 
monitoren van antilichaamresponsen over de tijd. Belangrijk is tevens dat ratten, in 
tegenstelling tot muizen, routinematig in toxiciteitstudies gebruikt worden, waar-
door een dergelijk model ook makkelijker hierin geïntegreerd zou kunnen worden. 
 
Blootstelling aan het allergeen of kruisreactieve eiwitten via het dieet 
Een belangrijk aspect om te beschouwen bij het ontwikkelen van een model voor 
voedselallergie is onbedoelde voorblootstelling (de reeds opgetrede blootstelling 
voorafgaande aan de daadwerkelijke proef), middels het dieet, van de proefdieren 
en de voorouders daarvan aan het allergeen van interesse. Blootstelling van de 
ouderdieren aan het te testen antigeen beïnvloedt de uitkomst van orale sensibilisa-
tie, om dit te voorkomen dienen studies met het nageslacht worden voorafgegaan 
door ten minste twee generaties gefokt op een diet dat vrij is van het te onderzoe-
ken antigeen. Zo beschreven Knippels et al. (Knippels et al., 1998a) bijvoorbeeld dat 
sojaspecifieke IgG antilichamen niet meer gedetecteerd konden worden indien twee 
generaties lang op soja-vrij dieet werd gefokt. Diëten voor knaagdieren kunnen 
eiwitten bevatten die ofwel identiek zijn aan de te onderzoeken eiwitten, danwel 
kruisreactiviteit vertonen met de te onderzoeken eiwitten. Het is duidelijk dat voor-
blootstelling van de proefdieren aan de te onderzoeken eiwitten invloed uitoefent 
op de status van sensibilisatie en/of tot orale tolerantie leidt. Dit proefschrift toont 
aan dat exclusie van dergelijke eiwitten in het dieet van de proefdieren gedurende 
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een aantal opeenvolgende generaties een vereiste is voor het juist functioneren van 
het model (Hoofdstuk 2). Deze resultaten bevestigen het belang van dieetcontrole, 
zoals eerder is aangetoond (Knippels et al, 1998a, Brix et al. 2005, Christensen et al 
2003, 2004). 
 
Blootstellingsroute 
Mensen worden voornamelijk via het dieet blootgesteld aan voedselallergenen. 
Eenmaal in de darmen aangekomen worden de eiwitten verteerd door het spijsver-
teringskanaal, waarbij verschillende antigene structuren ontstaan. Deze worden 
gepresenteerd aan het immuunsysteem van de darmen. Een andere blootstellings-
route zal ook kunnen leiden tot een andere presentatie van de antigene structuren 
aan het immuunsysteem. Er zijn diermodellen beschreven die gebruik maken van 
i.p. sensibilisatie. Het is mogelijk om op deze manier allergische responsen te indu-
ceren. In Hoofdstuk 2 wordt aangetoond dat na zowel i.p. als orale blootstelling 
allergische responsen worden geïnduceerd. Echter, de allergenen die herkend wor-
den verschillen. Het allergeen Ara h1 werd in beide modellen herkend, maar voor 
Ara h2 en Ara h3 werden verschillen gevonden. De specifieke IgG2a respons gericht 
tegen Ara h2 in ratten die i.p. blootgesteld waren was twee keer zo hoog als in de 
oraal blootgestelde ratten. Een specifieke IgG2a respons tegen Ara h3 werd geheel 
niet gevonden in i.p. behandelde dieren, maar werd in 50% van de oraal behandelde 
ratten wel aangetoond. Na orale blootstelling, kunnen eiwitten in het maag-
darmkanaal verteerd worden, wat vervolgens weer kan leiden tot de presentatie 
van andere antigene structuren in vergelijking tot de situatie na i.p. blootstelling 
waarbij de verteringsstap ontbreekt. In tegenstelling tot i.p. dosering, zijn bij orale 
dosering zowel de orale slijmvliezen als de darmen betrokken (Madsen and Pile-
gaard, 2003), inclusief de bijbehorende immuunsystemen, wat vervolgens mogelijk 
kan leiden tot de inductie van IgE responsen tegen andere allergenen dan bij i.p. 
blootgestelde ratten het geval zou zijn. 
De data zoals gepresenteerd in Hoofdstuk 2 attenderen ons erop dat de orale sen-
sibilisatie ten opzichte van de i.p. sensibilisatie van BN ratten, een nauwkeurigere 
reflectie oplevert van de responsen in patiënten met pinda-allergie, waar specifieke 
IgE responsen tegen Ara h1-3 worden waargenomen (Koppelman et al., 2004). 
 
Gebruik van adjuvantia 
In het merendeel van de diermodellen, zowel i.p. als oraal blootgesteld, worden 
adjuvantia toegepast om ervoor te zorgen dat de dieren succesvol gesensibiliseerd 
kunnen worden tegen het gewenste eiwit. Het adjuvant heeft als doel om de allergi-
sche respons te versterken. Mogelijke nadelen hiervan zijn dat dergelijke adjuvantia 
de complexiteit van het model kunnen verhogen en dat de manier van sensibilisatie 
mogelijk verschilt van de normale humane situatie. Hoewel het gebruik van een 
adjuvant de sensitiviteit kan verhogen, kan dit ten koste gaan van de selectiviteit. In 
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BN ratten kan zonder gebruik van adjuvantia een voedselallergische respons geïn-
duceerd worden na orale blootstelling. In dit BN rat model kan bovendien onder-
scheid worden gemaakt tussen sterke allergenen (ovalbumine), zwakke allergenen 
(serum albumine afkomstig van een rund) en eiwitten die niet allergeen zijn (aard-
appel zure fosfatase) (Jia et al., 2005). Zelfs zonder gebruik van een adjuvant kan 
orale blootstelling resulteren in 100% IgE-responders, als zorgvuldig aan randvoor-
waarden zoals het gebruik van allergeen vrije diëten wordt voldaan (Hoofdstuk 2). 
 
Andere factoren 
Naast bovengenoemde, spelen andere factoren ook een rol in dit model. Pilegaard 
en Madsen (Pilegaard and Madsen, 2004) demonstreerden dat vrouwelijke BN rat-
ten gevoeliger waren voor kippeneiwit allergenen dan mannelijke exemplaren. Na 
orale blootstelling waren er meer vrouwelijke ratten met een positieve IgE respons 
(38-75%) dan bij mannelijke BN ratten (13-38%) het geval was. Veroudering leidt bij 
BN ratten tot verminderde Th2-dominantie (Ide et al., 1999; van der Meide et al., 
1995), waardoor het moeilijk wordt om een allergische respons te induceren (Ide et 
al., 1999; Pauwels et al., 1979). Om deze redenen hebben wij jonge (3-4 wk oude) 
vrouwelijke ratten gebruikt in onze studies. 
De voeding zelf kan ook van invloed zijn, omdat sommige voedselbestanddelen in 
potentie de voedselallergische respons kunnen veranderen. De matrix waarin het 
eiwit in contact komt met het immuunsysteem is van belang om de allergeniciteit 
van het eiwit in het experimentele model voor voedselallergie te kunnen bepalen 
(van Wijk et al., 2005). 
 
In het ideale model vertonen de proefdieren, naast sensibilisatie zoals gemeten 
door allergeenspecifieke IgE responsen, reacties die overeenkomen met menselijke 
reacties na een acute blootstelling aan (een hoge dosering van) het allergeen. Ver-
der moet het proefdiermodel relatief makkelijk uitvoerbaar en reproduceerbaar zijn 
(Penninks and Knippels, 2001). Hoewel al deze factoren moeilijk te vatten zijn in één 
enkel model, lijkt het orale voedselallergiemodel in BN ratten mogelijk zoals gepre-
senteerd in deze thesis een geschikt model om de allergeniciteit van voedselaller-
genen in mensen te bestuderen. Dit gedachtengoed vind ook steun middels eerdere 
publicaties betreffende studies in BN ratten (Atkinson et al., 1996; Atkinson and 
Miller, 1994; Jia et al., 2004; Jia et al., 2005; Knippels et al., 1999a; Knippels and 
Penninks, 2002; Knippels et al., 1999b; Knippels et al., 1998b; Knippels et al., 1999c; 
Knippels et al., 2000; Ogawa et al., 2003; Pilegaard and Madsen, 2004).  
 
BEPERKINGEN VAN DE BN RAT ALS EEN EXPERIMENTEEL MODEL VOOR VOEDSEL-
ALLERGIE 
Hoewel ons BN rat model voor voedselallergie vele voordelen kent voor gebruik als 
een experimenteel model, heeft ook dit model nadelen voor risico-inschatting: 
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1. de BN rat is een inteeltstam: alhoewel de hoge inteeltcoëfficiënt de waarschijn-
lijkheid verhoogt dat de immuunreactie van een BN rat overeenkomt met die 
van een andere BN rat (en als gevolg daarvan het benodigde aantal dieren in el-
ke blootstellinggroep helpt verminderen), is de keerzijde van dit effect dat de 
BN rat als een model niet de brede genetische variatie heeft die wel in atopi-
sche mensen voorkomt; 
2. afwezigheid van anafylactische reacties: dit verschilt met de sterke anafylacti-
sche reacties die in menselijke patiënten voorkomen. Dit verschil tussen BN rat-
ten en atopische patiënten is van speciaal belang aangezien anafylaxis zowel le-
vensbedreigend is als een grote impact heeft op het leven van voedselallergi-
sche patiënten in algemenere zin; 
3. beperking tot één geslacht: het gebruik van vrouwelijke BN ratten, zoals toege-
past in de door ons uitgevoerde verdere doorontwikkeling van de BN rat als 
model voor voedselallergie, verhoogt weliswaar de sensitiviteit tegen de te on-
derzoeken antigenen (en als gevolg daarvan een vermindering in het benodigde 
aantal dieren in elke blootstellinggroep), maar vertegenwoordigt aan de andere 
kant niet de humane situatie waarbij atopische patiënten beide geslachten om-
vatten; en 
4. mogelijke onderschatting van het effect van immunostimulatoren: in Hoofdstuk 
2 werd beschreven dat het adjuvant CT niet in staat was om de kracht van de al-
lergische reactie tegen pinda eiwitten substantieel te verhogen, dit kan beteke-
nen dat in het hier gebruikte experimentele model al optimaal immuunreacties 
worden geïnduceerd, en het model daardoor suboptimaal is om het effect van 
dergelijke immunostimulatoren op de voedselallergische respons te bestude-
ren. 
 
GEBRUIK VAN EEN BN RAT MODEL VOOR VOEDSELALLERGIE 
De eerste regel van de toxicologie is dat alle stoffen een effect hebben, maar dat de 
dosering bepaalt of het effect wenselijk of onwenselijk is (Paracelcus (1493-1541); 
“Dosis sola facit veneum” (alleen de dosis bepaalt of iets een vergif is)). Zoals eerder 
aangegeven, spelen naast de dosis ook andere factoren, inclusief omgevingsfacto-
ren en andere voedselcomponenten in het voedsel buiten het allergeen zelf, een rol 
in de het uiteindelijke effect op (het onstaan van) voedselallergie. Er is een verschil 
tussen “hazards” (het potentieel om een negatief effect te veroorzaken) en risico’s 
(het negatieve potentieel gekoppeld aan de kans dat deze effecten ook daadwerke-
lijk optreden). Binnen voedselallergie kunnen gevalideerde diermodellen voor voed-
selallergie naast hun toepassing voor “hazard” identificatie, ook gebruikt worden 
voor de inschatting van risico’s en dan met name om risicobeïnvloedende factoren, 
zoals omgevingsfactoren of voedselcomponenten in het voedsel buiten het aller-
geen zelf, op te pikken. 
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Immunodulerende effecten onderzocht met het BN rat model voor voedselallergie 
De effecten van drie verschillende immunomodulatoren werden voor dit proef-
schrift bestudeerd. Hoofdstuk 2 beschrijft het effect van het mucosale adjuvant CT. 
Het adjuvant CT was in dit model slechts in beperkte mate effectief in het verster-
ken van de voedselallergische respons. CT adjuvatie verhoogde wel de kracht van de 
IgE respons en in mindere mate die van de IgG1 respons, maar niet die van de IgG2a 
respons, niet de hoogte van de rat mest cel protease 2 (RMCPII) concentraties, en 
ook niet de hoeveelheid granulocyten of het niveau van de cytokines. Deze resulta-
ten impliceren dat in ratten die gefokt zijn op een soja- en pinda-vrij dieet, orale 
sensibilisatie mogelijk reeds dicht tegen een optimaal resultaat aan zit en dat CT 
daarom de sensitiviteit van het model niet aanzienlijk kon verhogen. 
Hoofdstuk 3 beschrijft de invloed van de in de voedselketen voorkomende conta-
minant, de immunosuppressieve verbinding TBTO, op de ontwikkeling van voedsel-
allergie tegen pinda of ovalbumine in BN ratten. Blootstelling aan TBTO resulteerde 
niet alleen in afgenomen algemene immunologische parameters, maar had tevens 
een onderdrukkend effect op allergische parameters. TBTO verminderde de produc-
tie van allergeenspecifieke Th2 cytokines door miltcellen, de allergeenspecifieke IgE 
niveaus, de hoeveelheden eosinofiele en basofiele granulocyten in het bloed en de 
productie van mest cel protease II na een orale acute hoge dosering van het aller-
geen. 
Na het onderzoeken van de effecten van de immunosuppressieve verbinding (TBTO) 
en de immunostimulerende verbinding (CT), werd het effect van Lactobacillus casei 
Shirota (LcS) op de voedselallergische respons tegen pinda onderzocht (Hoofdstuk 
4). Figuur 1 toont een versimpeld overzicht van de interacties van de immunomodu-
latoren CT en TBTO met het immuunsysteem, en toont ook waar Lactobacillus casei 
Shirota (LcS) invloed uitoefent. We veronderstelden een remmend effect van deze 
bacteriële stam, vanwege haar effect op Th1 immuniteit. LcS verminderde de voed-
selallergische respons tegen pinda niet. Integendeel, in ons allergiemodel tegen 
pinda (Hoofdstuk 4) verschoof LcS de Th1/Th2 balans in de richting van Th2 domi-
nantie op zowel het niveau van de productie van cytokines als op het niveau van de 
productie van de antilichamen IgG1 en IgG2a. Het meest uitgesproken effect van LcS 
dat in deze studie werd gevonden was haar effect op de productie van IL-4 door 
milt- dan wel mesenterische lymfeklier (MLK) cellen. LcS was tevens in staat om 
vroege pinda extract (PE)-specifieke IgE niveaus en PE-specifieke IgG niveaus te 
stimuleren. De resultaten van onze studie staan in contrast met de resultaten uit 
drie dierstudies met knaagdieren die een afname van IgE beschrijven (Matsuzaki 
and Chin, 2000; Matsuzaki et al., 1998; Shida et al., 2002). In een respiratoir allergie 
model had LcS geen effect op IgE (Ezendam and van Loveren, 2008). LcS verminder-
de ook de in vitro IgE productie in miltcellen van aan OVA blootgestelde muizen 
(Shida et al., 1998). 
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Wat betekenen deze resultaten voor de menselijke situatie? Allereerst dient de kant-
tekening gemaakt te worden dat de effecten van probiotica afhangen van stam, viabi-
liteit, dosering, duur en wijze van de behandeling, en tijdstip van (prenatale) blootstel-
ling (Broekaert and Walker, 2006; de Waard et al., 2003; Kalliomaki and Isolauri, 2004; 
Prescott et al., 2005; Savilahti et al., 2008). Daarnaast is aangetoond dat de effecten 
die bacteriële stammen op het immuunsysteem kunnen uitoefenen afhangen van de 
individuele immunologische status (Pelto et al., 1998; Roessler et al., 2007). Pelto et 
al. (Pelto et al., 1998) lieten zien dat inname van Lactobacillus GG (LGG) resulteerde in 
een toegenomen expressie van fagocytose receptoren in gezonde personen, terwijl 
LGG-supplementatie in personen die overgevoelig zijn tegen melk een onderdrukte 
expressie van deze receptoren veroorzaakte. Roessler et al. (Roessler et al., 2007) 
claimen dat perifere parameters verschillend beïnvloed worden door probiotica in 
gezonde volwassen vrijwilligers ten opzichte van volwassenen met atopische dermati-
tis. Waarschijnlijk is het onderliggende mechanisme gedeeltelijk geassocieerd met het 
bestaande verschil in de competitie en de stabiliteit van microbiota. De gastheer lijkt 
van invloed te zijn op de effecten van bacteriën, bijvoorbeeld door competitie voor 
epitheliale bindingsplekken. Mogelijk spelen in gezonde personen ten opzichte van 
allergische patiënten andere factoren een rol die van invloed zijn op de effecten van 
probiotica (Christensen et al., 2002; Perdigon et al., 2000; Roessler et al., 2007). 
Onderzoek in proefpersonen (Abrahamsson et al., 2007; Brouwer et al., 2006; Gruber 
et al., 2007; Kalliomaki et al., 2001; Kalliomaki et al., 2003; Osborn and Sinn, 2007; 
Rosenfeldt et al., 2003; Savilahti et al., 2008; Sistek et al., 2006; Taylor et al., 2007; 
Viljanen et al., 2005) toont aan dat bacteriële stammen verschillende effecten kunnen 
uitoefenen op allergieën en zodoende probiotisch werken, terwijl sommige probiotica 
ook ongewenste immunostimulatie kunnen veroorzaken (Taylor et al., 2007). 
Het is evident dat meer onderzoek nodig is om de preventieve effecten van probiotica 
op allergieën te onderbouwen. Het lijkt waarschijnlijk dat bepaalde bacteriestammen 
een gunstige uitwerking kunnen hebben op de gezondheid van patiënten met bepaal-
de aandoeningen, terwijl deze zelfde stammen mogelijk negatieve effecten kunnen 
hebben bij patiënten met andere ziektebeelden. Het blijft daarom van belang om de 
zoektocht te vervolgen naar specifieke bacteriestammen die het ontwikkelen en/of de 
hevigheid van voedselallergische responsen kunnen verminderen, temeer daar niet 
alle probiotische stammen dezelfde eigenschappen vertonen en zelfs de ontwikkeling 
en/of de hevigheid van voedselallergische responsen kunnen verhogen. 
Experimentele diermodellen voor allergie zijn bruikbaar als een eerste screening om 
bacteriestammen te selecteren die potentieel effectieve probiotica kunnen zijn in 
preventie of behandeling van allergie. In deze diermodellen kunnen ook onderlig-
gende mechanismen bestudeerd worden. Vervolgens zullen werkzaamheid en vei-
ligheid in humane studies moeten worden vastgesteld. 
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Nieuwe biomarkers: genexpressie profielen 
Een gevalideerd diermodel kan van belang zijn voor de identificatie van eiwitten die 
in potentie allergenen kunnen zijn in voedsel waaraan nog geen eerdere blootstel-
ling heeft opgetreden (“hazard” identificatie). Ter aanvulling van de klassieke me-
tingen van allergische sensibilisatie, zou in de toekomst een potentiële rol wegge-
legd kunnen zijn voor nieuwe markers, zoals bijvoorbeeld allergiespecifieke genen 
(Hoofdstuk 5). Er vindt een doorlopende discussie plaats aangaande het ethisch 
verantwoord gebruik van proefdiermodellen en er is een behoefte aan alternatie-
ven voor proefdiermodellen. In de zoektocht naar alternatieven voor diermodellen 
worden drie categorieën (de 3 V’s) in beschouwing genomen, te weten: Verminde-
ring, Verfijning en Vervanging (Russell and Burch, 1959). Vermindering refereert aan 
methoden om het aantal dieren dat in deze experimenten noodzakelijk is te ver-
minderen of minimaliseren. Verfijning refereert aan verbeterde experimentele 
technieken die stress en ongemak in proefdieren elimineren of verminderen. Ver-
vanging refereert aan methoden, die onderzoekers in staat stellen een onderzoeks-
doel te realiseren zonder gebruik te hoeven maken van proefdierexperimenten. In 
de context van dit proefschrift, kan onderzoek van het gebruik van genexpressie 
profielen vooral gezien worden als een verdere verfijning binnen het huidige model. 
Alle hoofdstukken van dit proefschrift tonen duidelijk aan dat in ons experimenteel 
model voor voedselallergie, de noodzaak bestaat om parameters op verschillende 
niveaus van het voedselallergische proces te onderzoeken (enkele van deze para-
meters zijn verwerkt in Figuur 1). 
In Hoofdstuk 5 van dit proefschrift worden de effecten van orale toediening van 
pinda op genexpressie profielen van MLK beschreven. Na drie dagen blootstelling 
aan pinda werden al veranderde genexpressie profielen waargenomen, dit is het 
eerste tijdspunt dat was meegenomen. Optimale regulatie op het niveau van gen-
expressie werd gevonden na zeven dagen blootstelling en deze effecten waren na 
14 dagen sterk verminderd. In deze context is het vermeldenswaardig dat conventi-
onele parameters slechts (sterk) gereguleerd zijn op relatief late tijdstippen: zo was 
PE-specifieke IgE optimaal na 42 dagen van orale dosering met PE. 
Blootstelling aan pinda induceerde regulatie van genen die betrokken waren bij celde-
ling of bij algemene immunologische processen. Daarnaast werden ook immunologi-
sche processen geactiveerd. De genen die betrokken waren bij immunologische pro-
cessen waren niet specifiek indicatief voor allergie. Aanvullende studies om deze eer-
ste resultaten te versterken zijn nodig om te bepalen of het effect op het niveau van 
genexpressie zoals in ons BN rat model werd gevonden, beperkt was tot een immuno-
logische respons of tevens indicatief kan zijn voor een allergische respons. Vervolgstu-
dies moeten daarom immunologisch actieve, maar niet-allergene eiwitten naast be-
kende allergenen zoals pinda meenemen. Dergelijk additioneel onderzoek zal waar-
schijnlijk meer informatie kunnen verschaffen over de specifieke genen en “pathways” 
(in dit geval in genen met onderlinge afhankelijkheid), die indicatief zijn voor voedsel-
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allergenen en als zodanig van waarde kunnen zijn voor het mechanistisch inzicht in 
het voedselallergische proces, en heeft daarnaast een mogelijke toepassing in het 
voorspellend onderzoek om potentiële allergenen door te lichten. 
Verder anticiperend op toekomstige mogelijkheden, kunnen genexpressie profielen 
in een later stadium mogelijk een erg interessant gereedschap zijn om vast te stel-
len waarom sommige dieren en mensen wel een allergie ontwikkelen na blootstel-
ling aan een allergeen terwijl andere dieren en mensen na blootgesteld te zijn aan 
hetzelfde allergeen geen allergie ontwikkelen. We verwachten dat het inschatten 
van de discrepantie op het niveau van betrokken genen en “pathways” tussen deze 
twee immunologische uitkomsten een sleutelrol in het beantwoorden van deze 
vraag kan spelen en daarmee onze kennis op dit onderwerp aanzienlijk kan vergro-
ten. Deze kennis kan vervolgens weer een hulp zijn in de preventie en behandeling 
van voedselallergie en ons ook van wat aanwijzingen voorzien voor verschillende 
immunologische uitkomsten na blootstelling aan allergenen in andere soorten van 
allergie/ allergie in het algemeen. 
 
 
FIGURE 1. Het effect van de immunomodulatoren: cholera toxine (CT), 
bis(tributyltin)oxide (TBTO) en Lactobacillus casei Shirota (LcS) op parameters op 
verschillende niveaus binnen de voedselallergische respons tegen pinda.  
Het potentiële effect dat elke immunomodulator uitoefent staat afgebeeld door middel van pijlen, die 
het niveau aangeven waarop de modulatie van de voedselallergische respons geschiedt. De richting van 
het effect op de voedselallergische respons is aangegeven door ‘-’ (inhibitie), ‘+’ (stimulatie) of ‘++’ (erg 
sterke stimulatie). 
RMCPII is de afkorting voor “rat mest cel protease 2”, een mest cel product dat vrijkomt tijdens het 
degranulatieproces na herhaalde blootstelling aan het allergeen waartegen sensibilisatie heeft plaatsge-
vonden. 
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Na ruim vier jaar onderzoek, fifty fifty verdeeld over twee onderzoeksinstituten, en 
er meer dan 250.000 km voor afgelegd te hebben ligt hier dan het proefschrift waar 
het allemaal om ging. Dit proefschrift is niet alleen het eindpunt van mijn promotie 
traject, maar ook de afsluiting van een leerzame, leuke, van tijd tot tijd hectische, 
maar bovenal uitdagende periode. Terugblikkend ben ik een groot aantal mensen 
dank verschuldigd. 
 
Allereerst mijn promotor Henk: voor het schrijven en begeleiden van dit promotie-
onderzoek. Ondanks je drukke schema en de tussenliggende afstand tijdens mijn 
periode in Maastricht was het altijd fijn om te weten dat ik indien nodig altijd over 
jouw kennis en kunde kon beschikken. Ik heb veel bewondering voor je wijze waar-
op jij zo goed het overzicht kon houden en de rode lijn kon bewaken, hier heb ik 
veel van geleerd. Bedankt voor het vertrouwen en je wijze woorden! 
 
Janine, ook aan jou heb ik enorm veel te danken, je was net als Henk bij alle publica-
ties betrokken. Ondanks dat je in korte tijd voor de tweede keer moeder werd, heb 
ik zelfs tijdens de laatste schrijffase veel aan je gehad. Een welverdiende plaats als 
copromotor dus! 
 
Léon, dank voor de kans om uit jouw kennis van het Brown Norway model voor 
voedselallergie te kunnen putten en ook jouw als copromotor te mogen verwelko-
men. 
 
Raymond, jouw kritische noot en stimulerende interactie hield mij scherp en heeft 
de artikelen gepolijst. 
 
André, dank voor jouw commentaar op de stukken, ondanks je verantwoordelijkhe-
den. 
 
Jeroen, voor het microarray artikel heb ik enorm veel te danken aan jou, want zon-
der jouw hulp, je schat aan bioinformatica kennis en de supersnelle analyses had ik 
de microarray data nooit zo snel kunnen uitwerken en publiceren. 
 
Kirsten, bedankt voor je kritische blik over het microarray artikel en het doorgeven 
van je handige verzendlijst voor de distributie van het proefschrift, succes met je 
carrièreswitch van onderzoekster naar lerares. 
 
Ex-collega’s. Eerst bij de afdeling TOX op het RIVM en later bij de afdeling GRAT op 
de Universiteit Maastricht was de hulpvaardigheid en collegialiteit van iedereen 
steeds een enorme steun in de rug. TOX - Met name Arja: enorm betrokken bij zo-
wel het lab werk als op persoonlijk vlak. Dankjewel! Eric en Bert waren naast een 
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steun bij de grootschalige experimenten ook een bron van humor en plezier. Dat 
doorbrak de sleur! Moeder Selva, voor korte tijd mijn kamergenootje op het RIVM, 
helaas van korte duur maar nu kom ik je in het Mestreechse toch weer tegen tijdens 
het doen van de boodschappen. Maar ook Henny, Liset en Yvonne: bedankt voor 
jullie hulp waar nodig. Verder veel dank aan het duo Hans en Piet, afgewisseld met 
Christine, voor de hulp bij de secties en Ruud voor zijn rol in de huisvesting en fok 
van de ratten. Geen lab zoals het GRAT-lab: met name de hulp van Marcel als assis-
tent gedurende de secties en zowel Marcel als Ralph voor de introductie in de we-
reld van de microarrays. Onze super secretaresse Marie-Claire, bedankt voor je 
warme betrokkenheid en het assisteren of uitvoeren van allerlei hand en spandien-
sten. 
 
Een warm gevoel houd ik ook over aan mijn ex-kamergenootjes Pim, Joep en later 
Kevin. Jullie hebben veel bijgedragen aan de gezelligheid van de laatste twee jaar 
van mijn project. Bedankt voor de inhoudelijke conversaties en de lol, binnen en 
buiten werktijden, een welkome afwisseling tijdens het onderzoek en het typen. 
Ook dank aan alle anderen die op GRAT aan de uitstekende sfeer bijdroegen, en de 
enorm gezellige “Mestreechse” PhD-groep. Jullie zijn geweldig! 
 
Daarnaast wil ik zeker ook mijn collega’s van BioMedbooster (Jasper, Inge, Erik, 
Hera, Lia; maar zeker ook Rene, Paul en Winand) bedanken voor de stimulerende, 
enorm leuke, interactieve werksfeer, gezelligheid, teamspirit en de belangstelling 
voor en de ondersteuning van mijn promotie. 
 
Applaus ook voor mijn studenten die stuk voor stuk een belangrijke bijdrage hebben 
geleverd: Jennie (alle begin is moeilijk, maar een goed begin is het halve werk!), 
Milanthy (salsa-dansende dokter-wannabe), Renske (project-hopper) en Joke (inge-
togen potentieel). Bedankt voor de gezellige tijd, het was een genoegen om jullie te 
begeleiden! En in het geval van Joke: veel succes met het traject naar je eigen PhD. 
 
De docenten en de medestudenten tijdens de opleiding tot toxicoloog boden een 
welkome verdiepingsslag door het combineren van kennisuitwisseling met netwer-
ken. 
 
Vanzelfsprekend wil ik ook de Voedsel en Waren autoriteit bedanken voor het fi-
nancieel faciliteren van dit project. Ook de leden van the Immunotoxicology and 
Chemical Allergy Speciality Section en the Centre of Food Allergy ben ik dank ver-
ontschuldigd voor stimulerende discussies en het inhoudelijke commentaar op mijn 
presentaties. 
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Nu ook een woord van dank aan al mijn vrienden, bekenden en familieleden die de 
afgelopen jaren met me mee hebben geleefd. Enkelen zal ik specifiek noemen. 
 
Germaïn, Nataly en de kleine Trixton: vrienden door dik en dun. Al zitten jullie nu in 
Aruba, in mijn hart en tijdens mijn vakantie(s?) zijn jullie altijd dichtbij! 
Dave en Milevis: bedankt voor het altijd meedenken, de gezelligheid en de relative-
rende gesprekken. 
Robbert, ik ken je nu al 17 jaar, wat vliegt de tijd!: gezellige lunches en medelief-
hebber van het wat rapper vervoer. 
Damiën, studiegenootje, vriend, medepromovendus en nu paranimf naast mij. Ook 
voor jou ligt binnen no-time een prachtige promotie in het verschiet. 
‘Ome’ Ron en ‘tante’ Rita, bedankt voor het hele jaar dat ik doordeweeks op jullie 
riante zolderkamer mocht verblijven om het eerste jaar van dit project onderzoek te 
verrichten! 
Jeroen S., spraakwaterval, beste vriend van Don, maar ook ik geniet van onze 
vriendschap. 
Chris, ken jou nog niet zo lang als de rest maar wel direct een leuke “click”, “No man 
can be condemned for owning a dog. As long as he has a dog, he has a friend; and 
the poorer he gets, the better friend he has”. 
 
Ten slotte wil ik de mensen bedanken die er echt altijd voor mij zijn. 
 
Mijn broer Donovan, van jongs af aan al de beste maatjes. Fijn om iemand te heb-
ben die je door en door kent en waarmee het uitstekend relativeren, vernieuwen en 
lol beleven is. Het is ook niet voor niets dat ik jou als paranimf op het erepodium 
naast mij wil. Geen betere kandidaat om mijn rug te dekken, en vice versa. Op naar 
vele nieuwe avonturen: “The world is ours!”. 
 
Zoveel warmte en liefde in een gezinnetje, altijd en voor iedereen gezellig, een 
thuishaven van rust in alle hectiek, zoveel steun en vertrouwen: Lieve Dick en Hilly, 
jullie zijn geweldig! Lieve mam, regelaar van alles, spil van la familia, zo zie je maar 
wat er van dat straatschoffie is geworden. Pap, jouw humor, creatieve “drive”, on-
voorwaardelijke steun en heerlijk nuchtere relativering zijn doorgekomen, reken 
maar. Beiden, nogmaals bedankt voor de genoten opvoeding, de oneindige steun en 
het heerlijke familiegevoel, dat nu alweer de volgende generatie ingaat met jullie als 
opa en oma. 
 
Ook mijn schoonouders, Wim en Annie, en mijn schoonbroer Shane, jullie hebben 
een en ander ook van zeer dichtbij mogen meemaken. Vooral tijdens de tijd dat wij 
noodgedwongen bij jullie terecht konden voor een tijdelijk adres zodat Arlene kon 
blijven werken in Rotterdam en ik in Bilthoven. Ik heb het gevoel dat ik een tweede 
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gezin erbij heb gekregen. En dat voor maar drie (pluche) kamelen . . .  . . . Over valo-
risatie gesproken. ☺ 
 
Save the best for last: mijn lieve vrouw Arlene, mijn allergrootste steun en toever-
laat. Idioot hoeveel er alleen al in deze promotieperiode met ons (inmiddels gezin-
netje) is gebeurd: getrouwd, tweemaal verhuist, tweemaal zwanger, nu al een 
prachtig dochtertje en een zoontje op komst! Veel van mijn tijd en energie zijn de 
laatste jaren in de aanloop van het nu voor je liggende boekje gaan zitten, de hoog-
ste tijd dus om vanaf nu een en ander in te gaan halen. “Buckle up!, and enjoy the 
ride”. 
J. & A.?, JA! 
 
En als aller-allerlaatste jullie: Nikita en Anakin, heerlijke rolmopsjes, kleine J. & A. 
recombinanten, jullie atopische predispositie hebben jullie van beide ouders mee-
gekregen, toch zal het nog wel heel wat tijd vergen voordat zelfs jullie wijsneusjes 
dit kunnen begrijpen. Maar aan de andere kant, de vooruitgang van de wetenschap 
gaat zo snel, wie weet? Aan jullie draag ik dit proefschrift dan ook op. 
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Jonathan Dennis de Jonge werd op 27 februari 1979 geboren te Rotterdam. In 1997 behaalde 
hij het Atheneum aan de Serviam scholengemeenschap (tegenwoordig de Trevianum scho-
lengroep) te Sittard. Aansluitend studeerde hij Gezondheidswetenschappen aan de Universi-
teit Maastricht, met als afstudeerrichting Milieugezondheidkunde. Zijn afstudeerstage vond 
plaats bij de afdeling Gezondheidsrisico Analyse en Toxicologie (GRAT) van de Universiteit 
Maastricht, waarna in 2002 het doctorale diploma werd behaald. Aansluitend was Jonathan 
aangesteld als junior onderzoeker op verscheidene projecten bij de afdeling GRAT, totdat hij 
van december 2003 tot december 2007 werd aangesteld als promovendus bij deze afdeling. 
Zijn promotieonderzoek, dat is beschreven in dit proefschrift, betrof een samenwerking met 
de afdeling Toxicologie, Pathologie en Genetica (TOX) van het Rijksinstituut voor Volksge-
zondheid en Milieu (RIVM) te Bilthoven, alwaar de eerste twee jaar van het onderzoek zijn 
uitgevoerd. Tijdens deze aanstelling werden de certificaten ‘Stralingshygiëne, deskundig-
heidsniveau 5b’ en ‘Proefdierkunde op grond van artikel 9 van de Wet op de Dierproeven’ 
behaald, en werd de Postdoctorale Opleiding Toxicologie (POT) gevolgd ten behoeve van 
registratie als toxicoloog bij de Nederlandse Vereniging voor Toxicologie (NVT). Sinds mei 
2008 is Jonathan werkzaam als Manager Technology Transfer bij BioMedbooster en houdt 
zich in deze hoedanigheid bezig in het commercialiseren van nieuwe kennis door middel van 
licentie transacties of middels het opstarten van nieuwe bedrijven. Vanaf mei 2009 is Jona-
than begonnen aan een door de Nederlandse Biotechnologie Associatie (NIABA) en De Baak 
Management Centrum VNO verzorgde postdoctorale Masterclass opleiding in BioBusiness. 
 
 
 
Jonathan Dennis de Jonge was born on February 27th in Rotterdam. He graduated from his 
secondary education at the Serviam College in Sittard in 1997. In the same year he started 
studying Health Sciences at Maastricht University, with a specialization in Environmental 
Health Sciences. After an internship at the department of Health Risk Analysis and Toxicology 
(GRAT) of the University Maastricht, he received his master degree in 2002. After which 
Jonathan was a junior researcher on various projects at the department of GRAT, until he was 
appointed as a PhD student at this department from December 2003 until December 2007. 
The research, conducted in these years and presented in this thesis, occurred within a coop-
eration framework with the Laboratory for Toxicology, Pathology and Genetics (TOX) at the 
National Institute for Public Health and the Environment (RIVM) in Bilthoven, at which the 
first two years of the research took place. During this research period, Jonathan obtained 
licenses for working with laboratory animals (according to article 9 of the Dutch law on ex-
perimental animals) and with radioactive material (competence level 5b, as accredited by the 
Dutch government). In addition, a Postgraduate Education in Toxicology (PET) was completed 
resulting in the registration as a toxicologist by the Netherlands Society of Toxicology (NVT). 
As of May 2008, Jonathan has been working as a Manager Technology Transfer at BioMed-
booster, in this function he commercializes new ideas through either licensing deals or new 
start-up ventures. As of May 2009 Jonathan has started his post-graduate degree Masterclass 
program in BioBusiness, as presented by the Netherlands Biotechnology Association (NIABA) 
and De Baak Management Centrum VNO. 
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